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ABSTRACT 
 
Inflammatory bowel disease (IBD) is a common condition in dogs that is 
challenging to diagnose. A dysregulated innate immunity plays a major role in its 
pathogenesis, and surrogate inflammatory markers that reflect disease severity would be 
clinically useful. S100A12, a damage-associated molecular pattern molecule, is involved 
in phagocyte activation. S100A12 binds to the receptor of advanced glycation end 
products (RAGE), a pattern-recognition receptor, and results in human studies suggest a 
role of S100A12 and RAGE in chronic inflammation. Soluble RAGE (sRAGE), a decoy 
receptor, functions as an anti-inflammatory molecule. S100A12 and RAGE/sRAGE have 
not been studied in canine IBD. Canine S100A12 has not been purified, and while an 
immunoassay for measurement of S100A12 in humans is available, human antibodies do 
not cross-react with canine S100A12 (cS100A12). Canine RAGE has been cloned and 
characterized. 
 The aims of this project were to purify and partially characterize cS100A12, to 
develop and analytically validate an immunoassay for cS100A12, and to determine the 
relationship between cS100A12 and systemic sRAGE concentrations and clinical, 
endoscopic, and histologic disease severity in dogs with IBD. Markers of gastrointestinal 
inflammation were also evaluated in dogs with acute hemorrhagic diarrhea syndrome 
(AHDS). 
 Canine S100A12 was successfully purified from canine whole blood, and a 
competitive liquid-phase radioimmunoassay was developed and analytically validated. 
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Fecal cS100A12 concentrations were shown to be increased in dogs with IBD and were 
associated with clinical disease activity, the severity of endoscopic lesions, and the 
severity of colonic inflammation. Serum sRAGE concentrations were decreased in dogs 
with IBD, but were not correlated with disease severity, cS100A12 concentrations, or 
outcome. Dogs that were euthanized had higher fecal cS100A12 concentrations than 
dogs that were alive at the end of the study, and serum sRAGE concentrations increased 
only in IBD dogs with complete clinical remission. A significant but transient increase in 
fecal cS100A12 was also seen in dogs with AHDS. 
 Fecal cS100A12 may be clinically useful as a biomarker of inflammation in dogs 
with IBD, and the sRAGE/RAGE axis appears to be altered in canine IBD. Lack of 
correlation between sRAGE and cS100A12 is consistent with sRAGE being a non-
specific decoy receptor. 
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1. INTRODUCTION 
 
1.1.  Canine Inflammatory Bowel Disease (IBD) 
1.1.1.  Definition 
Idiopathic inflammatory bowel disease (IBD) in dogs is a chronic inflammation 
of the small and/or large intestine that may also involve the stomach, the exact cause of 
which is unknown (Hall and German, 2008). It is a chronic relapsing condition and its 
diagnosis and management can be challenging for the clinician and frustrating to the 
owner. The diagnosis of IBD requires a comprehensive diagnostic work-up, including 
invasive diagnostic procedures, to exclude other causes of chronic gastrointestinal signs 
such as food-responsive diarrhea (FRD), antibiotic-responsive diarrhea (ARD), 
infiltrative infectious diseases (e.g., gastrointestinal histoplasmosis), or neoplasia (e.g., 
lymphoma) (Day et al., 2008; Washabau et al., 2010; Simpson and Jergens, 2012; 
Jergens and Simpson, 2012; Suchodolski et al., 2010). 
 
1.1.2.  Pathogenesis 
The current consensus concerning the pathogenesis of IBD in dogs stipulates an 
impaired immunoregulation in a genetically predisposed host that results in an 
inflammatory response against dietary and/or microbial antigens (Fig. 1) (Jergens and 
Simpson, 2012; German et al., 2001; Burgener et al., 2008). Cells of the adaptive 
immune system have long been associated with the pathogenesis of idiopathic IBD in 
dogs, but evidence is mounting that impaired innate immunity also plays a critical role in 
 2 
 
 
 
 
 
 
 
 
 
Figure 1 – Pathogenesis of canine inflammatory bowel disease (IBD). The exact cause 
of canine IBD is unknown. The pathogenesis appears to be complex and the current 
consensus is that it is multifactorial in nature and that innate immunity appears to play a 
central role. 
 
 
 
 3 
 
 
the development of idiopathic IBD (German et al., 2001; Burgener et al., 2008; 
Luckschander et al., 2010; Allenspach, 2011a; Wilke et al., 2012). Thus, biomarkers of 
phagocyte activation may potentially serve as clinically useful biomarkers of 
inflammation in dogs with idiopathic IBD. 
 
1.1.3.  Biomarkers for canine IBD 
 Biomarkers are used as an aid to evaluate organ function, assess the risk for 
disease development, diagnose a specific disease process, assess disease severity, predict 
the patient’s response to treatment or predict the disease outcome, and/or to monitor the 
disease process. Disease biomarkers are generally said to be either static or dynamic, and 
they are classified as functional, biochemical, cellular, genomic, or proteomic 
biomarkers. 
 The few minimally invasive biomarkers that have been evaluated in dogs with 
idiopathic inflammatory bowel disease (IBD) belong to the groups of biochemical, 
functional, and genomic biomarkers. These include (1) functional biomarkers: (i) serum 
and fecal alpha1-proteinase inhibitor (α1PI) concentrations, (ii) serum folate (vitamin B9) 
and cobalamin (vitamin B12) concentrations, and (iii) tests evaluating gastrointestinal 
permeability and absorptive function, such as 
51
Cr-EDTA absorption, iohexol 
absorption, serum or urine lactulose/rhamnose ratio or the xylose/methylglucose ratio 
(the last group of markers is impractical and not used clinically); (2) biochemical 
biomarkers: (i) serum C-reactive protein (CRP), (ii) perinuclear anti-neutrophilic 
cytoplasmic antibodies (pANCA), (iii) perinuclear anti-Saccharomyces cerevisiae yeast 
 4 
 
 
antibodies (pASCA), (iv) urine and fecal N-methylhistamine (NMH) concentrations, (v) 
serum and fecal calprotectin concentrations, (vi) serum and fecal immunoglobulin A 
concentrations, and (vii) various cytokines and chemokines; and (3) genomic 
biomarkers: (i) single nucleotide polymorphisms (SNPs; e.g., in TLR4, TLR5, NOD2, 
NCF2), (ii) reduction of genetic diversity (e.g., Ig and TCR repertoire), and (iii) 
alterations in gene expression (e.g., TLR2, TLR4, TLR5, TLR9, CCL2, CCL20, CCL25, 
CCL28, CXCL8, Casp3, Bcl-2, and other genes involved in cell replication, iron/calcium 
transport, innate immunity/inflammation, cellular detoxification, intestinal barrier 
function, and extracellular matrix degradation). Selected biomarkers are discussed 
below. 
 
1.1.3.1.  Fecal alpha1-proteinase inhibitor (α1PI) 
 Alpha1-proteinase inhibitor (α1PI; also referred to as alpha1-antitrypsin) is a 
major serum proteinase inhibitor that is mainly produced in the liver and protects the 
body from the detrimental effects of neutrophil proteases, trypsin, and chymotrypsin 
(Travis et al., 1988). Compared to humans, there is no definitive evidence to suggest that 
canine α1PI is an acute-phase reactant (Conner et al., 1988; Ganrot et al., 1973). Canine 
α1PI is a proteolysis-resistant protein that has a molecular weight similar to that of 
albumin (Melgarejo et al., 1996). It is theoretically only present at high concentrations in 
the gastrointestinal lumen when there is loss of proteins as a result of gastrointestinal 
disease, and the rate of α1PI loss should be approximately that of albumin. However, 
unlike albumin, cα1PI is expected to resist proteolysis due to its inhibitory activity 
 5 
 
 
towards proteinases, and can therefore be quantified in fecal samples (Fig. 2) (Heilmann 
et al., 2011c). 
 Pathologic chronic losses of cα1PI into the gastrointestinal lumen may (in theory) 
deplete systemic cα1PI concentrations, as hepatic α1PI synthesis and secretion is a 
continuous process that normally does not involve intracellular storage of α1PI (Carlson, 
1984), and change the systemic proteinase-proteinase inhibitor balance. Decreased 
serum cα1PI concentrations have been measured in dogs with protein-losing enteropathy 
due to IBD (Equilino et al., 2015) and in cobalamin-deficient Yorkshire Terriers 
(Grützner et al., 2013). 
 The concentration of canine α1PI in feces has been shown to be clinically useful 
as a marker for gastrointestinal protein loss in dogs as it increased before the onset of 
clinical signs and/or hypoalbuminemia or panhypoproteinemia in Soft Coated Wheaten 
Terrier dogs with familial protein-losing enteropathy (PLE) (Vaden et al., 2002). Thus, 
fecal α1PI appears to be useful for the early detection of gastrointestinal protein loss. In a 
recent study, fecal α1PI concentration distinguished dogs with moderate or severe 
gastrointestinal crypt abscesses and/or lacteal dilation from those without such lesions or 
only mild lacteal dilation with moderate sensitivity and specificity; the serum-to-fecal 
α1PI ratio may improve the diagnostic accuracy in hypoalbuminemic dogs (Heilmann et 
al., 2014c). 
 Concentrations of α1PI in fecal extracts from individual healthy dogs vary greatly 
from day-to-day (with %CVs up to 102% reported), and collection of a fecal sample for 
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Figure 2 – Fecal canine α1-proteinase inhibitor (α1PI). Canine α1-proteinase inhibitor 
(α1PI) has a molecular weight similar to that of albumin and is only present at high 
concentrations in the gastrointestinal lumen when there is loss of proteins as a result of 
gastrointestinal disease. Unlike albumin, α1PI resists proteolysis due to its inhibitory 
activity towards proteinases, and can therefore be quantitatively analyzed in fecal 
samples. (With permission from: Heilmann, R.M., Paddock, C.G., Ruhnke, I., et al., 
2011. Development and analytical validation of a radioimmunoassay for the 
measurement of alpha1-proteinase inhibitor concentrations in feces from healthy puppies 
and adult dogs. Journal of Veterinary Diagnostic Investigation 23: 476-485, © 2011 by 
SAGE) 
 
 
 
 
each of three consecutive days from the same patient has been suggested to 
counterbalance this physiological variation (Steiner et al., 2003; Heilmann et al., 2011c). 
 A fecal α1PI of ≥13.9 µg/g for the mean of 3 samples from consecutive days 
and/or ≥21.0 µg/g for the maximum of these 3 fecal extracts collected on 3 consecutive 
days is considered abnormal. Increased fecal canine α1PI concentrations in dogs <1 year 
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of age, and especially in dogs <6 months old, should be interpreted with caution as fecal 
α1PI levels have been shown to be significantly higher in healthy dogs <1 year of age 
(Heilmann et al., 2011c). 
 
1.1.3.2.  Serum cobalamin and folate concentrations 
 Cobalamin (vitamin B12) and folate (vitamin B9) are water-soluble vitamins that 
are often measured in dogs with chronic gastrointestinal signs. Cobalamin absorption 
occurs exclusively in the distal small intestine (ileum) via specific cobalamin receptors 
that take up intrinsic factor-cobalamin complexes. Hypocobalaminemia is frequently 
detected in dogs with chronic small intestinal disease (18-54%), and this can be due to 
distal small intestinal malabsorption, but may also reflect an increased utilization of 
cobalamin by the intestinal microbiota due to small intestinal dysbiosis (Allenspach et 
al., 2007; Berghoff et al., 2013; Heilmann et al., 2014a). Hypocobalaminemia (<200 
ng/L) has been shown to be a risk factor for negative outcome and to be associated with 
hypoalbuminemia (<20 g/L) in dogs with IBD (Allenspach et al., 2007). 
Hypocobalaminemia, however, is not a specific finding for IBD, and exocrine pancreatic 
insufficiency is an important differential diagnosis in patients with hypocobalaminemia 
and chronic gastrointestinal signs (especially weight loss and voluminous stools) 
(Heilmann et al., 2014b). Parenteral supplementation with cyanocobalamin (once weekly 
for 6 weeks, then every 2-4 weeks) is indicated if serum cobalamin concentrations are 
<350 ng/L in a patient with chronic gastrointestinal signs. Patients with EPI may need 
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life-long cobalamin supplementation. Oral cobalamin supplementation may also be 
effective if given daily (Toresson et al., 2014), but this needs further investigation. 
 Folate is predominantly absorbed in the proximal small intestine (duodenum, 
proximal jejunum) via folate carriers and after dietary folate has been broken down from 
folate polyglutamate to folate monoglutamate. Serum folate concentrations can thus be 
decreased due to malabsorption in dogs with chronic proximal small intestinal disease, 
but a decreased serum folate is also not specific for IBD and a normal serum folate 
concentration does not rule out significant small intestinal disease (Ruaux, 2008). Serum 
folate can also be falsely normal or increased due to small intestinal dysbiosis (with an 
increased production of folate by the intestinal microbiota) or due to hypocobalaminemia 
(and should thus be monitored with cobalamin supplementation) (Ruaux, 2008). Oral 
folic acid supplementation (10 µg/kg/day or 200-400 μg/day for 30 days) is 
recommended if folate is severely decreased. 
 
1.1.3.3.  Serum C-reactive protein (CRP) 
 CRP is a positive acute-phase protein of the pentraxin family and is produced by 
the liver in response to IL-6 and IL-1β during states of infection, inflammation, or cancer 
(Rhodes and Fürnrohr, 2011). The expression of CRP in the liver is regulated by NF-κB. 
CRP in its annular pentameric form can opsonize bacteria and/or apoptotic/necrotic cells 
to facilitate complement (C3b) binding and opsonin-mediated phagocytosis. CRP 
monomers may bind to cell surfaces in inflamed tissue and activate neutrophils and 
monocytes (Rhodes and Fürnrohr, 2011). 
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 CRP is a nonspecific biomarker of inflammation that can be useful to evaluate 
disease progression and response to treatment. Several assay formats are available for 
measurement of canine CRP in serum, these include canine-specific enzyme-linked 
immunosorbent assays (ELISAs) (Berghoff et al., 2006), immunoturbidimetric canine 
CRP-assays (Eckersall et al., 1991; Klenner et al., 2010; Hillström et al., 2014), an 
immunofluorometric assay (TR-IFMA) (Parra et al., 2006), and a point-of-care (POCT) 
lateral flow immunoassay (Plickert et al., 2011). Most canine CRP assays have a 
reference interval in the 0-8 mg/L range. A high-sensitivity CRP (hs-CRP) test, which 
has been shown to be superior to standard CRP assays for the detection of very low 
systemic levels of CRP (<5 mg/L) in humans (Poullis et al., 2002; Roberts et al., 2000; 
Shine et al., 1985), is currently not available for use in dogs. 
 The concentration of C-reactive protein (CRP) in serum, measured by a canine-
specific enzyme-linked immunosorbent assay (ELISA), has been suggested to be 
clinically useful for assessment of disease progression and response to treatment in dogs 
with idiopathic IBD (Jergens et al., 2003; Jergens et al., 2010a; Heilmann et al. 2012a). 
However, in other studies, serum CRP concentration was not associated with clinical or 
histopathologic disease severity in dogs with idiopathic IBD (Allenspach et al., 2007; 
McCann et al., 2007; and Münster et al., 2010). Also, a high biological variability of 
serum CRP concentrations within individual dogs (Carney et al., 2011) and nonspecific 
increases in serum CRP concentration in response to infectious, neoplastic, or other 
inflammatory conditions (Dabrowski et al., 2007; Nakamura et al., 2008; Griebsch et al., 
2009; Lowrie et al., 2009; Chan et al., 2009; Gebhardt et al., 2009) appear to limit the 
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clinical usefulness of serum CRP concentration for diagnosing and/or monitoring 
idiopathic IBD in dogs. 
 
1.1.3.4.  Perinuclear anti-neutrophilic cytoplasmic antibodies (pANCA) 
 Perinuclear anti-neutrophilic cytoplasmic antibodies are circulating auto-
antibodies directed against neutrophil granule constituents, which are detected by 
indirect immunofluorescence staining (Allenspach et al., 2004). It has been suggested, 
but remains undefined, that pANCA is directed to a nuclear histone, proteinase 3 (Pr3), 
and/or myeloperoxidase (MPO) and represents an autoantibody representative of cross-
reactivity with a luminal bacterial antigen. 
 In dogs, pANCA positivity was found to have a low sensitivity (23-51%) but 
moderate to high specificity (83-95%) for the detection of IBD (Mancho et al., 2011; 
Luckschander et al., 2006). The positive rate of pANCA and pANCA titers were shown 
to be higher in dogs with food-responsive diarrhea (FRD; 62%) than in dogs with 
idiopathic IBD (23%; Luckschander et al., 2006). Detection of pANCA does not 
distinguish dogs with IBD from dogs with intestinal lymphoma (Mancho et al., 2011). In 
a Soft Coated Wheaten Terrier colony, a positive pANCA test was significantly 
associated with hypoalbuminemia due to protein-losing enteropathy (PLE) and/or 
protein-losing nephropathy (PLN), with the positive test result preceding the 
development of hypoalbuminemia by >2 years (Allenspach et al., 2008). Thus, pANCA 
may be a useful test for the detection of FRD in dogs and/or the early detection of PLE 
and/or PLN in Soft Coated Wheaten Terriers. 
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1.1.3.5.  N-methylhistamine (NMH) 
 N-methylhistamine (NMH) is a stable metabolite of histamine and is a biomarker 
of mast cell degranulation. After its release from mast cells, histamine (and other 
inflammatory mediators) has proinflammatory effects on other immune cells and has 
similar effects also on nerve and smooth muscle cells (Berghoff and Steiner, 2011). 
NMH can be measured in urine and fecal samples. Fecal NMH and mast cell 
degranulation have been shown to be increased in Norwegian Lundehunds (Berghoff et 
al., 2008) and Soft Coated Wheaten Terriers (Vaden et al., 2000) with chronic 
enteropathies, respectively. Recently, urine NMH was shown to be increased in a 
subgroup of dogs with chronic gastrointestinal disease and to correlate with the severity 
of histologic lesions and serum C-reactive protein (CRP) concentrations (Berghoff et al., 
2014) suggesting that NMH may be a marker of mast cell-mediated inflammation in 
dogs with chronic enteropathies. However, another study did not find a correlation 
between NMH and the number of mast cells in the duodenal mucosa or the clinical 
disease severity (as assessed by the CCECAI scoring system [Allenspach et al., 2007]) 
(Anfinsen et al., 2014). 
 
1.1.3.6.  Cytokines and chemokines 
 Several studies have investigated the cytokine and chemokine signature in canine 
IBD. The first study by German et al. (2000) found a heightened immune response in the 
duodenal mucosa of German Shepherd dogs with chronic enteropathy, but the 
expression of IL-2, IL-4, IL-5, IL-10, IL-12p40, IFN-γ, TNF-α, and TGF-β1 mRNA did 
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not demonstrate a polarization toward Th1 or Th2 as described in humans with Crohn’s 
disease and ulcerative colitis, respectively (Neurath et al., 2002). Peters et al. (2005) 
evaluated the duodenal mucosal expression of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-
18, IFN-γ, TNF-α, and TGF-β by RT-PCR, and did not find a predominant CD4+ cell 
type in dogs with chronic enteropathies. A meta-analysis by Jergens et al. (2009) 
revealed that the inflamed mucosa in dogs with IBD fails to show either Th1- or Th2- 
cytokine skewing as only IL-12 mRNA expression was consistently increased in small-
intestinal IBD with no differences seen in canine IBD colitis. Kołodziejska-Sawerska et 
al. (2013) evaluated the mucosal expression of pro-inflammatory (IL-1, IL-2, IL-5, IL-6, 
IL-12, IL-18, IFN-γ, and TNF-α) and anti-inflammatory cytokines (IL-4 and IL-10), and 
reported no distinct T lymphocyte signature. Okanishi et al. (2013) found no significant 
difference in duodenal mucosal mRNA levels for TNFα or IL-1β in dogs with 
lymphoplasmacytic enteritis compared to healthy controls. Tamura et al. (2014) 
investigated the mRNA expression of helper-T-lymphocyte cytokines (IFN-γ, IL-4, IL-
17, and IL-10) and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-8, IL-12, and 
IL-23) in the colonic mucosa from dogs with lymphoplasmacytic colitis, and as opposed 
to human IBD, did also not show a predominant cytokine profile in the inflamed colonic 
mucosa in dogs with lymphoplasmacytic colitis. 
 Few canine studies have evaluated the Th17 subset of T lymphocytes. Schmitz et 
al. (2012) evaluated the duodenal mucosal expression of IL-17A, IL-22, IL-10, IFN-y, 
and TGF-β, and did not find evidence for the involvement of Th17 signature cytokines in 
canine IBD. A similar study by Ohta et al. (2014) evaluated the gene and protein 
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expression of duodenal mucosal IL-17A, IFN-γ, and IL-10, and found also no significant 
difference between dogs with IBD and healthy controls, thus concluding that there is no 
evidence of a distinct T cell signature in canine IBD. 
 Maeda et al. (2011) studied the mRNA expression of chemokines of the CC and 
CXC family in canine IBD, and found an increase in chemokines that are chemotactic 
for T and B lymphocytes and were shown to be up-regulated in human IBD. However, 
the role of chemokines in the Th1/Th2/Th17 polarization is unclear. 
 The results of studies in dogs have to be interpreted with caution as several 
factors, including the method of mRNA quantification, the possibility of mRNA 
instability, the stage, severity, and location of IBD, as well as other factors 
(antimicrobial therapy, diet, and demographic differences) differed significantly among 
the different groups of dogs evaluated. Further limitations of most studies included a 
small sample size and the lack of a disease control group. 
 Analyses of the expression of other signaling molecules of the innate immune 
response have revealed a dysregulation in the expression of several cytokines and 
chemokines (e.g., CCL2, CCL20, CCL25, CCL28, and CXCL8) (Maeda et al., 2011), 
intracellular signaling (e.g., nuclear factor-κB) and intercellular adhesion molecules 
(e.g., VCAM-1, MAdCAM-1, and ICAM-1) (Luckschander et al., 2010; Okanishi et al., 
2013), and other genes involved in cell replication, innate immunity/inflammation, 
cellular detoxification, iron/calcium transport, intestinal barrier function, and 
extracellular matrix degradation (Jergens et al., 2010b; Wilke et al., 2012). 
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1.1.3.7.  Genomic biomarkers 
 Genetic studies have shown that polymorphisms in the genes encoding the Toll-
like receptor (TLR)-4, TLR5, and nucleotide oligomerization domain (NOD)-2 are 
significantly associated with canine IBD in German shepherd dogs and other breeds 
(Allenspach, 2011a). The TLR4 SNPs A1571T and G1807A (both recessive) and the 
TLR5 SNP G22A (likely dominant) were associated with an increased risk of IBD, 
whereas the TLR5 SNPs C100T and T1844C (both dominant) were protective for IBD 
(Kathrani et al., 2010a). Another breed-independent candidate gene approach confirmed 
that the TLR5 SNPs C100T (dominant) and T1844C (recessive) are protective for IBD 
(Kathrani et al., 2011a). A mutational analysis in Boxer dogs with IBD revealed another 
SNP (T443C) in the leucine rich repeat domain of TLR5 (Kathrani et al., 2011b), 
suggesting that individual breeds may harbor unique SNPs in addition to shared 
polymorphisms among breeds. Analysis of the significance of the 2 TLR5 SNPs 
associated with IBD (C100T and T1844C) and the 3 TLR5 SNPs in German shepherd 
dogs with IBD (G22A, C100T, and T1844C) on receptor function revealed a hyper-
responsiveness of TLR5 to stimulation with flagellin (Kathrani et al., 2011c; Allenspach 
et al., 2011b). Mutational analyses in German shepherd dogs and other breeds also 
revealed an association between IBD and polymorphisms in the gene encoding 
nucleotide oligomerization domain-2 (NOD2), a cytosolic pattern recognition receptor 
that recognizes MDP of Gram
–
 and Gram
+
 bacteria (Kathrani et al., 2010b; Kathrani et 
al., 2011d; Kathrani et al. 2014). Although no longer classified as a subgroup of canine 
IBD, a genome-wide analysis of granulomatous colitis (GC) in boxer dogs has revealed 
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polymorphisms in the phagocytic cytosolic factor (NCF)2 gene, which codes for a 
subunit of neutrophil NADPH oxidase and is involved in bacterial killing and the 
cellular autophagy pathway (Craven et al., 2010). 
 Gene expression studies revealed a significantly higher mucosal expression of 
TLR2, TLR4, and TLR9 mRNA in dogs with IBD at the time of diagnosis, but no 
correlation with histology or clinical disease activity (as assessed using the CIBDAI 
scoring system [Jergens et al., 2003]) and also no change post-treatment despite clinical 
improvement (Burgener et al., 2008). Also, TLR2 and TLR4 were shown to be 
expressed at the apical epithelial surface whereas TLR9 was expressed intracellular. 
Another study showed a 20-fold increase of TLR2-mRNA in IBD dogs and a weak 
correlation between TLR2-mRNA expression and clinical disease severity (as assessed 
by the CCECAI scoring system [Allenspach et al., 2007]) but no correlation with 
histopathology scores (McMahon et al., 2010). Expression of TLR4 was up-regulated 
and that of TLR5 down-regulated in all segments of the intestine evaluate in German 
shepherd dogs with IBD, and the expression of TLR did not correlate with clinical 
disease activity (CCECAI), histopathology scores, or the number of bacterial clones in 
the duodenum (Allenspach et al., 2010). However, none of these studies confirmed their 
findings at the protein level. 
 
1.1.4.  Characteristics for an ideal biomarker 
 For a marker of inflammation to be clinically useful, it needs to be measurable 
without temporal delay in expression and/or secretion following changes of the 
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inflammatory activity. The marker should also be organ-specific in expression or the 
type of specimen used to determine its concentration, and be specific for the disease 
process. Moreover, such a marker needs to be easy, inexpensive, and minimally-invasive 
to measure, and be stable in the specimen under clinical conditions. Fecal biomarkers 
that are specific for gastrointestinal disease, correlate with disease severity, and 
objectively assess gastrointestinal inflammation would be very useful in clinical practice 
but such markers are currently lacking in veterinary medicine; and the lack of stability in 
fecal samples hampers the routine analysis of many small molecular inflammatory 
proteins (e.g., cytokines or chemokines). Thus, additional biomarkers that are more 
specific for IBD would be useful for the diagnosis and assessment of disease progression 
in dogs with IBD. 
 
1.2.  Calgranulin/S100 Proteins 
 S100/calgranulins, a group of three phagocyte-specific damage-associated 
molecular pattern (DAMP) molecules (Pietzsch and Hoppman, 2008), accumulate at 
sites of inflammation and appear to be candidates for fecal markers because of their 
stability in feces (Föll et al., 2009) and their increase at the mucosal mRNA level in dogs 
with IBD (Wilke et al., 2012). 
 The S100 proteins represent a genetically highly conserved family of 
intracellular Ca
2+
-modulated signaling proteins with a tightly clustered organization of 
their respective genes (Schäfer and Heizmann, 1996), and were eponymously termed 
after its first member was shown to be soluble in 100% (NH4)2SO4 (Moore, 1965). 
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Calprotectin was the first calgranulin/S100 complex discovered in the cytosol fraction of 
human neutrophilic granulocytes (PMN) (Fagerhol, 1980) and consists of two Ca
2+
-
binding proteins assigned to the S100 protein family: S100A8 and S100A9 (Schäfer and 
Heizmann, 1996). Both calprotectin proteins contain two Ca
2+
-binding motifs of the EF-
hand type (α-helix-loop-α-helix model) with disparate Ca2+ affinities, flanked by 
hydrophobic regions at either terminus that are exposed upon Ca
2+
-binding. It has been 
postulated that these regions play an important role in the hydrophobic interactions with 
S100-specific target proteins (Hunter and Chazin, 1998; Kligman and Hilt, 1988; Odink 
et al., 1987; Schäfer and Heizmann, 1996; Yousefi et al., 2005). 
 
1.2.1.  S100A8/A9 protein complex 
Calprotectin, the S100A8/A9 complex, is expressed and released into the 
extracellular space by activated macrophages and neutrophils and can be induced in 
epithelial cells. Serum concentrations of calprotectin are often increased in human 
patients with IBD (Leach et al., 2007; Lügering et al., 1995). Calprotectin may be 
involved in the expression of proinflammatory cytokines and chemokines downstream of 
Toll-like receptor-4 (Fig. 3) (Vogl et al., 2007), which is up-regulated in dogs with 
idiopathic IBD (Burgener et al. 2008). Canine calprotectin has been recently purified and 
partially characterized (Heilmann et al., 2008a), and immunoassays for the quantification 
of calprotectin in serum and fecal samples from dogs have been developed and 
analytically validated (Heilmann et al., 2008b; Grützner et al., 2014). Serum and fecal 
calprotectin concentrations have been evaluated in dogs with chronic gastrointestinal 
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inflammation (Grellet et al., 2013; Heilmann et al., 2012a; Otoni et al., 2012) and may 
serve as a biomarker of inflammation in dogs. 
 
 
 
 
 
 
Figure 3 – S100A8/A9 and S100A12 play a role in the immune response. Both 
S100A8/A9 and S100A12 represent endogenous damage-associated molecular pattern 
(DAMP) molecules that bind to receptors of the innate immune system. Upon ligand 
binding, these receptors have been shown to activate NF-κB, leading to the production of 
pro-inflammatory cytokines and chemokines. A positive feedback on RAGE expression 
has been shown for S100A12. 
IRAK = IL-1 receptor-associated kinase; Kras = V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog; MAPK = mitogen-activated protein kinases; MyD88 = myeloid 
differentiation factor 88; NF-κB = nuclear factor-kappa B; RAGE = receptor for 
advanced glycation end products; TLR4 = Toll-like receptor 4; TNF-α = tumor-necrosis 
factor α; TRAF = TNF-receptor associated factor. 
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1.2.2.  S100A12 protein 
 S100A12, also referred to as calgranulin C, migration inhibitory factor-related 
protein (MRP)-6, p6, or extracellular newly identified RAGE-binding protein (EN-
RAGE) (Hofmann et al., 1999; Ilg et al., 1996; van den Bos et al., 1998), was first 
identified in the cytosol of human neutrophils and monocytes (Guignard et al., 1995). It 
belongs to the calgranulin subfamily of the highly conserved S100 proteins, a 
superfamily of EF-hand proteins with a high Ca
2+
-binding capacity and binding sites for 
other divalent cations such as Zn
2+
 and Cu
2+
 (Heizmann, 2002). S100A12 has been 
reported to show a subcellular distribution pattern similar to that of S100A8/A9 
(Guignard et al., 1995; Vogl et al., 1999). As has been demonstrated for several other 
S100 proteins, the essentiality to oligomerize in the presence of Ca
2+
 and Zn
2+
 has been 
confirmed for the target protein interaction and function of S100A12 (Moroz et al., 
2003; Moroz et al., 2009; Xie et al., 2007). A number of different target proteins of 
S100A12 have been identified and led to the proposal of various regulatory cellular 
functions for this protein (Hofmann et al., 1999; Pietzsch and Hoppmann, 2008; 
Hatakeyama et al., 2004). Extracellular S100A12 was shown to exert cytokine-like 
effects and to function as a phagocyte-specific damage associated molecular pattern 
(DAMP) molecule, and therefore appears to play a central role in innate and acquired 
immune responses (Föll et al., 2007). The S100A12 protein has been postulated to play a 
role in host defense against microorganisms and parasites (Gottsch et al., 1999) and to 
have chemotactic properties (Hofmann et al., 1999; Miranda et al., 2001; Yang et al., 
2001). 
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 Following its release from neutrophils/monocytes due to cell damage, infection, 
or inflammation, S100A12 was shown to present a ligand for the receptor for advanced 
glycation end products (RAGE), a pattern recognition receptor (PRR), and to activate the 
nuclear factor kappa B (NF-kB) signal transduction pathway (Fig. 3) (Hofmann et al., 
1999). As a result of the proinflammatory activation of this PRR, expressed by 
mononuclear phagocytes, endothelial cells, and lymphocytes, proinflammatory cytokines 
such as tumor necrosis factor-α (TNF-α) were shown to be released, which in turn 
modulate the inflammatory response (Hofmann et al., 1999; Miranda et al., 2001; Yang 
et al., 2001). The S100A12 protein has been suggested to be involved in the 
amplification and perpetuation of the traditional inflammatory response by triggering a 
positive feedback cycle on the expression of RAGE (Fig. 4) (Hofmann et al., 1999; 
Gebhardt et al., 2008), and thus to be linked to the pathogenesis of inflammatory 
disorders such as inflammatory bowel disease (IBD) in humans (Föll et al., 2003b). 
Moreover, soluble RAGE (sRAGE), a truncated variant of RAGE, has been shown to 
function as a decoy receptor sequestering ligands such as damage-associated pattern 
molecules (e.g., S100A12), thus preventing ligand interaction with cell surface RAGE 
and abrogating cellular RAGE signaling (Fig. 5) (Bierhaus et al., 2005). In human 
medicine, S100A12 has been reported to be a very sensitive and specific marker of 
localized inflammatory processes, such as gastrointestinal inflammation (Föll et al., 
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Figure 4 – S100A12-RAGE interaction. In humans, S100A12 has been shown to bind to 
the receptor of advanced glycation end products (RAGE), a multi-ligand pattern-
recognition receptor that has been shown to play a role in chronic inflammation 
(Hofmann et al., 1999; Bierhaus et al., 2005). The ligand-RAGE interaction has been 
shown to induce sustained post-receptor signaling, including activation and nuclear 
translocation of nuclear factor-kappa B (NF-κB), and the up-regulation of RAGE 
(positive feedback loop) is believed to lead to perpetuation and amplification of the 
inflammatory response (Schmidt et al., 2000). 
MAPK = mitogen-activated protein kinases; NF-κB = nuclear factor-kappa B; RAGE = 
receptor for advanced glycation end products; TNF-α = tumor-necrosis factor α. 
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Figure 5 – Blockage of the RAGE pathway by sRAGE. As a truncated variant of RAGE 
(panel A), soluble RAGE (sRAGE; panel B), has been shown to function as a decoy 
receptor (panel C) sequestering ligands such as damage-associated pattern molecules 
(e.g., S100A12), thus preventing ligand interaction with cell surface RAGE (panel D) 
and abrogating cellular RAGE signaling (Bierhaus et al., 2005). Soluble RAGE has been 
shown to be decreased in inflammatory diseases in people and has been suggested as a 
potential therapeutic target in chronic inflammatory conditions (Hudson et al., 2003). 
DAMP = damage-associated molecular pattern; RAGE = receptor for advanced 
glycation end products; sRAGE = soluble receptor for advanced glycation end products. 
 
 
 
 
2009; Kaiser et al., 2007), and to be increased in plasma and serum in patients with 
various inflammatory disorders (Föll et al., 2003a; Föll et al., 2003c; Basta et al., 2006). 
 Only human, porcine, bovine, and rabbit S100A12 have been purified to date 
(Dell’Angelica et al., 1994; Hitomi et al., 1996; Ilg et al., 1996; van den Bos et al., 1998; 
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Yamashita et al., 1999; Yang et al., 1996), and an immunoassay for the quantification of 
S100A12 is available only for use in human patients. A high sequence divergence has 
been reported for S100A12 proteins from different species, thus substantiating the 
necessity of using species-specific immunologic methods for the detection of S100A12 
(Moroz et al., 2003). Availability of an immunological method for the measurement of 
canine S100A12 would allow to further study the role of canine S100A12 in 
inflammatory diseases, such as IBD, in canine patients. Moreover, although the function 
of S100A12 may be species-specific, the fact that a homologue of this calgranulin exists 
in dogs while rodents lack S100A12 (Fuellen et al., 2004) (and S100A8 appears to 
functionally resemble S100A12 [Föll et al., 2004; Hsu et al., 2009]) also renders a 
canine IBD model superior to rodent models for studying S100/calgranulins and the 
S100A12-RAGE/sRAGE axis in human IBD. Thus, future studies into the function of 
S100/calgranulins and the S100A12-RAGE/sRAGE axis in chronic inflammatory 
conditions and their proposed use as novel selective therapeutic targets should benefit 
from such studies in dogs. 
 
1.3.  Pattern Recognition Receptors (PRRs) 
 Toll-like receptors (TLRs) and the receptor for advanced glycation end products 
(RAGE) are pattern-recognition receptors (PRRs) that are expressed by innate immune 
cells and recognize pathogen-associated molecular pattern (PAMP) and damage-
associated molecular pattern (DAMP) molecules. Both TLRs and full-length RAGE are 
transmembrane proteins with a similar but distinct structure (Fig. 6). TLRs consist of (1) 
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an ectodomain of leucine-rich repeats (LRRs) that mediates PAMP/DAMP recognition 
and has a horseshoe-like structure, (2) a transmembrane domain functioning as an 
anchor, and (3) the cytoplasmic domain Toll/IL-1R (TIR), which initiates downstream 
signaling. Full-length RAGE consists of five domains: (1) a variable (V-type) domain 
responsible for ligand binding, (2-3) two constant (C-type) domains, (4) a 
transmembrane domain (anchor), and (5) a cytosolic domain that initiates signal 
transduction. 
 
 
 
 
 
 
 
Figure 6 – Structure of the receptor for advanced glycation end products (RAGE) and 
Toll-like receptors (TLRs). 
LPP = leucine-rich repeats; RAGE = receptor for advanced glycation end products; 
TLR4 = Toll-like receptor 4. 
 
 
 
 
 Natural alternative splicing or protease cleavage can produce isoforms that lack 
the cytosolic domain (e.g., dominant-negative RAGE), isoforms lacking a ligand-binding 
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domain (e.g., N-truncated RAGE), or decoy receptors (e.g., soluble RAGE [sRAGE]). 
Their presence can modulate (i.e., abrogate) cell signaling, and thus neutralize the effect 
of receptor ligands (Fig. 5). 
 
1.3.1.  Ligands of TLRs and RAGE 
 While most TLRs recognize distinct PAMPs (e.g., TLR4 recognizes bacterial 
lipopolysaccharide [LPS], TLR5 recognizes flagellin) there is some overlap between the 
different TLRs. Depending on the receptor and its ligand(s), TLRs are localized to either 
the cell surface (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) or the intracellular 
space (TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13). 
 In contrast to TLRs, RAGE is a multi-ligand receptor that can bind several 
different ligands, including advanced glycation end products (AGEs, a heterogeneous 
group of non-enzymatically altered proteins that are enhanced at sites of inflammation), 
S100/calgranulin-like molecules, high-mobility group box-1 (HMGB-1, amphoterin), 
amyloid-β-protein (which plays a role in Alzheimer’s disease), Mac-1 (CD11b/CD18, 
also known as integrin or complement receptor-3), and phosphatidylserine. RAGE has 
also been shown to bind bacterial lipopolysaccharide (LPS), and for some ligands the 
presence of glycans and/or redox state of the ligand appears to be essential for the 
mediation of the ligand-RAGE interaction. 
 Several TLR/RAGE ligands have also been shown to form complexes, such as 
HMGB-1 and LPS. These complexes are believed to elicit stronger responses than the 
individual partner molecules alone. Furthermore, the binding affinity and preferential 
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receptor activation by some ligands of TLR/RAGE (such as S100/calgranulins) appears 
to also depend on the cell type, concentration and 3D-conformation of the ligand, and 
the underlying pathophysiological condition of the tissue or the organism. 
 
1.3.2.  Signaling pathways of TLRs and RAGE 
 Both TLRs and RAGE can be activated by microbes (PAMPs) and/or danger 
signals released from damaged cells (DAMPs or alarmins). Signaling pathways of both 
TLRs and RAGE involve the activation and nuclear translocation of nuclear factor-κB 
(NF-κB) leading to the downstream activation of innate immune responses as an 
immediate host defense response (e.g., against microbes) as well as the modulation of 
adaptive immune responses (i.e., against specific antigens) and cell growth and 
proliferation. 
 
1.3.2.1.  Toll-like receptors (TLRs) 
Depending on type and ligand(s) of TLR, PAMPs/DAMPs are recognized by either a 
TLR homodimer or a heterodimer with co-receptors or accessory molecules. Ligand 
recognition by TLRs leads to the recruitment of an adaptor protein, the major two being 
myeloid differentiation factor 88 (MyD88) and TIR domain-containing adaptor inducing 
interferon-β (TRIF): 
 MyD88-dependent signaling pathway – MyD88 recruits the protein kinases 
IRAK-4 and IRAK-1 (Myddosome), which associate with the adaptor protein TRAF6. 
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The IRAK1-TRAF6 complex then dissociates from the receptor and downstream 
activates I-κB kinase (IKK) and MAP kinases (MAPK), the latter of which causes 
activation/nuclear translocation of nuclear factor-κB (NF-κB). In addition, MyD88 
interacts with the transcription factor IRF-5 and activates it by phosphorylation (Fig. 7). 
TRIF-dependent signaling pathway – TRIF associates with TRAF3 and recruits 
the kinases IKK-ε and TBK-1, both of which activate the transcription factor IRF-3 via 
phosphorylation. TRIF can also directly associate with and activate TRAF6, resulting in 
the activation of I-κB kinase (IKK) and MAP kinase (MAPK), but this is to a lesser 
extent than via the MyD88-dependent signaling pathway. 
Activation of TLRs culminates in the activation/nuclear translocation of nuclear 
factor-κB (NF-κB) and the activation of interferon regulatory factors (IRFs) and 
mitogen-activated protein kinases (MAPK; such as p38 or JNK). Most TLRs, with the 
exception of TLR3 (which recognizes dsRNA), signal through MyD88 and induce the 
expression of proinflammatory cytokines (such as TNF-α, IL-1). TLR3 signals through 
TRIF and induces interferon-β. TLR4 is a dual receptor and signals through both 
pathways, but instead of associating directly with MyD88 or TRIF it uses two additional 
adaptor proteins (TIRAP which binds to MyD88, and TRAM which associates with 
TRIF). 
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Figure 7 – RAGE and TLR/MyD88 signaling pathways play a role in the immune 
response. Both RAGE and TLR represent pattern recognition receptors (PRR) that 
recognize pathogen-associated molecular pattern (PAMP) molecules and endogenous 
damage-associated molecular pattern (DAMP) molecules. Upon binding of those 
ligands, these receptors of the innate immune system have been shown to activate NF-
κB, leading to the production of cytokines (pro-inflammatory and/or interferon-β) and 
chemokines. A positive feedback on RAGE expression has also been shown. 
IRAK = IL-1 receptor-associated kinase; IRF = interferon regulatory factor; Kras = V-
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; MAPK = mitogen-activated 
protein kinases; MyD88 = myeloid differentiation factor 88; NF-κB = nuclear factor-
kappa B; RAGE = receptor for advanced glycation end products; TLR4 = Toll-like 
receptor 4; TNF-α = tumor-necrosis factor α; TRAF = TNF-receptor associated factor. 
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TLR signaling is controlled by negative regulators that target specific molecules 
in the TLR signaling pathways, and trafficking of TLRs after synthesis in the 
endoplasmic reticulum is controlled by several mechanisms. Both prevent or terminate 
excessive immune responses that could be detrimental to the host and lead to 
autoinflammation, maintaining a fine balance between positive and negative regulation 
of TLR signaling. 
 
1.3.2.2.  Receptor for advanced glycation end products (RAGE) 
 Similar to TLRs, signaling pathways of RAGE also lead to the activation of 
several kinases (MAPK p38/Erk, and NF-κB). Several signaling pathways, including 
KRAS signaling pathways (Fig. 7), have been identified to require RAGE. However, 
RAGE can also signal through the MyD88-dependent pathway through interaction with 
TIRAP and MyD88. 
 
1.3.3.  Role of TLRs and RAGE in host defense 
 Both types of receptors, TLRs and RAGE, can signal individually and 
independently from each other, but they may also interact functionally. In light of 
several shared ligands of both innate immune receptors (such as HMGB-1, LPS, or 
S100/calgranulins), this potential synergism or convergence between the TLR and 
RAGE signaling pathways may modulate the downstream activation of transcription 
factors and can potentially amplify associated cellular responses, and thus alter the 
pathophysiological state of the respective tissue. 
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 TLRs and RAGE signaling pathways orchestrate a complex interplay of cellular 
mediators and transcription factors, and thus appear to play a central role in homeostasis 
and host defense. PAMP signaling is crucial for host defense responses to infection, 
whereas the response to cell components released in response to inflammation and organ 
injury (DAMPs) is an essential mechanism to stimulate cytokine production and activate 
cells of the innate immune system (macrophages and dendritic cells) with the goal to 
alert the immune system to danger. However, aberrant activation of TLR and/or RAGE 
signaling, mutations of the receptors and/or downstream signaling molecules (including 
positive and/or negative regulators), and/or DAMP/PAMP-complex-mediated TLR 
signaling can potentially lead to chronic autoinflammatory diseases as well as cancer. 
Thus, both TLR and RAGE signaling pathways appear to present an interesting new 
avenue for the modulation of inflammatory responses and serve as potential novel 
therapeutic targets. 
 
1.3.4.  Role of RAGE in inflammatory disorders 
 S100/calgranulins, such as S100A12, accumulate at sites of inflammation, and 
represent ligands for the receptor of advanced glycation end products (RAGE) (Hofmann 
et al., 1999). Results of studies in humans with IBD suggest a role of RAGE in chronic 
inflammation (Basta et al., 2002). The ligand–RAGE interaction has been shown to 
induce sustained post-receptor signaling, including activation and nuclear translocation 
of nuclear factor (NF)-kappa B (Basta et al., 2002; Bucciarelli et al., 2002), and the 
upregulation of RAGE itself is believed to lead to perpetuation and amplification of the 
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inflammatory response (Fig. 4) (Bierhaus et al., 2005; Li and Schmidt, 1997). Human 
RAGE is only constitutively expressed in the lung and skin, whereas in other cell lines 
(e.g., monocytes/macrophages, endothelial cells) postembryonic RAGE expression is 
induced by either accumulation of its ligands and/or activation of transcription factors 
(e.g., NF-kappa B) that regulate RAGE expression (Bierhaus et al., 2005; Schmidt et al. 
2000). Human RAGE is believed to have the potential to convert a transient 
inflammatory response (e.g., cell stress, NF-kappa B activation) into a sustained cellular 
inflammatory response (Bierhaus et al., 2005). The expression of RAGE coincides with 
a proinflammatory microenvironment (e.g., in IBD), and the upregulation of RAGE has 
been shown to increase the recruitment of inflammatory cells through the upregulation 
of endothelial adhesion molecules VCAM-1 and ICAM-1 (Bierhaus et al., 2005; 
Schmidt et al., 2000). 
 Soluble RAGE (sRAGE), a truncated splice-variant of RAGE, functions as a 
decoy receptor sequestering ligands such as DAMPs (e.g., S100A12), thus preventing 
ligand interaction with cell surface RAGE (Fig. 5). Soluble RAGE has been shown to be 
decreased in humans with chronic inflammatory diseases (Bierhaus et al., 2005) such as 
inflammatory bowel disease (Meijer et al., 2014), juvenile idiopathic arthritis (Myles et 
al., 2011), Sjögren’s syndrome (Stewart et al., 2008), asthma and chronic obstructive 
pulmonary disease (Sukkar et al., 2012), and acute Kawasaki disease (Wittkowski et al., 
2007). Soluble RAGE has also been suggested to be a potential therapeutic target in 
patients with chronic inflammatory conditions (Hudson et al., 2003) based on an 
improved outcome in an experimental model of colitis (Hofmann et al., 1999). 
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Moreover, experimental studies suggest that sequestration of ligands by sRAGE prevents 
interaction of these ligands with RAGE, but also with other PRRs (Bierhaus et al., 
2005). Canine RAGE has been characterized (Murua Escobar et al., 2006; Sterenczak et 
al., 2009), and the existence of its naturally occurring splicing variants (total of 24) and 
the expression of RAGE in different tissues has been described (Sterenczak et al., 2009; 
Sterenczak et al., 2011). However, the sRAGE/RAGE axis has not yet been studied in 
canine IBD. 
 
1.4.  Diagnostic Tests: Immunoassays 
 Biomarkers can be quantified by immunoassays that yield a fixed response to a 
given amount of analyte (Law, 1996; Crowther, 2001). The response unit depends on the 
detection mechanism and thus the immunoassay system used, and the quantitative nature 
of an immunoassay is based on the conversion of data into suitable units (e.g., 
concentration) requiring standardization or calibration of the immunoassay. The 
calibration function (i.e., standard curve) is derived from a series of standards that are 
samples of known and increasing concentrations of the analyte, and the standard curve is 
used as an equation to relate and thus estimate the immunoassay response to the 
concentration of the analyte in unknown samples. The relationship between 
immunoassay response and concentration of analyte is usually non-linear and can be 
affected by a large number of variables. However, for simplicity, convenience, and 
universal applicability, this relationship can also be standardized in a linear model 
(linearization). 
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1.4.1.  Enzyme-linked immunosorbent assay (ELISA) 
 Enzyme-linked immunosorbent assays (ELISAs) are diagnostic tests that are 
based on a specific antigen-antibody interaction and that use an enzyme-labeled reporter 
antibody to quantify or detect a specific analyte (e.g., peptides, protein, or hormones) 
following its immobilization to a solid surface. The activity of the enzyme label is used 
to quantify or detect the analyte in test samples by conversion of a substrate into a 
measureable product (e.g., color development) (Crowther, 2001). 
 ELISAs are commonly used to detect or quantify biomarkers in various types of 
specimens, and they can be performed using one of  several different ELISA formats. 
Depending on the sample type, an extraction or enrichment step may be needed prior to 
quantification of the substance. Advantages of ELISAs are that they can be more 
sensitive for the measurement of protein analytes than radioimmunoassays and do not 
require the use of radioactive tracers (Crowther, 2001). Thus, ELISAs are often used as a 
first-line diagnostic assay format for the evaluation of new biomarkers. 
 ELISAs involve several steps (Fig. 8). First, an ELISA plate is coated with the 
capture antibodies by covalent attachment through the Fc region of the antibodies. 
Unoccupied sites are then blocked to reduce background interference and improve assay 
sensitivity, which is followed by incubation with test samples containing the analyte to 
be measured. The wells of the ELISA plate are then incubated with the detection 
antibodies, which can be directly labeled (primary conjugate; direct ELISA) or detected 
by a secondary labeled antibody (secondary conjugate; indirect ELISA). The label can 
be the stabilized enzyme (e.g., peroxidase) or biotin, which is then complexed with 
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avidin-conjugated enzyme. As a final step the substrate (chromogenic, chemifluorescent, 
or chemiluminescent) is added and, by the activity of the bound enzyme, is converted to 
a detectable product (signal), the intensity of which is proportional to the concentration 
of the detection antibody and thus to the respective antigen (analyte) (Crowther, 2001). 
 Other ELISA formats include immobilization of the antigen by direct absorption 
to the ELISA microplate (instead of a capture antibody) or a competitive ELISA by 
adding labeled antigen as competitor. An acceptable ELISA should be (1) highly 
sensitive to detect small amounts of the analyte, (2) robust and reproducible for the 
sample tested, and (3) of a wide dynamic range for the analyte. 
 
1.4.1.1.  Sandwich ELISA 
 The so-called “sandwich” ELISA is the most sensitive and robust type of a 
capture ELISA. This assay is called “sandwich” ELISA because the analyte measured or 
detected is bound between the capture (primary) and the detection (secondary) antibody 
(Fig. 8). The detection antibodies can be recognized through a secondary labeled 
antibody or can be directly conjugated with the enzyme or biotinylated (Crowther, 
2001). 
 Sandwich ELISAs can also be performed as competitive assays, which is of 
advantage if the analyte is small or has only one antibody-binding site (epitope). A 
standardized amount of the labeled antigen is added to the wells together with the assay  
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Figure 8 – Steps of an enzyme-linked immunosorbent assay (ELISA).  Shown are the 
different steps involved in an ELISA, exemplified by the direct sandwich ELISA for 
canine calprotectin. (panel A) The wells of the ELISA plate are coated with the capture 
antibody, (panel B) test samples or assay standards are added, followed by incubation 
with (panel C) the peroxidase-labeled detection antibody and, finally, (panel D) the 
peroxidase substrate (TMB), which is converted to a soluble quantifiable signal (color). 
HRP = horseradish peroxidase; TMB = tetramethylbenzidine. 
 
 
 
standards or test samples. Due to the unlabeled antigen competing for binding to the 
capture antibody, a decrease in signal indicates the presence of antigen in the sample. 
 An important consideration for „sandwich“ ELISAs is that the capture antibody 
and the detection antibody must recognize two non-overlapping antibody-binding sites 
(epitopes) of the analyte (antigen), so that when the analyte binds to the capture antibody 
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it does not obscure the epitope(s) recognized by the detection antibody. This concept of a 
“matched pair“ is particularly important when using a monoclonal antibody due to its 
inherent monospecificity toward a single epitope. As opposed to monoclonal antibodies, 
polyclonal antibodies may be used in a "self-sandwich" ELISA (where the same 
polyclonal antibody is used as capture and detection antibody) but this approach can 
limit the dynamic range as well as the sensitivity of the assay (Crowther, 2001). The 
most sensitive and specific design of a “sandwich” ELISA is by using a polyclonal 
antibody as capture antibody to allow for binding of as much analyte as possible, and to 
use a monoclonal antibody to allow specific detection. 
 
1.4.2.  Radioimmunoassay (RIA) 
 Radioimmunoassays are diagnostic tests that are also based on a specific antigen-
antibody interaction but that use a radioactively labeled antigen (called tracer) as a 
competitor for antibody binding to quantify the amount of bound and/or free antigen. 
RIAs are usually liquid-phase assays (Fig. 9); the most commonly used radioactive 
isotope is 
125
I, which is a gamma emitter. The performance and stability of an RIA is 
mainly affected by the quality of the antibody and the tracer, but also depends on the 
type of buffer and its molarity, protein additives, incubation volume and temperature, 
and the incubation time, separation system, and sample matrix. 
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Figure 9 – Steps in a radioimmunoassay (RIA). Shown are the different steps involved 
in an RIA, exemplified by a liquid phase, double antibody RIA for canine calprotectin. 
(A) Test samples or assay standards and 
125
I-tracer are added to the test tubes followed 
by (B) vortexing the tubes, (C) adding anti-calprotectin rabbit antiserum, and (D) 
incubation of the reaction mixture. (E) Rabbit serum is added. (F) Larger complexes are 
formed using anti-rabbit antibody and these larger complexes (G) are precipitated with 
polyethylene glycol. (H) After the supernatant has been decanted, the tubes are placed in 
a γ-counter to the measure the radioactivity (in counts per minute) in the test tubes. 
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 There are three categories of separating systems that can be used for RIAs. Their 
selection is largely based on the expected efficiency (i.e., accuracy with which bound 
and free analyte are separated) and practicality (i.e., speed, simplicity, applicability, 
reproducibility, and cost). Adsorption methods use dextran-coated charcoal to which the 
tracer, but not antibodies or antibody-bound tracer, is adsorbed. This method requires 
that the incubation time and temperature, amount of charcoal used, and the sample type 
and buffer are consistent. Fractional precipitation methods use a separation agent (e.g., 
18% polyethylene glycol 6000 or half-saturated [NH4]2SO4) to "salt out" and precipitate 
the antibody fraction regardless if it has bound antigen or not, and the radioactivity is 
measured in the compacted pellet (bound fraction) after separation of the supernatant 
(free fraction). Second antibody methods use anti-species antibodies to precipitate the 
antibody fraction, either in a liquid-phase (i.e., secondary antibodies and primary 
antibody-bound antigen produce an insoluble macromolecular complex) or solid-phase 
assay (i.e., antibodies attached to the surface of the assay tubes or to small cellulose 
beads) format. Other RIA formats include a second antibody–fractional precipitation 
combination and scintillation proximity assay (SPAs), which uses second antibody-
coupled scintillate microspheres. 
 Most RIAs are highly sensitive, robust, and reproducible, and have a large 
capacity with the possibility of analyzing thousands of samples per day. Disadvantages 
are the need for expensive equipment (i.e., a gamma counter and other equipment, such 
as centrifuges and vacuum sources/aspirators, designated for the use with radioactive 
materials) and the use of a radioactive tracer (i.e., a labeled antigen with a relatively 
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short shelf-life and the limitation to be used at institutions with the license and oversight 
required to handle radioactive materials). 
 
1.4.3.  Immunoassay development and analytical validation 
 Limited validation work is necessary to demonstrate the validity of the method 
prior to establishing it for routine use (Law, 1996; Crowther, 2001; Valentin et al., 
2011). Establishment of an immunoassay requires that accuracy, precision, sensitivity, 
specificity, suitability of the calibration model, robustness of the immunoassay, and 
stability of the analyte be documented (Midgley et al., 1969; Law, 1996; Crowther, 
2001; Valentin et al., 2011) to demonstrate the performance and reliability of the 
immunoassay and to determine the confidence that can be placed in the results generated 
using the immunoassay. 
 
1.4.3.1.  Immunoassay development 
 Stages in assay development and optimization are similar for ELISAs and RIAs, 
and include the selection of basic operating conditions (e.g., buffer, incubation 
temperature), the selection of a separating system, the assessment (i.e., specificity and 
sensitivity), and selection of antisera, the introduction of a matrix, and the optimization 
of the assay conditions to give the desired characteristics. Potential difficulties or 
problems that require step-wise optimization strategies are also similar for ELISAs and 
RIAs (Law, 2005; Crowther, 2001). These include the measurement of lipophilic 
analytes and the encountering of bridge-recognition or matrix effects requiring 
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sensitization/desensitization strategies, the use of non-equilibrium assays, and/or sample 
pre-treatment by extraction and/or enrichment. Thus, the final selection of a specific 
assay format (i.e., RIA vs. ELISA) is dependent on the required sensitivity, precision, 
and expected sample throughput, and available equipment, and financial constraints. 
 
 
1.4.3.2.  Immunoassay analytical validation 
 For a diagnostic assay, a complete analytical validation is essential to show that 
all validation parameters meet the acceptance criteria outlined by the Clinical and 
Laboratory Standards Institute (CLSI). Assay analytical validation also includes the 
establishment of a reference interval from a minimum of 120 reference individuals. 
Good quality control (QC) practices as well as Good Laboratory Practice (GLP) are 
essential to maintain an established and validated diagnostic test and guarantees that it 
continues to meet the CLSI criteria for a diagnostic test. Method re-evaluation is usually 
also included into routine laboratory operations as a continual QC measure. 
 Validation parameters include (i) the working range of the assay, determined as 
the range between the minimum and maximum detection limit of the assay, (ii) 
dilutional parallelism to test assay linearity (Fig. 10), (iii) spiking recovery to determine 
assay accuracy (Fig. 11), (iv) intra-assay variability to assess assay precision (Fig. 12), 
(v) inter-assay variability to determine reproducibility of the assay (Fig. 13), (vi) assay 
analytical specificity, (vii) analyte stability, (viii) interference testing, and (ix) biological 
 41 
 
 
 
 
 
 
Figure 10 – Assay linearity (dilutional parallelism). Linearity of an assay is evaluated by 
dilutional parallelism (e.g., at serial twofold dilutions) and calculation of the observed-
to-expected ratio as a percentage ([observed value/expected value]×100). Example 
shown: RIA. 
 
 
 
 
 
 
 
 
Figure 11 – Assay accuracy (spiking recovery). Accuracy of an assay is tested by 
spiking samples with known concentrations of the protein analyte (e.g., standard protein) 
followed by calculation of the percentage of standard antigen recovery ([observed 
value/expected value]×100). Example shown: RIA. 
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Figure 12 – Assay precision (intra-assay variability). Precision of the assay is evaluated 
by assaying the same sample ten times within the same assay followed by calculating the 
intra-assay coefficient of variation (%CV = [standard deviation/mean]×100). Example 
shown: ELISA. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Assay reproducibility (inter-assay variability). Reproducibility of the assay 
is determined by analyzing the same sample in ten consecutive assay runs and 
calculating the inter-assay coefficient of variation (%CV = [standard 
deviation/mean]×100). Example shown: ELISA. 
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variability of the analyte (Midgley et al., 1969; Law, 1996; Crowther, 2001; Valentin et 
al., 2011). 
 
1.4.4.  Immunoassay clinical validation 
 Understanding the diagnostic performance properties of diagnostic tests is an 
important prerequisite for its correct interpretation, and the integration of the test results 
with the patient’s clinical signs, physical examination findings, and potentially the 
results of other diagnostic tests performed are important to arrive at a definitive 
diagnosis. While this is often not within the area of the clinician’s responsibility, it is 
important to realize that determining the diagnostic performance of an assay assumes 
that its analytical performance has been established. This aspect is equally important for 
diagnostic tests performed patient-side (i.e., in-house). 
 Descriptive statistics for the performance of diagnostic tests (diagnostic 
accuracy) are expressed as estimates of the sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV). It is important to understand that 
sensitivity and specificity are inherent characteristics of a diagnostic test, whereas the 
predictive values are dependent on the prevalence of the disease and the diagnostic 
accuracy of the test in question. Further, when evaluating diagnostic accuracy of a test it 
is crucial to understand the difference between qualitative and quantitative assays. 
Qualitative assays produce a dichotomized result (i.e., a positive or negative result) 
whereas quantitative assays yield a numerical result (i.e., continuous data for which a 
‘cut-off’ concentration will be or have to be established and that allows for results to fall 
within a ‘gray range’). 
 44 
 
 
1.4.4.1.  Sensitivity 
 Sensitivity of a test, in essence, is the chance of testing positive for a patient that 
truly has the disease (i.e., the true positive rate), which has been diagnosed based on an 
independent gold-standard diagnostic method or technique. Sensitivity is calculated as 
the quotient of the number of all individuals with the disease that test positive and the 
number of all individuals with the disease. The higher the sensitivity, the lower the false 
negative rate (i.e., greater confidence can be placed on negative test results being true). 
Thus, a test with a high diagnostic sensitivity would be useful for ruling out a disease 
(i.e., as a screening test). The sensitivity of a diagnostic test can be overestimated when 
selecting patients that are obviously diseased. 
 
1.4.4.2.  Specificity 
 Specificity of a test is the rate of testing negative if the patient truly does not 
have the disease (i.e., the true negative rate) as has been determined by an independent 
gold-standard diagnostic method. Specificity is calculated as the quotient of the number 
of all individuals without the disease that test negative and the number of all individuals 
without the disease. The higher the specificity, the lower the false positive rate (i.e., 
greater confidence can be placed on positive test results being true). Thus, a test with a 
high diagnostic specificity is useful to rule-in a disease (i.e., as a confirmatory diagnostic 
test). Specificity of a diagnostic test can be overestimated when selecting healthy 
individuals as a control group instead of patients with a similar signalment and/or 
clinical signs that overlap with the disease in question. 
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1.4.4.3.  Positive and negative predictive values 
 While sensitivity and specificity are important to assess the performance of a test 
in a well-defined population of diseased patients, the predictive values are far more 
important in clinical practice when the diagnostic test is used to determine the patient’s 
disease status. Predictive values allow inferences regarding the probability of a test result 
(positive vs. negative) to indicate the correct diagnosis. They are a function of the 
sensitivity, specificity, and the prevalence of the disease in the population, and therefore 
reflect the behavior of a diagnostic test given the prevalence of the disease in the 
population tested. Predictive values can help the clinician understand and correctly 
interpret a test result obtained given the presentation of the patient in whom the test was 
performed and/or to decide in which patient population a diagnostic test is likely going 
to yield a meaningful result (also called pre-test probability). Thus, evidently performing 
the test in a patient population with a high likelihood of having the disease (e.g., based 
on signalment, clinical signs, results of other diagnostics, etc.) will improve the pre-test 
probability. This is particularly important for diagnostic tests with a relatively low 
sensitivity or specificity. 
 Positive predictive value (PPV) is the chance for a patient to have the disease if 
the test result is positive. The PPV is calculated as the quotient of the number of all 
individuals with the disease that test positive and the number of all individuals with a 
positive test result. Tests with a low diagnostic specificity (i.e., a high false positive rate) 
have a low PPV if the disease prevalence is low (e.g., when the test is used as a 
screening test for an uncommon disease). Thus, such a test performs better as a 
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confirmatory test in a patient with a strong suspicion for the disease and in the absence 
of factors (e.g., medication, concurrent conditions) that can produce a false positive 
result. 
 Negative predictive value (NPV) is the chance that the patient does not have the 
disease if the test result is negative. The NPV is calculated as the quotient of the number 
of all individuals without the disease that test negative and the number of all individuals 
with a negative test result. Tests with a low diagnostic sensitivity (i.e., a high false 
negative rate) have a low NPV if the disease prevalence is high (e.g., when the test is 
used as a confirmatory test in a patient with a strong suspicion of the disease being 
present). Thus, such a test performs better when screening large populations of patients. 
 Because predictive values are dependent on the disease prevalence (pre-test 
probability), it is important for the clinician to critically evaluate studies that report PPV 
and NPV as these values are most likely derived using the study prevalence. However, 
chances are high that the pre-test probability is going to be different when using the test 
in clinical practice and, unfortunately, for most diseases in veterinary medicine the true 
prevalence is unknown. Thus, any reported sensitivity, specificity, PPV, and NPV for a 
given diagnostic test should be interpreted with caution and in light of the respective 
study design.  
 
1.5.  Acute Hemorrhagic Diarrhea Syndrome (AHDS) 
 The syndrome of acute hemorrhagic diarrhea (AHDS), formerly known as 
idiopathic hemorrhagic gastroenteritis (HGE), is characterized by peracute hemorrhagic 
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diarrhea, vomiting, severe hemoconcentration, depression, and anorexia, and can be 
associated with a high mortality if untreated (Burrows, 1977; Post and Feldman, 1978; 
Spielman and Garvey, 1993). The etiology of AHDS is unknown, but it is speculated 
that an abnormal response to bacterial endotoxins, bacteria (such as enterotoxin-
producing C. perfringens), or dietary components may play a role (Cave et al., 2002; 
Schlegel et al., 2012). AHDS is characterized by an increased vascular and mucosal 
permeability, thought to represent a type I-hypersensitivity reaction, whereas 
gastrointestinal inflammation and mucosal necrosis appear to be rarely seen in canine 
patients with AHDS (Hall and German, 2010; Unterer et al., 2014). Markers of 
gastrointestinal inflammation and changes in the intestinal microbiota have not been 
studied extensively in dogs with AHDS (Suchodolski et al., 2012). 
 
1.6.  Hypotheses and Research Objectives 
1.6.1.  Hypotheses 
 The hypotheses of this study are that: (i) S100A12 concentrations in canine 
serum and fecal samples and sRAGE reflect the degree of intestinal inflammation; (ii) 
serum and/or fecal S100A12 and/or serum sRAGE concentrations in dogs with 
inflammatory bowel disease (IBD) can serve as a potential minimally- or non-invasive 
marker of the degree of inflammation in tissues; and (iii) dogs with acute hemorrhagic 
diarrhea syndrome (AHDS) have an altered fecal microbiota and show increases in fecal 
S100A12 concentrations. 
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1.6.2.  Research objectives 
 The objectives to prove or disprove the aforementioned hypotheses are: (i) to 
purify canine S100A12 from canine whole blood and to partially characterize canine 
S100A12; (ii) to generate and purify antibodies against canine S100A12, and to develop 
and analytically validate an immunoassay for the measurement of canine S100A12 
concentrations in canine serum and fecal samples; (iii) to evaluate canine S100A12 
concentrations and determine its biological variation in serum and fecal samples from 
healthy dogs; (iv) to evaluate canine S100A12 concentrations in serum and fecal 
samples from dogs with idiopathic inflammatory bowel disease (IBD), and to correlate 
fecal canine S100A12 concentrations with the histologic, endoscopic, and clinical 
disease severity to determine the clinical usefulness of fecal S100A12 concentrations as 
a marker of intestinal inflammation in dogs with IBD; (v) to develop and analytically 
validate an immunoassay for the measurement of sRAGE in serum samples from dogs; 
(vi) to evaluate serum sRAGE concentrations in dogs with IBD and to correlate serum 
sRAGE concentrations with the severity of clinical disease, histologic lesions, outcome, 
and the concentration of S100A12 in serum and fecal specimens from dogs; and (vii) to 
evaluate fecal canine S100A12 and bacterial groups that have previously been shown to 
be decreased (i.e., Faecalibacterium spp., Ruminococcaceae, Bifidobacterium spp.) or 
increased (i.e., Proteobacteria) in fecal samples from dogs with AHDS. 
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2. PURIFICATION AND PARTIAL CHARACTERIZATION OF CANINE S100A12
*
 
 
2.1  Introduction 
 S100A12, also referred to as calgranulin C, migration inhibitory factor-related 
protein (MRP)-6, p6, or extracellular newly identified RAGE-binding protein (EN-
RAGE) (Ilg et al., 1996; Hofmann et al., 1999; van den Bos et al., 1998), was first 
identified in the cytosol of human neutrophils and monocytes (Guignard et al., 1995). It 
belongs to the calgranulin subfamily of the highly conserved S100 proteins, a 
superfamily of EF-hand proteins with a high Ca
2+
-binding capacity and binding sites for 
other divalent cations such as Zn
2+
 and Cu
2+
 (Heizmann, 2002). S100A12 has been 
reported to show a subcellular distribution pattern similar to that of S100A8/A9 
(Guignard et al., 1995; Vogl et al., 1999). As has been demonstrated for several other 
S100 proteins, the essentiality to oligomerize in the presence of Ca
2+
 and Zn
2+
 has been 
confirmed for the target protein interaction and function of S100A12 (Moroz et al., 
2003; Moroz et al., 2009; Xie et al., 2007). 
 A number of different target proteins of S100A12 have been identified and led to 
the proposal of various regulatory cellular functions for this protein (Hofmann et al., 
1999; Pietzsch et al., 2008; Hatakeyama et al., 2004). Extracellular S100A12 was shown 
to exert cytokine-like effects and to function as a phagocyte-specific damage associated 
molecular pattern (DAMP) molecule, and therefore appears to play a central role in 
                                                 
*
Reprinted with permission from Heilmann, R.M., Suchodolski, J.S., Steiner, J.M., 2010. 
Purification and partial characterization of canine S100A12. Biochimie 92, 1914-1922, 
Copyright (2010) by Elsevier. 
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innate and acquired immune response (Föll et al., 2007). The S100A12 protein has been 
postulated to play a role in host defense against microorganisms and parasites (Gottsch 
et al., 1999) and to have chemotactic properties (Hofmann et al., 1999; Yang et al., 2001; 
Miranda et al., 2001). 
 Following its release from neutrophils/monocytes due to cell damage, infection, 
or inflammation, S100A12 was shown to present a ligand for the receptor for advanced 
glycation end products (RAGE), a pattern recognition receptor (PRR), and to activate the 
nuclear factor kappa B (NF-kB) signal transduction pathway. As a result of the 
proinflammatory activation of this PRR, expressed by mononuclear phagocytes, 
endothelial cells, and lymphocytes, proinflammatory cytokines such as tumor necrosis 
factor-α (TNF-α) were shown to be released that modulate the inflammatory response 
(Hofmann et al., 1999; Yang et al., 2001; Roth et al., 2003). Moreover, the S100A12 
protein has been suggested to be involved in the amplification and perpetuation of the 
traditional inflammatory response by triggering a positive feedback cycle on the 
expression of RAGE (Hofmann et al., 1999; Gebhardt et al., 2008), and thus to be linked 
to the pathogenesis of inflammatory disorders such as inflammatory bowel disease (IBD) 
in humans (Föll et al., 2003a). 
 In human medicine, S100A12 has been reported to be a very sensitive and 
specific marker of localized inflammatory processes, such as gastrointestinal 
inflammation (Kaiser et al., 2007; Föll et al., 2009), and to be increased in plasma/serum 
in patients with various inflammatory disorders (Föll et al., 2003a; Föll et al., 2003b; 
Basta et al., 2006). 
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 To the authors’ knowledge, only human, porcine, bovine, and rabbit S100A12 
have been purified to date (Ilg et al., 1996; van den Bos et al., 1998; Dell’Angelica et al., 
1994; Yamashita et al., 1999; Yang et al., 1996; Hitomi et al., 1996), and an 
immunoassay for the quantification of S100A12 is available only for use in human 
patients. A high sequence divergence has been reported for S100A12 proteins from 
different species, thus further substantiating the necessity of using species-specific 
immunologic methods for the detection of S100A12 (Moroz et al., 2003). In view of the 
current lack of both sensitive and specific inflammatory markers in veterinary medicine, 
the aims of this study were to establish a rapid and reproducible protocol for the 
purification of canine S100A12 (cS100A12) from canine whole blood, and to partially 
characterize this protein as a prelude to the development of an immunological method 
for its detection and quantification in serum and fecal specimens from canine patients. 
The availability of such an immunological method would allow to further study the role 
of cS100A12 in inflammatory diseases, such as IBD, in canine patients. 
 
2.2.  Materials and methods 
2.2.1.  Materials 
 Unless otherwise indicated, all research materials were purchased from VWR, 
West Chester, PA, USA. All chemical reagents were obtained from Sigma-Aldrich, St. 
Louis, MO, USA, and were at least of analytical grade. All solutions were prepared in 
aqua bidestillata (Milli-Q), filtered (0.2 μm), and degassed. Whole blood from healthy 
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dogs was collected in accordance with a protocol approved by the University Laboratory 
Animal Care Committee at Texas A&M University (AUP# 2006-145). 
 
2.2.2.  Preparation of leukocytes and extraction of the cytosol fraction 
 Leukocytes were isolated as previously reported (Heilmann et al., 2008). Briefly, 
after mixing two volumes of EDTA blood with one volume of a 6% (w/v) dextran (T-
500) solution containing 0.9% (w/v) NaCl and sedimentation at room temperature 
(approximately 23 °C) for 180 min, the supernatant layer was collected and leukocytes 
were pelleted by centrifugation at 2000×g for 10 min at 4 °C. Remaining erythrocytes 
were lysed by incubating the sediment with RBC lysis solution (Qiagen, Valencia, CA, 
USA), followed by centrifugation as described above and storage of the pellets at -80 °C 
until further use. 
 Leukocyte pellets were resuspended in 20 mM Tris/HCl, 50 mM NaCl, pH 7.6 
containing 15 mM diisopropylfluorophosphate (DFP) and the cytosol fraction was 
extracted as has been described previously (Heilmann et al., 2008). Briefly, after 
homogenizing the solution for 5 min at room temperature (approximately 23 °C), the cell 
suspension was sonicated for 12 min at 50% intensity (150 W) on ice and subjected to 
two successive cycles of freezing (-20 °C), thawing and sonication. The soluble 
cytosolic fraction was then separated from cell debris by centrifugation at 16,000×g for 
12 min at 4 °C. 
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2.2.3.  Ammonium sulfate precipitation and hydrophobic interaction chromatography 
(HIC) 
 The soluble cytosol fraction of leukocytes was precipitated by adding ammonium 
sulfate to a final concentration of 30% (w/v). After centrifugation at 12,000×g for 25 
min at 1 °C, the supernatant was collected and adjusted to a final concentration of 2 mM 
CaCl2. Afterwards, the solution was filtered through a 0.1 μm-pore size filter and applied 
to a phenylsepharose HIC column (HiTrap™ Phenyl FF, GE Healthcare, Piscataway, 
NJ, USA) equilibrated with 20 column volumes of 20 mM Tris/HCl, 2 mM CaCl2, 1.55 
M (NH4)2SO4, pH 7.6 at a flow rate of 0.5 ml/min at room temperature on a fast protein 
liquid chromatography (FPLC) system (ÄKTA basic, GE Healthcare). Proteins bound to 
the column were eluted in a linear gradient of 0-100% 20 mM Tris/HCl, 5 mM EGTA, 
pH 7.6 over 200 min, and were analyzed by automated fluorescence-based reducing gel 
electrophoresis in a chip format (Protein 80 assay) using a Bioanalyzer 2100 system 
according to the manufacturer’s instructions (Agilent Technologies, Palo Alto, CA, 
USA). 
 
2.2.4.  Ion-exchange chromatography 
 Canine S100A12 containing fractions eluted from the HIC column were pooled 
and dialyzed against 50 mM CH3CO2Na, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 50 
mM NaCl, pH 5.0 (buffer A) using dialysis bags (2000 MW cutoff; Thermo Scientific, 
Waltham, MA, USA), clarified by 0.1 μm-filtration and subjected to strong cation-
exchange chromatography. The column (Econo-Pac
®
 High S, Bio-Rad Laboratories, 
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Hercules, CA, USA) was equilibrated with 25 column volumes buffer A at a flow rate of 
1 ml/min at approximately 23 °C, and fractions were eluted with a linear gradient of 
0.05-0.5 M NaCl in buffer A over 120 min and were again analyzed by the Protein 80 
assay. 
 Fractions containing cS100A12 were then pooled and dialyzed against 50 mM 
Tris/HCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 25 mM NaCl, pH 8.5 (buffer B) 
using dialysis cassettes (2000 MW cutoff; Thermo Scientific), filtered (0.1 μm-pore size) 
and applied to a strong anion-exchange chromatography column (HiPrep™ Q, GE 
Healthcare) equilibrated with 12 column volumes buffer B at a flow rate of 1 ml/min at 
room temperature. Elution of proteins bound to the column was achieved by application 
of a linear gradient of 0.025-0.25 M NaCl in buffer B over 180 min, and the fractions 
eluted were again analyzed by the Protein 80 assay. Fractions containing cS100A12 
were pooled, dialyzed against 50 mM NH4HCO3, pH 7.64 (buffer C) and lyophilized 
(Freeze Dry System, Labconco, Kansas City, MO, USA), followed by re-dissolution in 
20 mM CH3CO2Na, 3 mM CaCl2, pH 7.6 (buffer D) and storage at -80 °C. 
 
2.2.5.  Gel electrophoresis 
Protein purity was assessed by reducing sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE, 10% Bis/Tris) in a vertical mini-gel format (Invitrogen, 
Carlsbad, CA, USA), and protein bands were visualized by staining with Coomassie 
brilliant blue R-250 (Thermo Scientific) according to the manufacturers’ instructions. 
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 Native polyacrylamide gel electrophoresis (PAGE) was performed by use of the 
Mini-Protean
®
 3 electrophoresis cell and a discontinuous buffer system (Ornstein-Davis) 
according to the standard procedures given by the manufacturer (Bio-Rad Laboratories). 
The acrylamide concentration of the separating gel was optimized at 8, 10, 12 and 15%, 
and electrophoresis was performed at a constant voltage of 125 V for 70 min followed 
by Coomassie brilliant blue staining of the gels. Using native PAGE, pure cS100A12 
was evaluated in the presence of 0.3 mM Ca
2+
, 3 mM Ca
2+
, 10 mM Ca
2+
, 3 mM Ca
2+
 and 
5 mM or 10 mM Zn
2+
, 10 mM Ca
2+
 and 5 mM or 10 mM Zn
2+
 and 10 mM EGTA. 
 Scanned images of the respective gels were analyzed using the Quantity One
®
 
v4.6.5 software (Bio-Rad Laboratories). 
 
2.2.6.  Protein concentration assay 
 Protein concentration was measured using the Bradford dye-binding method 
(Bradford et al., 1976) with bovine serum albumin (BSA) as a reference protein in 
accordance with the manufacturer’s instruction (Bradford protein assay, Thermo 
Scientific). 
 
2.2.7.  Western blotting 
 Following reducing SDS-PAGE, electroblotting of proteins onto 0.2 μm-pore 
size polyvinylidene fluoride (PVDF) membranes was performed as described elsewhere 
(Heilmann et al., 2008a). Membranes were then blocked overnight at 4 °C by immersion 
in 10 mM Tris/HCl, 150 mM NaCl, 0.05% (v/v) polyoxyethylene sorbitan monolaurate, 
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pH 7.6 (blot buffer) supplemented with 5% (w/v) BSA (blocking buffer). All subsequent 
steps were carried out at approximately 23 °C on an orbital shaker at 80 rpm, unless 
otherwise stated. Blots were incubated for 3 h with the rabbit polyclonal anti-
recombinant human (rh) S100A12 antiserum (Novus Biologicals, Littleton, CO, USA) at 
a dilution of 1/300 or with the rabbit polyclonal anti-rhS100A12 ab37657 (Abcam, 
Cambridge, MA, USA) at a dilution of 1/250 in blocking buffer, then washed 4×5 min in 
blot buffer, and incubated with biotin-conjugated goat anti-rabbit IgG (Thermo 
Scientific) as secondary antibody for 2.5 h (dilution of 1/10,000 in blocking buffer). 
After 4×5 min washes with blot buffer, the membranes were incubated for 2 h with 
horseradish peroxidase-conjugated NeutrAvidin (Thermo Scientific) at a concentration 
of 0.3 mg/l in blot buffer supplemented with 5% (w/v) BSA. Again, the membranes were 
washed in blot buffer, and the antigen-antibody complexes were detected by incubation 
for 20 min at 37 °C with a stabilized 3,3’,5,5’-tetramethylbenzidine blotting substrate 
(Thermo Scientific). 
 
2.2.8.  Determination of molecular weight and relative molecular mass 
 Automated fluorescence-based reducing gel electrophoresis (Protein 80 assay; 
Agilent Bioanalyzer 2100) was used to estimate the molecular weight (MW) of 
cS100A12. 
 The relative molecular mass (Mr) of cS100A12 was estimated by surface-
enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-
MS; ProteinChip
®
 SELDI System, Bio-Rad Laboratories). Briefly, 220 ng of purified 
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cS100A12 were immobilized onto a Normal Phase (NP) 20 ProteinChip
®
 array using 
12.5 mg/ml 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid, SPA) in 
ACN:H2O:TFA (50:49.5:0.5) to allow desorption/ionization of the protein. Ten different 
TOF spectra were generated by 210 laser shots with a laser intensity of 1400 nJ each 
(partition 9.8%), and Mr accuracy was calibrated externally by use of the All-in-One 
protein standard solution covering a mass-to-charge ratio (m/z) range between 6,964 and 
147,300. 
 
2.2.9.  Isoelectric point 
 The isoelectric point (pI) was estimated by native isoelectric focusing (IEF) on a 
vertical format pre-cast polyacrylamide IEF gel covering a linear pH gradient from 3 to 
10 (Invitrogen). Hereafter, proteins were applied to the second dimension (2D-PAGE) 
consisting of native and non-reducing SDS-PAGE (12% Tris-glycine, Invitrogen), 
respectively. Protein bands were visualized by Coomassie blue stain. 
 
2.2.10.  Specific absorbance 
 The specific absorbance of cS100A12 was determined by the quotient of the 
spectrophotometric absorbance of serially diluted samples containing pure cS100A12 
measured at a wavelength of 280 nm (NanoDrop™ 1000, Thermo Scientific) and the 
corresponding protein concentrations determined by means of a Bradford assay. 
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2.2.11.  Tryptic peptide mass fingerprint (PMF) 
 Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF-MS) was used for the fingerprinting of peptides generated by tryptic 
digestion (PMF). Following SDS-PAGE, Coomassie blue staining and SDS removal, an 
in-gel proteolytic digestion was performed by incubation of the excised and destained 
protein band in 20 mg/ml bovine pancreatic trypsin in 22.5 mM ammonium bicarbonate, 
1 mM HCl, pH 8.0 for 16 h at 37 °C. Then, 2 ml of the extraction mixture were applied 
to a ProteinChip
®
 NP20 array using 200 mg/ml alpha-cyano-4-hydroxy cinnamic acid 
(CHCA) in ACN:H2O:TFA (50:49.5:0.5) as a matrix to facilitate desorption and 
ionization of peptides (Devarajan and Ross, 2008). Ten different TOF spectra were 
acquired at 210 laser shots with a laser intensity of 900 nJ each (partition 9.8%), and Mr 
accuracy was calibrated externally by use of the ProteinChip
®
 Peptide mass standard 
array covering a mass range between 1,084 and 5,964 (Bio-Rad Laboratories). After 
peptide masses were extracted from the mass spectra by use of the Peak-Erazor software 
(GPMAW. PeakErazor V.2.01; available at: http://www.gpmaw.com; accessed 08-12-
2009), in silico analysis was performed by searching the data obtained against a 
comprehensive database (Ensembl Genome Browser web-site. Canis Familiaris 
[CanFam2.0]; available at: http://www.ensembl.org; accessed 08-10-2009) using the 
ProFound search site (PROWL. ProFound; available at: http://prowl.rockefeller.edu; 
accessed 08-12-2009). The mass tolerance for matching peptide average masses was set 
at 100 ppm, and a maximum of 1 missed cleavage of trypsin was allowed in the search 
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that was restricted to the species (Canis familiaris) as well as the biochemical properties 
(pI and mass range) of the protein. 
 
2.2.12.  N-terminal amino acid sequence analysis 
 To ascertain protein identity, the N-terminal amino acid (AA) sequence of 
cS100A12 was analyzed by the Edman degradation method on a Model 492 automated 
protein sequencing system (Applied Biosystems, Foster City, CA, USA) at the Protein 
Chemistry Laboratory (Department of Biochemistry and Biophysics, Texas A&M 
University, College Station, TX, USA), followed by sequence comparison against a 
comprehensive database (Ensembl Genome Browser web-site. Canis Familiaris 
[CanFam2.0]; available at: http://www.ensembl.org; accessed 08-10-2009). 
 
2.2.13.  Purification of canine S100A8 
 The complex of the proteins cS100A8 and cS100A9 (canine calprotectin) was 
isolated from canine whole blood as described previously (Heilmann et al., 2008). 
During strong cation-exchange chromatography a minor fraction of cS100A8 was 
separated from the complex protein, and the identity of cS100A8 was ascertained by N-
terminal AA sequencing using the Edman degradation method. 
 
2.2.14.  Immunologic cross-reactivity 
 Polyclonal antibodies against cS100A12 were raised in New Zealand White 
rabbits by repeated inoculation with pure cS100A12 emulsified in complete and 
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incomplete Freund’s adjuvant as described previously (Vaitukaitis et al., 1971). 
Immunologic cross-reactivity between canine, feline, bovine, porcine, ovine, caprine, 
equine, marmoset, meerkat, sea lion and penguin S100A12 was evaluated by 
precipitation of the respective serum (all surplus samples from other research studies) 
against rabbit anti-canine S100A12 antiserum using radial double immunodiffusion 
(Ouchterlony test). An Ouchterlony test was also performed for extracts from fecal 
samples collected from dogs with hemorrhagic gastroenteritis as well as from healthy 
dogs, the purified cS100A8 monomer and the cS100A8/A9 complex (canine 
calprotectin). To demonstrate specificity of the rabbit anti-cS100A12 antiserum, a 
modified Western blot was used to analyze the affinity of the antibody against canine 
serum samples (at a dilution of 1:20), canine fecal extracts (at a dilution of 1:500), the 
soluble cytosol fraction of leukocytes as well as a sample from each of the following 
purification stages, pure cS100A12 in buffer D (positive control), and BSA (negative 
control). Immunodetection was performed as described above except that rabbit anti-
cS100A12 was used as primary antibody (primary antiserum dilution 1/2000 in blocking 
buffer) and the secondary antibody (biotin-conjugated goat anti-rabbit IgG) was diluted 
1/25,000 in blocking buffer. 
 
2.3.  Result 
2.3.1.  Purification of canine S100A12 
 Canine S100A12 was successfully purified from the cytosol fraction of canine 
leukocytes, and the summary of an exemplary purification procedure of cS100A12 is 
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presented in Table 1 and Fig. 14. The extracted cytosol fraction of canine leukocytes 
containing a maximum of 200 mg total protein was subjected to ammonium sulfate 
 
 
 
Table 1 – Purification of cS100A12 after various purification steps. 
 
Purification stage 
Total protein content 
(mg) 
Extraction of leukocyte cytosol fraction 165.3 
Ammonium sulfate precipitation 119.2 
Hydrophobic interaction chromatography     7.7 
Cation-exchange column 
chromatography     1.9 
Anion-exchange column chromatography     1.5 
Concentration (lyophilization and 
storage)     1.5 
 
 
 
 
 precipitation followed by injection onto a phenylsepharose hydrophobic interaction 
chromatography cartridge, where the majority of cS100A12 was eluted at approximately 
53.3% buffer B (Fig. 15a). Fractions containing cS100A12 were further fractionated on 
an S-Sepharose™ cation-exchange and a Q-Sepharose™ anion-exchange column, where 
cS100A12 eluted in a symmetric peak each at approximately 0.19 M NaCl and 0.09 M 
NaCl, respectively (Figs. 16a and 17a). During the Protein 80 assay, cS100A12 revealed 
a distinct peak at approximately 7,730 (Figs. 15b and 16b, and 17b). Once polyclonal 
antibodies (pAb) were produced in rabbits, the progress of the purification procedure 
could be monitored by Western blot analysis. With the detection system used, the rabbit 
anti-cS100A12 antiserum strongly recognized cS100A12, and there was no cross-
 62 
 
 
reactivity observed with either the complex of canine S100A8/A9 (canine calprotectin) 
or cS100A8 alone. Using the pAb anti-rhS100A12 and ab37657, however, did not result 
 
 
 
 
 
 
 
Figure 14 – Purification of cS100A12. This figure shows an SDS-PAGE of samples 
collected after each purification step. The following material was loaded into the lanes: 
lane 1, extracted cytosol fraction of canine leukocytes; lane 2, supernatant collected after 
ammonium sulfate precipitation; lane 3, pool of fractions containing cS100A12 after 
hydrophobic interaction chromatography; lane 4, pool of fractions that contained 
cS100A12 following strong cation-exchange chromatography; lane 5, pure cS100A12 
after strong anion-exchange chromatography; lane 6, pure cS100A12 after concentration 
by lyophilization and reconstitution in storage buffer. 
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Figure 15 – (a) Hydrophobic interaction chromatography of the extracted cytosol 
fraction of canine leukocytes. Proteins bound to the column were eluted by a linear 
gradient of 1.55-0.0 M (NH4)2SO4, 2.0-0.0 M CaCl2, and 0.0-5.0 mM EGTA in buffer A 
(open squares). The protein elution profile was obtained by UV absorption at 280 nm 
(bold line). Peak labeled A12: canine S100A12. (b) Protein 80 assay (reducing 
conditions) of the fractions eluted from the hydrophobic interaction chromatography 
column. The majority of cS100A12 eluted in a single major peak (labeled A12). 
Migration time (tM) proportional to the size (MW) of the proteins is indicated on the x-
axis. A standard curve of tM versus MW is plotted and used to calculate MW for each 
fragment in the sample based on tM measured. MW markers: 1600 (lower marker, LM), 
3500 (system peak, SP; quality control for each sample run), 6500, 15,000, 28,000, 
46,000, 63,000 and 95,000 (upper marker, UM). 
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Figure. 16 – (a) Cation-exchange column chromatography of fractions containing 
cS100A12 from hydrophobic interaction chromatography. Bound proteins were eluted 
by a linear NaCl gradient of 0.05-0.50 M in buffer A (open squares). The protein elution 
profile was obtained by UV absorption at 280 nm (bold line). Peak labeled A12: canine 
S100A12. (b) Protein 80 assay (reducing conditions) of the fractions eluted from the 
cation-exchange column. Canine S100A12 (peak A12) eluted in a single major peak. 
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Figure 17 – (a) Anion-exchange column chromatography of cS100A12-containing 
fractions following cation-exchange chromatography. Proteins bound to the column 
were eluted with an increasing concentration of buffer B containing 0.25 M NaCl (open 
squares) and monitored at 280 nm absorbance (bold line). Peak labeled A12: canine 
S100A12. (b) Protein 80 assay (reducing conditions) of purified fractions obtained from 
anion-exchange chromatography. Canine S100A12 (peak A12) was localized in one 
peak. 
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in the detection of any protein bands. The overall yield of the purification protocol was 
1.5 mg per 900 ml canine whole blood, and similar proportions were obtained by 
repeating the protocol two times. Stability of purified cS100A12 in buffer D (20 mM 
CH3CO2Na, 3 mM CaCl2, pH 7.6) was demonstrated after storage at -80 °C for 9 months 
by means of the Bradford assay and SDS-PAGE. 
 Due to the restricted MW analysis range of the Protein 80 assay (5,000-80,000), 
purity of cS100A12 in buffer D (storage buffer) was evaluated by SDS-PAGE (under 
reducing conditions) and revealed a single band in the expected MW range for cS100A12 
(7,300; Figs. 14 and 18). On SDS-PAGE under non-reducing conditions, a single protein 
band consistent with the respective monomeric form of cS100A12 was also observed 
(not shown). However, native PAGE revealed a major protein band consistent with the 
homodimeric form of cS100A12 and this was seen regardless of the presence of Ca
2+
 
ions or EGTA in the buffer (16,800; Fig. 18). A very minor fraction of the protein 
migrated as a homotetramer (with a MW of approximately 36,800) on native PAGE when 
the buffer contained 10 mM Ca
2+
 (Fig. 18), 10 mM Ca
2+
 and 5 mM Zn
2+
, or 10 mM Ca
2+
 
and 10 mM Zn
2+
, respectively. In buffers containing various concentrations of only Ca
2+
, 
Ca
2+
 and Zn
2+
 ions, or EGTA, no precipitation of cS100A12 was observed. 
 
2.3.2.  Purification of canine S100A8 
 A minor fraction of cS100A8 eluted with a distinct peak from the strong cation-
exchange column at approximately 0.25 M NaCl and was successfully isolated from the 
cS100A8/A9 protein complex. For the 15 N-terminal AA a sequence with the single 
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letter code MLTELESAINSLIEV was identified and revealed complete identity with the 
primary sequence published for cS100A8 (Ensembl Genome Browser web-site. Canis 
Familiaris [CanFam2.0]; available at: http://www.ensembl.org; accessed 08-10-2009). 
 
 
 
 
 
 
 
Figure 18 – Purity and dimer formation of purified cS100A12. (a) On the SDS-PAGE 
(10% Bis/Tris gel) under reducing conditions, cS100A12 represents a polypeptide chain 
with a MW of approximately 7300 (lane 1). (b, c) Native PAGE (10% Tris-glycine gel) 
yielded a molecule with a MW of approximately 16,800 (lane 2) and a very small fraction 
with an MW of approximately 36,800 (arrow) when the buffer contained 10 mM Ca
2+
 
(lane 3; 15% Tris-glycine gel), 10 mM Ca
2+
 and 5 mM Zn
2+
, or 10 mM Ca
2+
 and 10 mM 
Zn
2+
, respectively (not shown). MW, molecular weight markers. 
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2.3.3.  Partial characterization of canine S100A12 
 The Mr of cS100A12 was estimated at 10,379.5, and a doublet peak 
corresponding to the monomer of cS100A12 was the most intense signal in each of the 
spectra. A minor doublet peak detected was assigned to a non-specific double charged 
monomer of the protein (Fig. 19), and reducing SDS-PAGE excluded the possibility that 
this minor peak may have arisen from a contaminating substance. 
 Isoelectric focusing of cS100A12 revealed a single band in the presence as well 
as the absence of Ca
2+
 or EGTA in the solution (Fig. 20), which migrated as a 
homodimer in the second dimension consisting of native PAGE compared to a monomer 
during SDS-PAGE. 
 The approximate specific absorbance of cS100A12 at 280 nm was determined to 
be 1.78 for a 1 mg/ml solution. 
 Characterization of peptides generated by tryptic digestion revealed the 
separation of 16 different peaks with m/z values of 955, 1,399, 1,615, 1,679, 1,864, 
1,909, 2,072, 2,275, 2,528, 2,874, 2,987, 3,217, 3,286, 3,629, 4,252, and 4,861. As 
determined by in silico comparison, the m/z ion values of these peaks correlated well 
with the expected m/z values of digest fragments for the complete AA sequence of 
cS100A12 (Ensembl Genome Browser web-site. Canis Familiaris [CanFam2.0]; 
available at: http://www.ensembl.org; accessed 08-10-2009; PROWL. ProFound; 
available at: http://prowl.rockefeller.edu; accessed 08-12-2009) and covered 68% of the 
total length of the AA sequence of the protein. 
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 The AA sequence of the first 15 N-terminal residues was obtained for this 
protein, with the single letter code TKLEDHXEGIVDVFH (X denotes the AA at 
position 7, which was not unambiguously identified) (Table 2). A database search 
(Ensembl Genome Browser web-site. Canis Familiaris [CanFam2.0]; available at: 
 
 
 
 
 
 
 
Figure 19 – SELDI-TOF-mass spectrum of the purified cS100A12. Mr (m/z) range was 
5000-40,000. Average of 10 single shot spectra. To ensure accurate protein Mr 
assignments, generated TOF-mass spectra were externally calibrated using Mr standards 
(recombinant hirudin (6964), bovine cytochrome c (12,230), equine cardiac myoglobin 
(16,951), bovine RBC carbonic anhydrase (29,023), yeast (S. cerevisiae) enolase 
(46,671)). A doublet peak corresponding to the singly charged cS100A12 monomer 
(m/z: 10,379.5; peak A12) yielded the most intense signal. A non-specific double 
charged monomer of the protein was also detected (m/z approximately 5178.3), but no 
other multimeric forms were evident. 
 
 
 
 70 
 
 
 
 
 
 
Figure 20 – IEF of purified cS100A12. In a Ca2+-free solution as well as in a buffer 
containing 3 mM Ca
2+
, one band was detected with an approximate pI of 6.0, which 
migrated to a 6.9 kDa position in the second dimension on a gel containing SDS and to a 
15.8 kDa position in the second dimension on a native gel (not shown). Left lane, IEF 
markers. 
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Table 2 – N-terminal amino acid (AA) sequence of canine, feline, equine, bovine, porcine, and human S100A12. 
 
Species  S100A12 NT (15) HNT(14) (%) HES (%) 
Canis familiaris (dog) (M) T K L E D H  X E G I V D V F H 100.0 100.0 
Felis catus (cat) (M) T K L E E H (L) E G I I N V F H   78.6   73.6 
Equus caballus 
(horse) (M) T K L E D H (L) E G V I N I F H   71.4   72.5 
Bos taurus (cow) (M) T K L E D H (L) E G I I N I F H   78.6   70.3 
Sus scrofa (pig) (M) T K L E D H (L) E G I I N I F H   78.6   68.1 
Homo sapiens 
(human) (M) T K L E E H (L) E G I V N I F H   78.6   63.7 
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http://www.ensembl.org; accessed 08-10-2009) using the 14 AA analyzed revealed 
complete identity with the primary sequence predicted from the cDNA sequence for 
cS100A12 with the exception that the first methionine residue was cleaved off from the 
protein. Thus, the protein purified was identified as pure canine S100A12 (cS100A12). 
The highest homology was found with cS100A8 and cS100A9 (38.5 and 44.6% identity, 
respectively [Ensembl Genome Browser web-site. Canis Familiaris [CanFam2.0]; 
available at: http://www.ensembl.org; accessed 08-10-2009]). 
 Radial double immunodiffusion yielded a single strong precipitin line between 
rabbit anti-cS100A12 antiserum and some canine sera from dogs with an unknown 
disease status, extracts of fecal samples collected from dogs with acute hemorrhagic 
gastroenteritis, and porcine serum (Fig. 21). However, no reactivity was found against 
feline, bovine, ovine, caprine, equine, marmoset, meerkat, sea lion and penguin serum. 
No precipitation occurred between rabbit anti-cS100A12 antiserum and extracts of fecal 
samples from healthy dogs, purified cS100A8 and cS100A8/A9, respectively. Western 
blot analysis using the anti-cS100A12 antiserum clearly revealed one band at a MM of 
approximately 7.8 kDa in samples from each of the purification stages, canine fecal 
extracts, and purified cS100A12, whereas the rabbit anti-cS100A12 pAb only weakly 
recognized cS100A12 in canine serum samples. No bands were detected for BSA. 
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Figure 21 – Radial double immunodiffusion (Ouchterlony test). Radial double 
immunodiffusion yielded a single strong precipitin line between rabbit anti-cS100A12 
antiserum and some canine sera (S1, S3), extracts of fecal samples collected from dogs 
with acute hemorrhagic gastroenteritis (F1, F3), and porcine serum (PS). However, no 
precipitation occurred between rabbit anti-cS100A12 antiserum and some canine sera 
(S2, S4), extracts of fecal samples collected from healthy dogs (F2, F4), purified 
cS100A8 (A8) and cS100A8/A9 (CP), respectively. P, positive control (purified canine 
S100A12 protein); N, negative control (BSA). 
 
 
 
 
2.4.  Discussion 
 Here we report the first purification of canine S100A12 (cS100A12) from canine 
whole blood using a rapid and reproducible protocol. Peptide mass fingerprinting and N-
terminal AA sequence analysis together allowed to confirm the identity of cS100A12. A 
rabbit polyclonal antibody raised against purified cS100A12 recognized the protein as 
determined by Western blot analysis and radial double immunodiffusion. Despite the use 
of a relatively sensitive detection system used for Western blot analysis, cS100A12 was 
not detected by two different pAb against recombinant human S100A12, where the 
efficiency of blotting was controlled for by staining the marker lane of the respective 
 74 
 
 
PVDF membrane as well as the gel with Coomassie blue following the transfer. This 
finding demonstrates that canine S100A12 (cS100A12) cannot be detected by use of 
these polyclonal antibodies produced against the human (recombinant) counterpart, the 
entire sequence of which has a 63.7% interspecies similarity with cS100A12 (Ensembl 
Genome Browser web-site. Canis Familiaris [CanFam2.0]; available at: 
http://www.ensembl.org; accessed 08-10-2009), and therefore substantiates the need for 
a species-specific immunologic method for the detection and quantification of 
cS100A12 in serum and fecal specimens from dogs. 
 The cS100A12 protein showed greatest homology with canine S100A8 (MRP8) 
and S100A9 (MRP14), both of which are consistent with those reported for human 
S100A12 (40% and 46% identity with human S100A8 and human S100A9, respectively 
[Ilg et al., 1996]). In this study, pAb raised against cS100A12 did not detect purified 
cS100A8 or the cS100A8/A9 complex as determined by radial immunodiffusion. While 
this finding is consistent with that for the respective human counterparts in one study 
(Robinson et al., 2000), it differs with those of other studies where polyclonal anti-
human S100A12 was found to be slightly cross-reactive to human S100A8 (Ilg et al., 
1996) or the human S100A8/A9 complex (Yang et al., 2001). Based on this finding, we 
speculate that the rabbit anti-cS100A12 pAb produced in this study is of valuable 
potential for the development of an analytically specific immunologic method for the 
detection of cS100A12. 
 The exposure of hydrophobic domains of the effector protein in order to interact 
with the respective targets has been shown for human S100A12 and several other 
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proteins belonging to the S100 superfamily (Hilt and Kligman, 1991). Leading to an 
altered chromatographic behavior of cS100A12 in the presence of Ca
2+
, this property 
was taken advantage of during the initial step of the purification procedure consisting of 
hydrophobic interaction chromatography, where cS100A12 was bound in the presence of 
2 mM Ca
2+
 and could be eluted from the cartridge by an increasing concentration of a 
Ca
2+
-free buffer containing 5 mM EGTA. To prevent any artefactual interaction with 
other reagents or materials due to an increased hydrophobicity in the presence of Ca
2+
, 
the buffers employed throughout the remaining purification stages contained DTT, 
EDTA, and EGTA, whereas the amount of Ca
2+
 in the storage buffer (3 mM) was chosen 
at a concentration similar to that found in extracellular biological fluid (Mischke et al., 
1996). 
 The pI value observed for cS100A12 is in agreement with the expected pI 
calculated based on the AA sequence (5.9) (ProteinProspector web-site. MS-Digest; 
available at: http://prospector.ucsf.edu; accessed 08.28.2009) and compares to that 
reported for human and porcine S100A12 (Ilg et al., 1996; Dell’Angelica et al., 1994). 
However, unlike in humans and porcines (Guignard et al., 1995; Dell’Angelica et al., 
1994), only one isoform was found for cS100A12. As the two different isoforms of the 
human counterpart have been demonstrated to exert different affinities for the binding of 
Ca
2+
 (Guignard et al., 1995), the possibility that cS100A12 molecules with a lower Ca
2+
-
binding affinity may have been eliminated during the HIC step of the purification 
procedure in this study cannot be ruled out. 
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 The MW of cS100A12 was determined to be approximately 7,730, which is 
consistent with the MM estimated by SDS-PAGE. As some Ca
2+
-binding proteins have 
been reported to show aberrant mobilities on SDS-PAGE gels, such as human S100A12 
due to its distinct nonspherical shape (Xie et al., 2007), a more precise determination of 
the relative molecular mass (Mr) of cS100A12 was aimed at using SELDI-TOF-MS 
analysis. Although purified cS100A12 appeared to be homogeneous during IEF, Protein 
80 assay, native and SDS-PAGE (revealing only one single band or peak formation, 
respectively) and N-terminal AA sequencing, SELDI-TOF-MS spectra unveiled the 
presence of two components. The m/z value of 10,379.5 that was revealed for the major 
component of cS100A12, is in good agreement with the expected masses derived from 
the AA sequence in the absence of the first methionine residue (10,376) 
(ProteinProspector web-site. MS-Digest; available at: http://prospector.ucsf.edu; 
accessed 08-28-2009), and compares to the Mr of human S100A12 as determined by 
SELDI-TOF-MS (10,444) (de Seny et al., 2008) and electrospray ionization mass 
spectrometry (ESI-MS; 10,444) (Ilg et al., 1996) but also to that of porcine (10,614 and 
10,654) (Dell’Angelica et al., 1994), bovine (10,554) (Hitomi et al., 1996) and rabbit 
S100A12 (10,680) (Yang et al., 1996). The absence of the N-terminal methionine 
residue has also been reported for human, porcine, bovine, and rabbit S100A12 (Ilg et 
al., 1996; Yang et al., 1996; Hitomi et al., 1996). The presence of a doublet peak with a 
difference in mass of about 208.2 and an m/z value for the second minor peak of 
approximately 10,587.7, could be speculated to indicate posttranslational modification of 
a minor fraction of cS100A12. This difference being the result of divalent cation binding 
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to the monomer cannot be ruled out but seems rather unlikely, especially because a 
buffer devoid of any such ions with the exception of Ca
2+
 (m/z ≈ 40) was used. A 
doublet peak has also been found for porcine S100A12 using electrospray ionization 
mass spectrometry (ESI-MS) (Dell’Angelica et al., 1994), where this difference in m/z 
was much smaller and therefore suggestive to be the result of Ca
2+
 binding to the 
S100A12 protein. The generated laser desorption/ionization-mass spectra also showed a 
smaller doublet peak with an m/z value of approximately 5178.3 and a peak area that 
was exceeded by that of the major peak by a factor of about 4–6. Therefore, this 
additional minor peak can be considered to represent a non-specific, double charged 
monomer of cS100A12. 
 In this study, the formation of a homodimer has been demonstrated for 
cS100A12 (Fig. 5) and was similar to the dimerization pattern shown for human 
S100A12 (with 2 Ca
2+
 ions per subunit) in the presence of >1 mM Ca
2+
 (Moroz et al., 
2003). Homohexamers were, however, not revealed for the cS100A12 protein but were 
for human S100A12 (with 3 Ca
2+
 ions per subunit) and proposed to be the extracellular 
form (Moroz et al., 2003). A possible explanation for this discrepancy could be that, 
while the AA residues found to participate in coordinating the canonical Ca
2+
 ions within 
the EF-hand (Moroz et al., 2003) are highly conserved between human and canine 
S100A12 (Ensembl Genome Browser web-site. Canis Familiaris [CanFam2.0]; available 
at: http://www.ensembl.org; accessed 08-10-2009), only one of the four residues shown 
to coordinate interdimer Ca
2+
 binding necessary for hexamer formation of human 
S100A12 (Moroz et al., 2003) exists in the AA sequence of cS100A12 as predicted from 
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cDNA analysis (Ensembl Genome Browser web-site. Canis Familiaris [CanFam2.0]; 
available at: http://www.ensembl.org; accessed 08-10-2009). These residues have been 
shown to vary widely among S100A12 from different species (Moroz et al., 2003), and 
the existence of two lysines instead of Glu-55 and Gln-64, both of which appear to be 
necessary for hexamer formation of human S100A12, suggests a structural similarity of 
cS100A12 with its bovine pendant, which has also been shown to lack a homohexameric 
form (Moroz et al., 2003; Ensembl Genome Browser web-site. Canis Familiaris 
[CanFam2.0]; available at: http://www.ensembl.org; accessed 08-10-2009). Further 
investigation comprising crystallography is, however, required to test this hypothesis. 
 The weak nature of non-covalent macromolecular interactions renders them 
relatively fragile to the disruptive nature of SDS and desorption/ionization processes 
during SELDI-TOF-MS analysis, thus resulting in their dissociation. In the presence as 
well as the absence of a strong reducing agent (DTT) during SDS-PAGE, cS100A12 
migrated to the same MW position within the gel that is consistent with the monomeric 
form, whereas during native PAGE it was shown to migrate as a homodimer (Fig. 5), 
which is consistent with results obtained for the human pendant (Miranda et al., 2001) 
and confirms our findings for cS100A12 in a preparative PAGE experiment under native 
conditions (data not shown). As has been reported for human S100A12 (Hatakeyama et 
al., 2004), the formation of a homodimer was found to occur both in the presence as well 
as in the absence of Ca
2+
, indicating that Ca
2+
 is not essential for cS100A12 
dimerization. These findings suggest that the native state of cS100A12 is dimeric with a 
non-covalent association of cS100A12 protein monomers. 
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 Homotetramerization of cS100A12 in a buffer with a higher Ca
2+
 molarity (with 
or without micromolar amounts of Zn
2+
) was evident under native conditions in this 
study, and thus interpreted to be also non-covalent in nature. The formation of higher 
order oligomers in the presence of Ca
2+
 and Zn
2+
 has been reported in humans and 
porcines (Moroz et al., 2009; Dell’Angelica et al., 1994), and the N-terminal AA His-15 
and Asp-25 together with the AA His-85 and His-89 in the C-terminal region of the 
protein that have been suggested to participate in the binding of Zn
2+
 ions (Moroz et al., 
2009) are also contained in the AA sequence of cS100A12 (Ensembl Genome Browser 
web-site. Canis Familiaris [CanFam2.0]; available at: http://www.ensembl.org; accessed 
08-10-2009). In view of the different composition of the intracellular and the 
extracellular milieu, further experiments are warranted to determine whether the 
homodimeric, the monomeric, or a higher order oligomeric form of cS100A12 occurs in 
vivo. 
 Immunologic cross-reactivity between different species serves as an indicator of 
high AA sequence similarity in the antigenic sites of a protein in these species. Given a 
high sequence divergence of a protein belonging to the highly conserved S100 
superfamily, as it has been reported for S100A12 from different species (Moroz et al., 
2003), a crossreactivity with porcine serum but not with feline, equine, or bovine serum 
was unexpected. This finding leads the authors to speculate that porcine S100A12 may 
present the highest sequence similarity with cS100A12 in the antigenic sites, although it 
is only conserved to 68.1% (as opposed to a 73.6, 72.5, and 70.3% AA sequence 
similarity of the feline, equine, and bovine pendant, respectively) (Ensembl Genome 
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Browser web-site. Canis Familiaris [CanFam2.0]; available at: http://www.ensembl.org; 
accessed 08-10-2009). Radial double immunodiffusion (RDI) yielded a precipitin line 
between rabbit anti-cS100A12 antiserum and canine sera from some dogs with an 
unknown disease status as well as extracts of fecal samples collected from dogs with 
acute hemorrhagic gastroenteritis but not from healthy dogs. While this may support the 
functional characterization of cS100A12, it should be noticed, however, that RDI is not a 
quantitative technique and an immunologic method for the quantification of cS100A12 
in serum and fecal samples from dogs is currently being developed. 
 In summary, this study is the first report of the successful purification and a 
partial characterization of canine S100A12. Similarities were found between canine, 
human, porcine, bovine, and rabbit S100A12 with regard to structural as well as 
biochemical properties (such as Mr and pI). It remains to be determined whether 
cS100A12 occurs as a homodimer, a monomer, or a higher order oligomer in vivo. 
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3. DEVELOPMENT AND ANALYTIC VALIDATION OF AN IMMUNOASSAY 
FOR THE QUANTIFICATION OF CANINE S100A12 IN SERUM AND            
FECAL SAMPLES AND ITS BIOLOGICAL VARIABILITY IN SERUM FROM 
HEALTHY DOGS
†
 
 
3.1  Introduction 
 In canine medicine, laboratory markers that aid in the detection and/or 
monitoring of localized (e.g., gastrointestinal, urogenital, or cerebrospinal) and/or 
systemic inflammation are needed but are currently scarce. Inflammatory diseases of the 
gastrointestinal tract, for example, often represent a diagnostic challenge for the 
veterinarian as it requires the integration of clinical signs, laboratory results, and 
frequently more invasive diagnostic modalities (i.e., upper and lower gastrointestinal 
endoscopy and histopathologic evaluation of tissue samples) (Washabau et al., 2010). Of 
markers examined to date, only the acute-phase protein C-reactive protein in serum 
appears to be useful for monitoring of canine patients with idiopathic gastrointestinal 
inflammation, although there is as yet no consensus as to this marker’s utility (Jergens et 
al., 2003; Jergens, 2004; Allenspach et al., 2007; McCann et al., 2007). Thus, objective 
markers that are minimally or noninvasive and will aid in the diagnosis and monitoring 
of disease activity and/or severity are needed in canine gastroenterology. 
                                                 
†
Reprinted with permission from Heilmann, R.M., Lanerie, D.J., Ruaux, C.G., Grützner, 
N., Suchodolski, J.S., Steiner, J.M., 2011. Development and analytic validation of an 
immunoassay for the quantification of canine S100A12 in serum and fecal samples and 
its biological variability in serum from healthy dogs. Veterinary Immunology and 
Immunopathology 144, 200-209, Copyright (2011) by Elsevier. 
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 A group of proteins that appear to represent good candidates as inflammatory 
markers are the calgranulins (S100A8, A9, and A12) as they reflect phagocyte activation 
and turnover in vivo. An immunoassay for the quantification of the canine S100A8/A9 
(or calgranulin A/B) complex has become available (Heilmann et al., 2008) and is 
currently being clinically validated. S100A12 (also referred to as calgranulin C, 
extracellular newly identified RAGE-binding protein (EN-RAGE), migration inhibitory 
factor-related protein (MRP)-6, or p6) is also a member of the calgranulin subfamily of 
S100 proteins (Ilg et al., 1996) that has been linked to both innate and acquired immune 
responses and thus, to acute and chronic inflammation (Hofmann et al., 1999; Föll et al., 
2004; Goyette and Geczy, 2011). S100A12 plays a role in intracellular homeostasis and 
is involved in extracellular processes such as chemotaxis, migration, activation, and 
sustained recruitment of leukocytes, oxidant scavenging, and generation of 
proinflammatory cytokines and chemokines (Miranda et al., 2001; Yang et al., 2001, 
2007), and thus represents an endogenous damage-associated molecular pattern (DAMP) 
molecule, or alarmin. Although its expression and functions are species-specific (Hsu et 
al., 2009), S100A12 is predominantly expressed in activated phagocytes (Vogl et al., 
1999), but can also be induced in keratinocytes (Mirmohammadsadegh et al., 2000) and 
eosinophils (Yang et al., 2007). Physiologic as well as pathologic (e.g., traumatic) 
stressors have been suggested to be the main modulators of calgranulin expression 
(Yang et al., 2001). 
 In humans, over-expression and/or increased concentrations of S100A12 in 
serum and/or stool samples have been detected in patients with inflammatory diseases, 
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such as rheumatoid arthritis (Föll et al., 2003a), respiratory disease (Föll et al., 2003b; 
Lorenz et al., 2008), and inflammatory bowel disease (Föll et al., 2003c; de Jong et al., 
2006; Kaiser et al., 2007; Leach et al., 2007; Sidler et al., 2008) for all of which serum 
S100A12 concentrations correlated well with disease activity. 
 An immunoassay for fecal and serum S100A12 measurement is currently 
available for human patients but antibodies against the human protein were shown not to 
immune cross-react with the canine analogue (Heilmann et al., 2010). The availability of 
an immunoassay for the measurement of cS100A12 would allow to further study the role 
and the diagnostic potential of cS100A12 in inflammatory diseases in canine patients. 
 Biological variation is an inherent characteristic of analytes in clinical chemistry 
and comprises within- as well as among-subject biological variation. Assessment of 
biological variation in healthy individuals may be used to assess the utility of 
population-based reference intervals for clinical chemistry analytes, and to derive critical 
change values (Fraser and Harris, 1989). Compared to establishing a reference interval, 
which requires a large reference sample group (Geffré et al., 2009), only a relatively 
small set of samples collected from a small group of individuals during a short time 
period is needed to study the biological variation of an analyte (Fraser and Harris, 1989). 
Given the possible future use of cS100A12 as a marker for disease activity in canine 
patients with inflammatory disorders, the investigation of its normal biological variation 
is warranted. 
 This study therefore aimed to develop and analytically validate an RIA for the 
quantification of cS100A12 in canine serum and fecal extracts as a potential clinical 
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marker in dogs with inflammatory conditions, and to evaluate the biological variability 
of serum cS100A12 in healthy dogs to determine the utility of a population-based 
reference interval for serum cS100A12. 
 
3.2  Materials and Methods 
3.2.1  Sampling population 
 Three groups of dogs were included in our study (Table 1): a group of 124 
healthy dogs of various breeds and ages that were used as reference individuals for 
serum cS100A12 concentrations (group A), 65 healthy dogs of various breeds and ages 
that were used as the reference sample group for fecal cS100A12 concentrations and to 
assess biological variability of cS100A12 concentrations in fecal samples (group B), and 
12 healthy pet dogs that were repeatedly sampled to determine the biological variability 
of cS100A12 concentrations in serum (group C). Surplus material was used for all 
remaining experiments.  
 
3.2.2.  Immunoassay development 
3.2.2.1.  Production of the tracer 
 A tracer was produced by labeling pure cS100A12 with radioactive iodine (
125
I) 
using the chloramine T method (Hunter and Greenwood, 1962). Briefly, 7.4 μg of 
previously purified cS100A12 (Heilmann et al., 2010) were dissolved in 0.25 M sodium 
phosphate (pH 7.5), and 7.4 μL Na125I (0.74 mCi at the time of production) and 20 μg 
chloramine T were added. After 40 s incubating at approximately 23 °C, 40 μg sodium 
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metabisulfite and 1.72 mg potassium iodide were added to a final volume of 1 mL. 
125
I-
tagged cS100A12 and free 
125
I were separated by size exclusion (PD-10 Desalting 
column, GE Healthcare Bio-Sciences, Piscataway, USA) and buffer-exchanged against 
0.05 M sodium phosphate, 0.02% (w/v) NaN3, 0.5% (w/v) BSA; pH 7.5 (RIAB). The 
125
I-labeled cS100A12 containing fractions were tested with the antiserum and selected 
based on a low non-specific binding (NSB, <1%) at a tracer-binding ratio for the zero 
standard (B0/TC) of approximately 30% (Berson and Yalow, 1968). Tracer was diluted 
in RIAB to approximately 30,000 cpm, and stored until further use during the RIA. 
Specific activity of the tracer was estimated (Chiang, 1987) and stability of 
125
I-labeled 
cS100A12 at different storage conditions investigated over 42 days (Law, 1996): 
aliquots of tracer were stored at +4 or −20°C at approximately 0.2 or 2.3 mCi/L in 
polypropylene containers, or at 4°C and approximately 0.2 mCi/L in non-inert glass 
containers. 
 
3.2.2.2.  Polyclonal antiserum production 
 Polyclonal antisera against purified cS100A12 (Heilmann et al., 2010) were 
generated in two New Zealand White rabbits (Oryctolagus cuniculus). Both animals 
were repeatedly inoculated s.c. with pure cS100A12 emulsified in complete (CFA) and 
incomplete Freund’s adjuvant (IFA). The initial inoculation of both rabbits consisted of 
200 μg cS100A12 in CFA, and was followed by two booster injections with 150 μg 
cS100A12 each in IFA every three weeks and another booster four weeks later. Due to 
an insufficient Ab response, one rabbit continued to receive four monthly boosters of 
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200 μg cS100A12 in IFA s.c. into the prescapular nodal area. Ten days after each 
inoculation, blood samples were collected for evaluation of Ab titers using a simplified 
RIA and reactivity of the antisera was tested by radial double immunodiffusion as 
described (Heilmann et al., 2010). Anti-cS100A12 antiserum from the rabbit that 
received four injections, collected following the third booster injection, was selected for 
the RIA with a final dilution of 1:12,000. 
 
3.2.2.3.  Radioimmunoassay development 
 The RIA was conducted in polypropylene tubes. Each tube received 100 μL 
cS100A12 standard (serial 2-fold dilution from 200.0 to 0.2 μg/L), serum (1:20 diluted) 
or fecal extract (in a 1:8 or 1:160 dilution) in RIAB, 100 μL antiserum (diluted 1:4000) 
in RIAB containing 0.05% polyoxyethylene sorbitan monolaurate and 10 mM EDTA, 
and 100 μL tracer. For the zero standard (B0), the cS100A12 standard was replaced by 
RIAB. NSB tubes received 200 μL RIAB with 0.025% polyoxyethylene sorbitan 
monolaurate and 5 mM EDTA, and 100 μL 125I-labeled cS100A12. Total count (TC) 
tubes contained 100 μL of tracer each. Following 4 hours of incubation at approximately 
23 °C, 100 μL rabbit carrier serum (Rabbit serum [sterile-filtered], Sigma–Aldrich, St. 
Louis, USA; diluted 1:100 in RIAB) and 1 mL 2° antibody solution (Precipitating 
solution (N6), Diagnostic Products Corporation, Los Angeles, USA) were added to all 
tubes except TC, free fractions were separated from bound fractions by centrifugation 
for 30 min at 3,360×g and 4°C, and the remaining pellets were washed with RIAB. 
Tubes were analyzed using an automated γ-counter (Wallac 1470 WIZARD, Perkin 
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Elmer Life and Analytical Sciences, Wellesley, USA) and software (MultiCalc
®
 
software, Perkin Elmer Life and Analytical Sciences, Wellesley, USA) to calculate a 
5PL-curve fit (y = f [x] = d + [(a–d)/(1 + (x/c)b)e]; y is the dependent variable, x is the 
independent variable, and a through e describe the shape of the curve) (Gottschalk and 
Dunn, 2005). Standard concentrations of cS100A12 (log scale) defined the abscissa, and 
ordinates were calculated as y = [(Bstd/B0)×100] (Midgley et al., 1969) where Bstd is the 
NSB-subtracted cpm for the standard and B0 the NSB-subtracted cpm obtained for B0. 
Sample concentrations of cS100A12 (in μg/L serum or ng/g feces) were determined by 
plotting the NSB-subtracted cpm against the standard curve. Samples with a cS100A12 
concentration beyond the standard range of the assay were further diluted and re-
assayed. Aliquots of diluted fecal extracts with low, moderate, and high cS100A12 
concentrations were stored at −80°C, and served as quality controls. 
 
3.2.3.  Immunoassay analytical validation 
3.2.3.1.  Collection and processing of serum and fecal specimens 
 Serum was obtained from 124 healthy dogs (group A; Table 3). The protocol for 
collection of blood samples from healthy dogs was reviewed and approved by the 
Clinical Research Review Committee at Texas A&M University. Fecal samples were 
collected from 65 healthy dogs (group B). All dogs were vaccinated, had been de-
wormed regularly, did not show clinical signs of any disease, and did not have any 
condition or receive any medications known to affect the gastrointestinal tract. Feces 
were collected, placed in pre-weighed polypropylene tubes (Fecal collection tube, 
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Table 3 – Number of animals, age, and sex distribution within the groups of dogs included in the study. 
 
 
Study part Group N 
Age, 
median 
[range] 
Sex 
male [neutered] / 
female [spayed] 
Determination of reference intervals 
Reference interval, serum A 124 4.5 [0.8–13.5] 55 [40] / 69 [56] 
Reference interval, feces
‡
  B
‡
 65
‡
 4.0 [0.8–11.1] 32 [31] / 43 [20] 
 
Analyte biological variation 
Biological variability, serum C 11 3 [2–8] 4 [4] / 7 [6] 
Biological variability, feces
‡
 B
‡
 65
‡
 4.0 [0.8–11.1] 32 [31] / 43 [20] 
‡
same dogs/samples 
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Sarstedt AG & Co., Nümbrecht, Germany), and immediately frozen until further use. 
Feces were then thawed and extracted using a previously established protocol (Heilmann 
et al., 2008). Fecal extracts were stored at −80°C until assayed. 
 
3.2.3.2.  Radioimmunoassay analytical validation 
 The minimum detection limit of the RIA was determined by analyzing 20 
duplicates of B0 in the same assay run, and calculating the mean and SD. The cS100A12 
concentration that corresponded to the mean cpm minus three SD plotted against the 
standard curve, was defined as lower limit of detection of the RIA. The upper limit of 
the working range was determined by evaluating ten duplicates of a solution containing 
cS100A12 in a concentration ten times the top standard in the same assay run (i.e., 2000 
μg/L), and calculating the mean and SD. The cS100A12 concentration that corresponded 
to the mean cpm plus three SD was defined as maximum cS100A12 concentration 
detectable by the RIA (upper limit of the working range). Analytical specificity was 
determined by assessing cross-reactivity of the RIA with 0.2–20,000 μg/L cS100A8/A9, 
the closest structural analogues of cS100A12 available. To determine linearity, accuracy, 
precision, and reproducibility of the RIA, surplus samples with low, moderate, and high 
cS100A12 concentrations were tested. Assay linearity was evaluated by dilutional 
parallelism for six different serum samples at serial twofold dilutions from 1:12 to 1:96. 
Linearity of the RIA for canine fecal extracts was tested using three different extracts at 
dilutions of 1:100–1:1600, and three and two different extracts with a higher cS100A12 
concentration diluted 1:200–1:3200 and 1:400–1:6400, respectively. Three different 
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fecal extracts with low cS100A12 concentrations were diluted 1:40–1:160. Assay 
accuracy was tested by spiking seven different sera and seven different fecal extracts 
with known concentrations of cS100A12 (i.e., 0, 0.2, 1, 2, 5, 10, 20, 50, and 100 μg/L 
for serum samples and 0, 200, 800, 1600, 4000, 8000, 16,000, 40,000, and 80,000 ng/g 
for fecal extracts). The percentage of standard antigen recovery was calculated as 
[observed value (μg/L or ng/g)/expected value (μg/L or ng/g)]×100. Precision of the 
assay was evaluated by assaying seven different serum samples and seven different fecal 
extracts from dogs ten times within the same assay followed by calculating the intra-
assay coefficients of variation (%CV = [SD/mean]×100). Reproducibility of the assay 
was determined by analyzing seven different canine sera and seven different canine fecal 
extracts in ten consecutive assay runs and calculating inter-assay %CVs. Species 
specificity of the RIA was tested by evaluating two different porcine sera at dilutions of 
1:10–1:80. 
 
3.2.3.3.  Assessment of interference with the RIA due to hyperlipidemia 
 Endogenous interference of increased concentrations of lipids as common sample 
matrix components with the assay was tested by spiking four different surplus canine 
serum samples (with low, moderate, and high cS100A12 concentrations) with known 
concentrations of a commercially available intravenous lipid formulation (Liposyn II
®
 
20% [Intravenous fat emulsion], Hospira, Lake Forest, USA; i.e., 0, 100, 250, 500, 750, 
1100, 1250, 1500, 1750, 2000, and 3000 mg/dL) followed by a Friedman test for data 
analysis. Also, concentrations of cS100A12 were measured in 32 grossly lipemic surplus 
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serum samples before and after high speed centrifugation at 16,000×g for 15 min 
followed by a Wilcoxon signed rank test for paired data analysis. 
 
3.2.3.4.  Reference interval for serum cS100A12 
 A reference interval for serum cS100A12 was established by evaluating serum 
samples from 124 healthy adult dogs (group A) and calculating the central 95th 
percentile. Serum cS100A12 concentrations were compared between healthy male and 
female dogs using a Mann–Whitney U test, and between dogs of different age groups 
(<2, 2–4, 4–6, 6–8, and >8 years) by a Kruskal–Wallis test. 
 
3.2.3.5.  Reference interval and intra-individual variation of fecal cS100A12 
 Distribution of cS100A12 in feces was assessed by determining the variation 
within a single defecation for 12 dogs. Three random aliquots of approximately 1.0 g 
were collected from different portions of feces (spot samples) and extracted as described. 
The remainder of the feces was diluted 1:2 in extraction buffer, homogenized (Tissue 
grinder Polytron
®
 PTMR-2100, Kinematica, Littau, Switzerland), and two aliquots 
(homogenates) were sampled and extracted with a final dilution of 1:5. Variability of 
fecal cS100A12 concentrations was evaluated for each dog by calculating the %CV for 
cS100A12 quantified in all extracts. Short-term intra-individual variation of fecal 
cS100A12 over five consecutive days was evaluated for 40 of the 65 healthy dogs 
(group B). To determine a reliable and efficient sampling strategy, mean fecal cS100A12 
concentrations and intra-individual variation (i.e., CV) were evaluated for various 
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numbers of sampling days (day 1; days 1 and 2; days 1–3; days 1–4; and days 1–5) by 
use of a Friedman test with a Dunn’s post hoc test. A reference interval for fecal 
cS100A12 concentration was established from the central 95th percentile of the mean 
fecal cS100A12 concentrations of three samples (collected on days 1–3) from each of 
the 65 healthy dogs (group B). Mean fecal cS100A12 concentrations of three sampling 
days were compared between healthy dogs of different age groups (<3, 3–6, and >6 
years) using a Kruskal–Wallis test.  
 
3.2.4.  Biologic variation of cS100A12 in serum 
 Twelve apparently healthy pet dogs of different breeds (group C) were enrolled 
into the study, the protocol for which had been reviewed and approved by the 
Institutional Animal Care and Use Committee at Oregon State University and has been 
detailed elsewhere (Carney et al., 2011). Briefly, biologic variation of serum cS100A12 
concentrations was evaluated over a period of 2.6 months in 11 of the dogs; one dog was 
excluded from the study due to the development of inflammatory skin disease 
immediately following the sample collection period. From each dog, blood was collected 
by venipuncture daily for seven days, weekly for six weeks, and a final sample one 
month later. Immediately after collection, serum was separated from the samples 
followed by storage at −80°C until analysis. 
 Serum cS100A12 was measured simultaneously in all specimens using standard 
assay criteria (i.e., samples that yielded a replicate CV of ≥15% were re-assayed). 
Samples were analyzed over five assay runs ensuring use of the same lots of reagents, 
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standards, and quality controls. To eliminate between-run analytical variation, serial 
samples from the same individual were assayed in the same RIA. Tests for outliers were 
carried out at three levels (i.e., within-run analytical variance, and intra- and inter-
individual variation), and a nested analysis of variance (ANOVA) model was used to 
calculate analytical and biological components of variation (Fraser and Harris, 1989): 
analytical (CVA), intra-individual (CVI), inter-individual (CVG), and total variation 
(CVT) (Fraser and Harris, 1989; Wu et al., 2009). Indices of biological variation were 
expressed as index of individuality (II; an II of ≤0.6 would indicate that individuals tend 
to be distinct from each other and thus, use of a population-based reference interval 
would not be appropriate whereas an II of ≥1.4 suggests a population-based reference 
interval may be useful), index of heterogeneity (IH; the ratio of CVI to the theoretical 
CV), and minimum critical difference (MCD0.05; the percentage difference in 
concentration that is significant at p ≤ 0.05 and is calculated using the 90th percentile of 
the observed distribution of within-subject variances) (Fraser and Harris, 1989; Wu et 
al., 2009). 
 Assumptions of normality and equality of variances were tested using a Shapiro–
Wilk W test and a Bartlett’s test, respectively. Microsoft Excel (Microsoft® Office 
Excel
®
 2007, Microsoft, Redmond, USA), GraphPad Prism (GraphPad Prism
®
 [v.5.0], 
GraphPad Software, San Diego, USA) or JMP (JMP [v.9.0], SAS Institute, Cary, USA) 
software were used for all calculations and statistical analyses. 
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3.3.  Results 
3.3.1.  Radioimmunoassay development and analytical validation 
 Immunization with pure cS100A12 yielded a moderate titer of anti-cS100A12 
Ab in both rabbits. Specific activity of the tracer was 636.4 ± 80.8 Ci/mmol (mean ± 
SD). 
125
I-labeled cS100A12 was least stable when stored at −20 °C and approximately 
2.3 mCi/L. For optimal stability, the tracer was stored in polypropylene tubes at −20 °C 
and a radiochemical concentration of approximately 0.2 mCi/L, and yielded a good 
performance of the RIA up to 42 days without any effect on NSB. 
 The assay was linear from 1 to 100 μg/L and had a working range between 0.6 
and 432.7 μg/L (Fig. 22). Thus, for serum and fecal samples assayed in a 1:20 and 1:800 
[1:40] dilution, respectively, the minimum detection limit of the assay was 11.2 μg/L and 
500 ng/g [24 ng/g], respectively, with a maximum detection limit of 8654.4 μg/L and 
346,200 ng/g [17,400 ng/g], respectively. No cross-reactivity was observed with the 
cS100A8/A9 protein complex up to 20,000 μg/L (Fig. 22). Dose–response curves for the 
serial dilution of serum and fecal samples with a wide range of cS100A12 concentrations 
paralleled the standard curve (Table 4), and expected and observed values for spiking 
recovery of the assay were closely correlated (Table 5). For precision and reproducibility 
testing of the RIA, mean values and intra- and inter-assay CVs are presented in Table 6. 
Aliquots of cS100A12 standard solutions were stored at −80 °C, and no change in the 
standards was observed after storage of 18 months. Spiking of sera with various 
concentrations of lipid components did not affect the results (p = 0.104) whereas 
cS100A12 concentrations (median: 201.2 μg/L) were significantly decreased after high 
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speed centrifugation (median: 138.1 μg/L; p < 0.0001). By use of this RIA, S100A12 
was detected in one of two porcine sera, the serial dilution of which yielded observed-to-
expected ratios of 103.2 ± 16.4% (mean ± SD). 
 
 
 
 
 
 
 
 
 
 
Figure 22 – Representative calibration plot for the estimation of cS100A12 (●) by a 
competitive, double antibody RIA. The gray shaded portion of the curve was used to 
quantify cS100A12 in serum and fecal extracts. No cross-reactivity was observed with 
the canine S100A8/A9 (canine calprotectin) protein complex (○). 
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Table 4 – Results for dilutional parallelism of serum samples and fecal extracts for the 
newly developed cS100A12 RIA. Observed-to-expected ratios for the serial dilution of 
six serum samples ranged from 97.2–146.8% (mean ±SD: 122.5 ±14.9%) and of 11 fecal 
extracts from 75.3–129.8% (104.8 ±12.5%). 
 
 
 
 
Specimen Dilutions 
cS100A12 
(µg/L or ng/g) 
Observed/ 
expected ±SD (%) 
    
Serum 1 1:2–1:16 181.7 123.1 ±16.2 
Serum 2 1:2–1:16 191.6 123.8 ±  8.5 
Serum 3 1:2–1:16 197.0 117.7 ±16.5 
Serum 4 1:2–1:16 217.6 132.1 ±17.5 
Serum 5 1:2–1:16 312.6 133.5 ±  9.5 
Serum 6 1:2–1:16 335.3 104.5 ±  7.1 
    
Fecal 1     1:40–1:160      186 104.4 ±24.3 
Fecal 2     1:40–1:160      648   95.3 ±15.0 
Fecal 3     1:40–1:160   1,887 112.7 ±  3.5 
Fecal 4 1:100–1:1,600      612 109.6 ±14.6 
Fecal 5 1:100–1:1,600   4,127 107.5 ±18.3 
Fecal 6 1:100–1:1,600 14,572 100.9 ±15.0 
Fecal 7 1:200–1:3,200 2,228 97.1 ±16.0 
Fecal 8 1:200–1:3,200 5,043 101.9 ±  8.8 
Fecal 9 1:200–1:3,200 12,159 110.0 ±  5.6 
Fecal 10 1:400–1:6,400 48,434 101.8 ±  5.2 
Fecal 11 1:400–1:6,400 688,947 115.8 ±  9.3 
        
SD: standard deviation 
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Table 5 – Results for spiking recovery of cS100A12 as determined by the newly 
developed RIA. Observed-to-expected ratios obtained by spiking seven canine serum 
samples and seven fecal extracts with eight different concentrations of cS100A12 ranged 
from 87.8 to 130.4% (mean ±SD: 100.6 ±6.5%) and from 84.8 to 143.8% (103.7 
±10.6%), respectively. 
 
 
 
Specimen 
cS100A12 
(µg/L or ng/g) 
Observed/ 
expected ±SD (%) 
   
Serum 1 83.5 97.1 ±  3.9 
Serum 2 103.1 97.2 ±  5.0 
Serum 3 113.2 98.0 ±  4.2 
Serum 4 187.3 100.6 ±  3.2 
Serum 5 402.3 104.0 ±  3.3 
Serum 6 442.0 99.7 ±  6.2 
Serum 7 772.2 107.7 ±10.4 
   
Fecal 1 6,623 97.4 ±  6.2 
Fecal 2 6,935 105.1 ±  4.8 
Fecal 3 8,054 109.6 ±  7.7 
Fecal 4 14,139 94.6 ±  6.7 
Fecal 5 24,847 99.7 ±  4.1 
Fecal 6 71,045 113.8 ±15.3 
Fecal 7 146,089 106.1 ±12.0 
      
SD: standard deviation 
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Table 6 – Precision and reproducibility of the RIA for cS100A12. 
 
 
 
Serum 
sample 
Mean 
(µg/L) 
CV 
(%)  
Fecal 
sample 
Mean 
(ng/g) 
CV 
(%) 
 
 1 196.5 1.5   1 5,236 3.8  
 2 204.1 8.1   2 6,728 5.5  
Intra-assay  3 224.0 6.3   3 7,299 3.8  
variability 4 342.1 4.5   4 18,900 4.2  
 5 437.5 6.6   5 79,720 6.1  
 6 713.0 5.7   6 189,851 7.4  
 7 2,021.3 6.2   7 215,221 7.8  
          
 1 169.2 5.6   1 6,977 5.3  
 2 246.4 5.9   2 7,684 5.9  
Inter-assay  3 265.5 7.8   3 10,190 5.7  
variability 4 272.9 5.8   4 12,694 4.0  
 5 299.2 5.1   5 26,025 2.9  
 6 394.3 3.3   6 92,566 7.5  
  7 463.7 6.5    7 228,744 8.7  
CV: coefficient of variation 
 
 
 
 
 99 
 
 
3.3.2.  Biological variation and reference interval for serum cS100A12 
 Serum cS100A12 concentrations in samples from 124 healthy pet dogs (group A) 
ranged from 30.4 to 300.2 μg/L (median: 84.4 μg/L) and the reference interval for serum 
cS100A12 concentration was established as 33.2–225.1 μg/L (Fig. 23). Serum 
cS100A12 concentrations were not significantly different (p = 0.819) between healthy 
male and female dogs. Although the number of sexually intact male (n = 15) and female 
(n = 13) dogs was small compared to neutered males (n = 40) and females (n = 56), 
serum cS100A12 concentrations were also not significantly different among those four 
groups (p = 0.068). Also, serum cS100A12 concentrations were not significantly 
different among healthy dogs of different age groups (p = 0.427). 
 For evaluation of the biological variability, a total of 14 serial specimens were 
collected from 9 dogs and 13 serial samples from 2 dogs (group C). Two within-subject 
outliers were detected (one each from dogs 2 and 10) and excluded from further analysis, 
yielding a total of 150 serum samples (Fig. 24) and slightly right-skewed data. No 
outlying observations (maximum variance/sum of the variances = 0.086; Cochrane test) 
or outliers among mean concentrations of subjects (extreme minus next highest 
concentration = 15% of the concentration range; Reed’s criterion) were detected. CVA 
was calculated as 5.7%, CVI as 29.2%, and CVG as 31.2% resulting in a CVT of 66.0%. 
Index of Individuality (II) was determined to be 0.95 and IH was 56.4, yielding a one-
sided MCD0.05 of 84.9%. 
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Figure 23 – Scatter plot of serum cS100A12 concentrations measured in specimens 
from 124 healthy dogs. Each symbol represents the concentration for a specific dog. 
Median cS100A12 concentration (solid horizontal line) and reference interval (gray 
shaded portion between dashed horizontal lines) were calculated. 
 
 
 
 101 
 
 
 
 
 
 
 
 
 
Figure 24 – Long-term biological variation of serum cS100A12 concentrations in 11 
healthy dogs. For each dog, the mean (circles) and range (horizontal bars) of serum 
cS100A12 concentrations over 2.6 months is shown. The gray shaded area (delineated 
by dashed vertical lines) indicates the reference interval; the overall mean serum 
cS100A12 concentration (77.4 μg/L) is shown by the dotted vertical line. None of the 
measurements were below the lower detection limit of the RIA (11.2 μg/L; solid vertical 
line) and all dogs (except for one of the two outlying observations; asterisks) measured 
below the upper limit of the reference interval (225.1 μg/L); three dogs had cS100A12 
concentrations below the lower limit of the reference interval (33.2 μg/L). 
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3.3.3.  Intra-individual variability and reference interval for fecal cS100A12 
 For cS100A12 concentrations in three fecal spot samples collected from one 
single defecation, CVs ranged from 0.0 to 152.9% (mean ± SD: 34.7 ± 53.9%). Fecal 
cS100A12 in three samples from each of the 65 healthy dogs (group B) ranged from <24 
to 2,305 ng/g (median: <24 ng/g), with three-day sample mean cS100A12 concentrations 
ranging from <24 to 926 ng/g (median: <24 ng/g) (Fig. 25). In five consecutive fecal 
samples from 40 dogs of group C, fecal cS100A12 ranged from <24 to 5,686 ng/g 
(median: <24 ng/g) and the five-day sample mean fecal cS100A12 from <24 to 1,381 
ng/g (median: <24 ng/g). Mean fecal cS100A12 concentrations were not significantly 
different (p = 0.581) among different numbers of sampling days; significance was 
reached for maximum fecal cS100A12 concentrations and CVs overall (both p < 0.001), 
but not in any of the post hoc tests. The reference interval for fecal cS100A12 
concentration was established as a three-day sample mean of <24–745 ng/g (Fig. 26). 
Three-sample mean fecal cS100A12 concentrations were not significantly different 
among healthy dogs of different age groups (p = 0.410) or between healthy male and 
female dogs (p = 0.464). 
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Figure 25 – Short-term biological variation of fecal cS100A12 concentrations in 65 
healthy dogs. The reference interval is indicated by the gray shaded area delineated by 
its upper limit (745 ng cS100A12/g feces) to the right (dashed vertical line). In 13 of the 
65 dogs (20%) fecal cS100A12 was detectable in at least one of the samples collected on 
3 consecutive days; the majority of the dogs had a three-day sample mean fecal 
cS100A12 concentration of <320 ng/g. 
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Figure 26 – Scatter plot showing the three-day fecal mean cS100A12 concentrations in 
specimens collected from 65 healthy dogs. Each symbol represents the three-day mean 
fecal cS100A12 concentration for a specific dog. Median (solid horizontal line) and 
reference interval (gray shaded portion between dashed horizontal lines) for 3-day mean 
fecal cS100A12 concentrations were calculated. 
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3.4.  Discussion 
 A radioimmunoassay for the measurement of cS100A12 in serum samples and 
fecal extracts was successfully established. The minimum detection limit of the assay 
was calculated to be 11.2 μg/L for serum and 24 ng/g feces for fecal samples, 
respectively, which appears to be adequate considering the upper limit of the reference 
intervals for serum (225.1 μg/L) and fecal samples (745 ng/g), and the intent to identify 
dogs with increased serum and/or fecal cS100A12 concentrations. Both a very dilute 
antiserum and tracer were chosen to increase the sensitivity of the assay and allow 
measuring cS100A12 in fecal samples from healthy dogs and dogs with gastrointestinal 
inflammation, assumed to have increased fecal cS100A12 concentrations. This decreases 
the range of binding ratios (Bstd/B0) but appeared to not affect the overall assay 
performance. However, as fecal cS100A12 concentrations were below the minimum 
detection limit of the RIA (24 ng/g) in 51/65 healthy dogs (78.5%), further studies in 
canine patients with gastrointestinal inflammation will need to be conducted to show 
whether this assay is sufficiently sensitive for detection of cS100A12 in fecal samples 
from clinical patients. 
 Dilutional parallelism and spiking recovery of cS100A12 in canine sera and fecal 
extracts indicate linearity and accuracy of the RIA, and the intra- and inter-assay CVs 
demonstrate precision and reproducibility of the assay. Due to the availability of only the 
cS100A8/A9 protein complex as a cS100A12 analogue, analytical specificity of the RIA 
for cS100A12 could only be demonstrated by testing a wide range of cS100A8/A9 
concentrations (i.e., concentrations exceeding that of the cS100A12 top standard by a 
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factor of 100). As more canine S100 proteins (e.g., psoriasin) and/or analogues may 
become available in the future, analytical specificity of this cS100A12 RIA may need to 
be further evaluated. 
 Compared to reports in humans (Larsen et al., 2007), concentrations of serum 
cS100A12 did not change after repeated freeze–thaw cycles in our study (data not 
shown), and attempts to analyze serum and fecal samples using RIAB devoid of EDTA 
yielded a matrix effect rendering quantification of cS100A12 impossible. Based on the 
signal (i.e., cpm) obtained and the fact that this was not seen in cS100A12 standards, 
whereas spiking cS100A12 standards into an “analyte-free” matrix consisting of feline 
serum samples and fecal extracts (shown to not cross-react using this assay) yielded the 
same effect, we speculate that 
125
I-cS100A12 was bound to matrix components (possibly 
forming multimers with the native protein in specimens) and that EDTA in a 
concentration expected to chelate most of the Ca
2+
 in serum or extraction buffer (Ca
2+
 
was added to increase the stability of S100 proteins) effectively neutralized this effect. 
However, an increased interaction of cS100A12 with the surface of the assay tubes 
(presumably due to its increased hydrophobicity upon Ca
2+
 binding) also needs to be 
considered. 
 Difficulties raising anti-cS100A12 antiserum in rabbits using a common 
vaccination protocol for producing pAb were unexpected and have not been reported for 
hS100A12. Similar difficulties were experienced when generating pAb against 
cS100A8/A9 in rabbits (Heilmann et al., 2008); however, S100A12 is reported to be less 
well conserved among species than S100A8/A9 (Moroz et al., 2003). As for 
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cS100A8/A9, modifying both the amount of antigen inoculated and injection site led to 
an increase in anti-cS100A12 titer. Thus, the insufficient pAb response against 
cS100A12 in one rabbit may be due to a high epitopic homology between canine and 
rabbit S100A12, the size of cS1000A12 being close to the minimum for immunogens 
(∼5 kDa), or idiosyncrasy. However, sequence homology of rabbit S100A12 with the 
canine (63%) and human protein (67%) is similar, and cS100A12 is assumed to form 
homooligomeric complexes in the Ca
2+
- containing buffer used for the inoculations 
(Heilmann et al., 2010). 
 Lipids represent matrix components that commonly interfere with immunoassay 
performance. While the spiking of samples with lipid components in concentrations 
measured in patients with severe hypertriglyceridemia/hyperlipidemia did not affect the 
results in our study, separating the majority of the lipid fraction from the sera by high 
speed centrifugation appeared to also remove a significant portion of cS100A12 from the 
samples. It seems plausible that a fraction of cS100A12 is found in the lipid portion of 
the samples (possibly due to its hydrophobicity at Ca
2+
 concentrations found in serum). 
Therefore, we suggest that lipemic serum samples should be assayed or an aliquot 
removed before separating the lipid fraction. 
 Concentrations of cS100A12 in feces from healthy dogs varied, which may be 
due to a patchy distribution of cS100A12-expressing cells within the gastrointestinal 
mucosa and/or variations in gastrointestinal passage leading to variation in the 
concentration of fecal proteins, and has also been shown for other fecal markers in dogs 
(Steiner et al., 2003; Heilmann et al., 2008). To counterbalance the intra-individual 
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variation of cS100A12 observed in this study, we recommend analyzing fecal samples 
collected on three consecutive days. However, results of further studies in dogs with 
gastrointestinal inflammation (assumed to have increased fecal cS100A12 
concentrations) are needed to definitively reveal the number of consecutive fecal 
samples required for reliable results. 
 Fecal cS100A12 concentrations were not significantly different among pet dogs 
of various age groups, which may suggest that, in contrast to humans (de Jong et al., 
2006; Kaiser et al., 2007; Sidler et al., 2008), age related changes do not occur. 
However, cS100A12 concentrations were not evaluated in healthy dogs <1 year, and 
further studies are warranted to evaluate serum and fecal cS100A12 in healthy puppies. 
 Detection of porcine S100A12 by this assay was expected as cross-reactivity 
between cS100A12 and porcine S100A12 has been shown previously (Heilmann et al., 
2010). Moreover, linearity of the RIA for porcine serum samples indicates a potential 
application of this assay for S100A12 quantification in this species. 
 Biological variation is determined by pre-analytic factors associated with the 
collection of samples and true biological variance, whereas analytical variance arises 
from the methodology, instrumentation, and technical skills (Fraser and Harris, 1989). 
The protocol that was used for collection and analysis of samples to determine the 
biological variation has the advantage of eliminating long-term (i.e., inter-assay) 
analytical variation, thus rendering intra-assay variability (CVA; estimated from 
analyzing duplicates of samples) the only component of analytical variation. The 
analytical goal of CVA ≤ ½×CVI (Fraser and Harris, 1989) has also been satisfied in this 
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study. Although serum cS100A12 appears to be maintained within a relatively narrow 
concentration window in individual dogs, it showed moderate individuality and, as 
indicated by the MCD0.05, moderate changes in serum cS100A12 between sequential 
measurements in a dog are necessary to be considered relevant rather than reflecting 
biological and/or analytical variation. Thus, the use of a conventional population-based 
reference interval to detect increased cS100A12 concentrations may or may not be 
appropriate, and needs to be further evaluated in dogs with acute and chronic 
inflammatory diseases. Interestingly, using the MCD0.05 with the median (84.4 μg/L) and 
the 75
th
 percentile determined for serum cS100A12 concentrations in the reference 
sample group yielded cS100A12 concentrations coinciding with the upper limit of the 
central 90
th
 percentile and the upper limit of the reference interval calculated (225.1 
μg/L), respectively. This demonstrates that the reference interval established is within 
reasonable limits. 
 
3.5.  Conclusions 
 In summary, the RIA described here is sensitive, linear, accurate, precise, and 
reproducible, and has the potential to distinguish healthy dogs from dogs with 
inflammatory diseases, assumed to be associated with increased serum and/or fecal 
cS100A12 concentrations. Further research into the clinical utility of measuring serum 
and/or fecal cS100A12 in dogs with systemic or localized inflammatory conditions (e.g., 
pancreatitis or gastrointestinal inflammation) is warranted and is currently under way. 
Further studies in dogs with gastrointestinal inflammation will show if the RIA is 
 110 
 
 
sufficiently sensitive to reliably measure cS100A12 in fecal samples. A population-
based reference interval for serum cS100A12 may or may not be a reasonable tool, but 
this will depend on the degree of change observed in dogs with acute and chronic 
inflammatory diseases. Further studies to evaluate the clinical utility of serum and/or 
fecal cS100A12 for the diagnosis (i.e., as “event marker”) and/or monitoring (i.e., as 
“chronic disease marker”) (Fraser and Harris, 1989) of canine patients with 
inflammatory diseases, and to determine whether stratification of the reference 
population based on variables other than age and sex (e.g., body condition score) may be 
necessary, are currently under way. 
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4. ASSOCIATION BETWEEN FECAL S100A12 CONCENTRATION AND 
HISTOLOGIC, ENDOSCOPIC, AND CLINICAL DISEASE SEVERITY IN DOGS 
WITH IDIOPATHIC INFLAMMATORY BOWEL DISEASE
‡
 
 
4.1  Introduction 
 Idiopathic inflammatory bowel disease (IBD) in dogs is a chronic relapsing 
condition. Its diagnosis and management can be challenging, requiring invasive 
diagnostic procedures after a tedious work-up to exclude other causes of chronic 
gastrointestinal (GI) signs (Washabau et al., 2010; Simpson and Jergens, 2012). Fecal 
markers that are specific for GI disease, correlate with disease severity, and objectively 
assess GI inflammation would be very useful in clinical practice but such markers are 
currently lacking in veterinary medicine. 
 S100/calgranulins, a group of 3 phagocyte-specific damage-associated molecular 
pattern (DAMP) molecules (Pietzsch and Hoppmann, 2009), accumulate at sites of 
inflammation and appear to be candidates for fecal markers because of their stability in 
feces (Föll et al., 2009) and their increase at the mucosal mRNA level in dogs with IBD 
(Wilke et al., 2012). S100A12 (also known as calgranulin C, myeloid-related protein-6 
[MRP6], or extracellular newly identified receptor for advanced glycation end products 
[EN-RAGE]) represents a ligand for receptors of the innate immunity, such as the 
                                                 
‡
Reprinted with permission from Heilmann, R.M., Grellet, A., Allenspach, K., 
Lecoindre, P., Day, M.J., Priestnall, S.L., Toresson, L., Procoli, F., Grützner, N., 
Suchodolski, J.S., Steiner, J.M., 2014. Association between fecal S100A12 
concentration and histologic, endoscopic, and clinical disease severity in dogs with 
idiopathic inflammatory bowel disease. Veterinary Immunology and Immunopathology 
158, 156-166, Copyright (2014) by Elsevier. 
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receptor for advanced glycation end products (RAGE) (Hofmann et al., 1999). The 
ligand–RAGE interaction has been shown to activate nuclear factor-kappa B, leading to 
the production of proinflammatory cytokines and chemokines. Also, a positive feedback 
on the expression of RAGE has been proposed to induce sustained post-receptor 
signaling, thus perpetuating and amplifying the inflammatory response (Bierhaus et al., 
2005). 
 Biomarkers of inflammation, such as the concentration of fecal S100A12, are 
considered useful tools for diagnosing and monitoring IBD in people (Föll et al., 2003, 
2009; Kaiser et al., 2007). For a marker of inflammation to be clinically useful, it would 
ideally be measurable without temporal delay in expression and/or secretion following 
changes of the inflammatory activity. The marker should also be organ-specific in 
expression or the type of specimen used to determine its concentration, and be specific 
for the disease process. Moreover, such a marker would need to be easy, inexpensive, 
and non-invasive to measure, and be stable in the specimen under clinical conditions. 
Although the last hampers the routine analysis of many small molecular inflammatory 
proteins (e.g., cytokines or chemokines), measurability and stability in feces are criteria 
applicable to fecal S100A12 (Heilmann et al., 2011b). Also, our preliminary work has 
shown that serum canine S100A12 (cA12) concentrations are increased in dogs with 
IBD (Heilmann et al., 2011a). However, fecal concentrations of cA12 (fcA12), assumed 
to be more specific for the GI tract, have not yet been investigated in canine IBD. 
 We hypothesized that fcA12 concentrations are increased in dogs with IBD, 
indicating an increased infiltration and/or activation of phagocytes; and that the 
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expression of fcA12 correlates with clinical, endoscopic, and/or histologic disease 
severity. Thus, the aims of the present study were to measure fcA12 concentrations in 
dogs with IBD, and to assess the relationship of fcA12 concentrations to the severity of 
clinical signs, macroscopic (i.e., endoscopic) mucosal lesions, and histopathologic 
findings. 
 
4.2  Materials and Methods 
4.2.1.  Animals 
 Dogs with chronic GI signs (vomiting, diarrhea, and/or weight loss) and a 
diagnosis of IBD based on clinical, clinicopathologic, endoscopic, and histopathologic 
criteria (Washabau et al., 2010), recruited at the Small Animal Teaching Hospital of the 
Royal Veterinary College (RVC) at the University of London (KA, FP) between April 
2009 and May 2010 (n = 9 dogs) and at St Priest’s Clinique vétérinaire des Cérisioz (PL, 
AG) between July 2010 and December 2010 (n = 17 dogs), were retrospectively enrolled 
in the study. Protocols for enrollment of dogs and use of specimens were approved by 
the RVC Ethics and Welfare Committee and the Royal Canin Internal Ethics Committee 
(St Priest’s Clinique vétérinaire des Cérisioz). Informed owner consent was obtained at 
the time dogs were enrolled for using material. 
  The control group comprised 90 apparently healthy dogs that were enrolled at the 
Texas A&M University (TAMU) College of Veterinary Medicine and the Region-
djursjukhuset Helsingborg, Sweden. An owner questionnaire served to assess the current 
health status of each dog and to ensure valid vaccination and other preventive 
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medications depending on the geographical location. No further blood testing or other 
invasive procedures were performed in the control group. The flow chart (Fig. 27) shows 
the group distribution of all 116 dogs enrolled in the study. 
 
 
 
 
 
 
 
Figure 27 – Study flow chart. Shown is the group distribution of the 116 dogs enrolled 
in the study. The two different parts of the present study are marked by the gray shaded 
area: (I) evaluation of fcA12 concentrations in healthy dogs and dogs with IBD; and (II) 
evaluation of the relation between fcA12 with clinical, endoscopic, and histologic 
disease severity in dogs with IBD. CCECAI: canine chronic enteropathy clinical activity 
index. 
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4.2.2.  Clinical disease activity 
 Dogs were diagnosed with IBD using established clinical, clinicopathologic, 
endoscopic, and histopathologic criteria (Washabau et al., 2010). The severity of their 
disease was then scored using an established clinical disease activity index (canine 
chronic enteropathy clinical activity index, CCECAI) (Allenspach et al., 2007), which 
considers general attitude and activity, appetite, frequency of vomiting, stool consistency 
and frequency of defecation, weight loss, serum albumin concentration, peripheral 
edema and ascites, and pruritus. The composite CCECAI score can range from 0 to 27, 
and according to the score, clinical disease is categorized as: clinically insignificant 
(score 0–3), mild (score of 4–5), moderate (score of 6–8), severe (score of 9–11), or very 
severe (score of ≥12) (Allenspach et al., 2007). A CCECAI score of at least 4 was 
required for inclusion into the study. 
 
4.2.3.  Clinical pathology and diagnostic imaging in dogs with IBD 
 A complete blood cell count, serum biochemistry profile, and the concentration 
of canine trypsin-like immunoreactivity (cTLI) in serum were used to rule out other GI 
or systemic diseases, and concentrations of serum cobalamin and folate were also 
measured at each institution. Diagnostic imaging consisted of an abdominal ultrasound 
examination in 25 of the 26 dogs with IBD to rule out non-intestinal disease. 
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4.2.4.  Endoscopic disease activity 
 Each of the 26 dogs in the IBD group underwent endoscopic evaluation 
conforming to existing standard protocols at each center, during which the mucosa was 
visually inspected and the severity of lesions were documented and scored. 
Gastroduodenoscopy was performed in 19 dogs, gastroduodenoscopy and colonoscopy 
in 6 dogs, and only colonoscopy in 1 dog. At the Clinique vétérinaire des Cérisioz (n = 
17 dogs), endoscopic disease severity was recorded at the time of endoscopy using a 4-
point grading system with 0 = normal mucosa, 1 = mild lesions (slightly friable and 
erythematous mucosa), 2 = moderate changes (friable and white-speckled mucosa), and 
3 = severe endoscopic disease (very friable, easily bleeding, ulcerated or cobblestone-
appearing mucosa; difficulties on endoscopic insufflation) (Allenspach et al., 2007). In 
order to be able to compare scores between the two centers, endoscopic disease activity 
in dogs enrolled at the RVC (n = 9 dogs) was retrospectively graded based on the 
endoscopy reports in the patient medical records. The endoscopic reports had been 
generated by different clinicians and by using guidelines established by the World Small 
Animal Veterinary Association (WSAVA) Gastrointestinal Standardization group 
(Washabau et al., 2010). Endoscopic lesions were retrospectively assigned a score by the 
investigator (RMH) who was blinded to the clinical disease activity, severity of 
histologic lesions, clinicopathologic findings, and any other parameters of the dogs at the 
time of scoring. Visual inspection of the colon was obscured in 2 (7.7%) of the dogs 
where biopsies were collected but the severity of macroscopic (endoscopic) lesions 
could not be assessed. 
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4.2.5.  Histologic disease activity 
 Endoscopically collected, formalin-fixed, and paraffin-embedded tissue biopsies 
were cut and H&E-stained in preparation for histological evaluation conforming to 
standard protocols at the respective institution. Tissues were evaluated and scored by a 
single, experienced pathologist at each center, using guidelines established by the 
WSAVA Gastrointestinal Standardization group (Washabau et al., 2010; Day et al., 
2008) and with the pathologist being blinded to the results of fcA12, the severity of 
endoscopic lesions, and clinicopathologic data from these dogs. The severity of 
histopathologic lesions in each section of the GI tract was recorded using a 4-point 
grading system with 0 = normal, 1 = mild lesions, 2 = moderate changes, and 3 = severe 
histopathologic changes. For correlation analysis, the individual inflammatory and 
morphologic criteria, composite scores for morphologic and inflammatory criteria, and 
the sum of both in each of the different GI sections and over all sections examined were 
considered. 
 
4.2.6.  Fecal S100A12 analysis 
 A single spot (1 g) fecal sample was collected from each dog, all samples were 
stored frozen as soon as possible after collection and were shipped on ice to the 
Gastrointestinal Laboratory at TAMU. All samples were then stored at −80°C until 
further analysis (up to 15 months). To allow quantification and stabilize fcA12, all 
samples were extracted as previously described (Heilmann et al., 2010), and fcA12 was 
quantified by ELISA. Briefly, 96-well immunoassay plates (Nunc-Immuno™ plates 
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MaxiSorp, Sigma-Aldrich, St. Louis, MO, USA) were coated with affinity-purified 
polyclonal anti-cA12 Ab (Heilmann et al., 2010) and were blocked with Tris-buffered 
saline (TBS)-Tween-10% BSA. Plates were then incubated with duplicates of standard 
cA12 (Heilmann et al., 2010) solutions, assay controls, or fecal extracts (Heilmann et al., 
2008) diluted in TBS-Tween-3% BSA, after which they were incubated with horseradish 
peroxidase-labeled (Horseradish peroxidase (HRP); Thermo Scientific, Rockford, IL, 
USA) anti-cA12 polyclonal Ab (Heilmann et al., 2010, 2011b). A 3,3’,5,5’-
tetramethylbenzidine-substrate (Tetramethylbenzidine [TMB]-substrate; 1-Step™ Ultra 
TMB ELISA, Thermo Scientific, Rockford, IL, USA) was used for color development; 
the absorbance at 450 nm was measured (Synergy 2 Alpha Microplate reader, BioTek
®
, 
Winooski, VT, USA), and a five-parameter logistic curve fit was used for the standard 
curve (Gen5™ Data Analysis Software [v1.11], BioTek®, Winooski, VT, USA). Lower 
detection limit of the assay was 1 ng fcA12/g fecal sample. Fecal cA12was measured 
using the same lot of reagents for all samples and was reported as μg fcA12 per g fecal 
wet weight. The investigator was blinded to each dog’s parameters at the time fcA12 
was measured. 
 
4.2.7.  Data and statistical analysis 
 Standards for reporting of diagnostic accuracy studies (Bossuyt et al., 2003a, 
2003b) were applied. All statistical analyses were performed using a commercial 
software package (JMP
®
 v10.0, SAS Institute, Cary, NC, USA; GraphPad Prism
®
 v5.0, 
GraphPad Software, San Diego, CA, USA). Normality and equality of variances were 
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tested using a Shapiro–Wilk W and a Brown–Forsythe test, respectively. Summary 
statistics were reported as medians and interquartile ranges (IQR), and nonparametric 
tests (Wilcoxon rank sum or Kruskal–Wallis test) were used for comparison of two or 
more groups, respectively. A Spearman ρ was calculated for correlation analysis. Cut-
offs for the concentrations of serum albumin and cobalamin shown to be associated with 
negative outcomes (20 g/L and 200 ng/L, respectively [Allenspach et al., 2007]) were 
used to compare fcA12 concentrations in patients dichotomized into 2 subgroups with 
concentrations below or above the respective cut-off values. A receiver operating 
characteristic (ROC) curve analysis was performed to determine the sensitivity and 
specificity of the test in distinguishing dogs with IBD from healthy dogs, and the 
Youden index and the likelihood ratio were used to determine the optimal cut-off 
concentration for the diagnosis of IBD. Statistical significance was defined as P ≤ 0.05, 
and Holm’s sequential Bonferroni correction (Holm, 1979), which controls the family-
wise error rate, was applied for multiple comparisons with the numbers of categories or 
subcategories considered (i.e., adjusted P = unadjusted P × [n − k + 1]; with n being the 
number of hypotheses tested and k being the ordered rank of the uncorrected P-values). 
 
4.3.  Results 
4.3.1.  Patient demographics 
 Twenty-eight dogs were considered for inclusion into the study. However, 1 dog 
was excluded because full-thickness biopsies had been obtained before sample 
collection, and another dog was excluded because of con-current exocrine pancreatic 
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insufficiency. There were no differences in age (dogs with IBD, median: 4.0 years, IQR: 
2.9–7.0 years; healthy dogs, median 3.9 years, IQR: 2.3–6.6 years; P = 0.487, Wilcoxon 
rank sum test) and sex distribution (dogs with IBD, male [neutered]/female [spayed]: 16 
[4]/10 [5]; healthy dogs, male [neutered]/female[spayed]: 45 [38]/45 [27]; P = 0.299, 
Pearson Chi-square test) between the 26 dogs with chronic GI inflammation (IBD) and 
the 90 healthy controls. Dogs in the healthy control group were of various breeds; and 
breeds that were represented by more than one dog included mixed breed (n = 26), 
German Shepherd dog (n = 8), Dachshund (n = 5), Australian Cattle dog (n = 4), 
Labrador Retriever (n = 4), Golden Retriever (n = 3), Australian Shepherd dog (n = 2), 
Border Collie (n = 2), Boston Terrier (n = 2), Boxer (n = 2), Great Pyrenees (n = 2), Rat 
Terrier (n = 2), Rottweiler (n = 2), Siberian Husky (n = 2), Weimaraner (n = 2), West 
Highland White Terrier (n = 2), and White Shepherd dog (n = 2). In the group of dogs 
with IBD, breeds included, German Shepherd dog (n = 4), Labrador Retriever (n = 3), 
Yorkshire Terrier (n = 3), Rottweiler (n = 2), mixed breed (n = 2), and 1 each of Akita 
Inu, Basset Hound, Belgian Malinois, Bernese Mountain dog, Boxer, Cane Corso, 
Cavalier King Charles Spaniel, French Bulldog, Great Dane, Shih Tzu, Siberian Husky, 
and Staffordshire Bull Terrier. 
 
4.3.2.  Clinical presentation and clinicopathologic findings in dogs with IBD 
 In the study group the most frequent clinical sign at presentation was diarrhea 
(25/26 dogs; 96%), followed by weight loss (20/26; 77%), anorexia/dysorexia (17/26; 
65%), vomiting/regurgitation (14/26; 54%), polydipsia (6/26; 23%), hematochezia/ 
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melena (5/26; 19%), tenesmus (5/26; 19%), and abdominal distension and pruritus (each 
1/26; 4%). Clinicopathologic abnormalities included hypoproteinemia in 14/26 dogs 
(54%) and hypoalbuminemia in13/26 dogs (50%; median serum albumin concentration: 
7 g/L, IQR: 6–13.9 g/L; reference interval: 23–40 g/L [St Priest’s Clinique vétérinaire 
des Cérisioz] and 28–39 g/L [RVC]); 15 of the 26 dogs (54%) were hypocobalaminemic 
(median serum cobalamin concentration: 187 ng/L, IQR: 167–234 ng/L; reference 
interval: 300–800 ng/L [St Priest’s Clinique vétérinaire des Cérisioz] and >200 ng/L 
[RVC]) and 21 dogs (81%) had a serum cobalamin concentration below 400 ng/L. 
Nineteen (73%) of the 26 dogs with IBD had a CCECAI score of ≥9 indicating severe or 
very severe clinical disease (Table 7); and endoscopic lesions in the duodenum were 
moderate or severe in 16/26 dogs (62%) and were at least of moderate severity in the 
colon in 2/5 dogs (40%). Clinical disease activity scores and the severity of endoscopic 
lesions and histopathologic findings are summarized in Tables 7 and 8. Eight of the dogs 
with IBD had been treated with steroids prior to evaluation and sample collection, and 
eight dogs had received an antibiotic. 
 
4.3.3.  Fecal S100A12 concentrations 
 Fecal cA12 concentrations in single spot samples were significantly higher in 
dogs with IBD than in healthy control dogs (P < 0.0001; Fig. 28). Using a cut-off 
concentration of 59 ng/g (Youden index and likelihood ratio), the sensitivity and 
specificity of fcA12 to distinguish dogs with IBD from healthy control dogs were 65% 
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Table 7 – Patient characteristics. Specific characteristics of dogs with inflammatory 
bowel disease (IBD; n=26) included in the study. 
 
  
Duration of clinical signs, months  (median [range]) 3.0 [0.75–24.0] 
Treated with glucocorticosteroids at the time of study (n [%])    8 [31%] 
Treated with antimicrobials at the time of study (n [%])    8 [31%] 
Clinical disease activity, CCECAI score (median [range])  10 [5–18] 
- mild (n [%])    2 [8%] 
- moderate (n [%])    5 [19%] 
- severe (n [%])    9 [35%] 
- very severe (n [%])  10 [38%] 
Endoscopic disease severity, composite score
#
 (median [range])     2 [0–6] 
- gastric (median [range])    0 [0–3] 
- duodenal (median [range])     2 [0–3] 
- colonic (median [range])    1 [0–3] 
Histologic disease severity, composite score
#
 (median [range])    1 [1–3] 
- gastric (median [range])    1 [0–2] 
- duodenal (median [range])    1 [0–3] 
- colonic (median [range])    1 [0–3] 
CCECAI: canine chronic enteropathy clinical disease activity index (range of 
possible scores: 0–27; insignificant disease: 0–3, mild disease: 4–5, moderate 
disease: 6–8, severe disease: 9–11, very severe disease: ≥12) (Allenspach et al., 
2007); 
#
sum of all segments evaluated (range of possible scores: 0–3). 
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Table 8 – Histopathologic disease severity in dogs with IBD. Severity of morphologic and inflammatory histopathologic 
lesions found within each segment of the gastrointestinal tract evaluated in dogs with inflammatory bowel disease (IBD; 
n=26). 
 
Histologic  findings 
  Severity of lesions
†
 
 N Normal Mild Moderate Severe 
      
Gastric fundus (composite score
$
) 10 5 4 1 0 
   Morphologic criteria
#
       
- Surface epithelial injury 10 10 0 0 0 
- Gastric pit epithelial injury 10 9 1 0 0 
- Fibrosis/glandular nesting/MA 10 6 4 0 0 
   Inflammatory criteria
#
      
- Intraepithelial lymphocytes 10 9 1 0 0 
- Lamina propria LPC 10 8 1 1 0 
- Lamina propria eosinophils 10 10 0 0 0 
- Lamina propria neutrophils 10 9 1 0 0 
- Lamina propria macrophages 10 10 0 0 0 
- Lymphofollicular hyperplasia 10 8 1 1 0 
Gastric antrum (composite score
$
)   9 6 2 1 0 
   Morphologic criteria
#
      
- Surface epithelial injury   9 8 1 0 0 
- Gastric pit epithelial injury   9 7 1 1 0 
- Fibrosis/glandular nesting/MA   9 8 1 0 0 
   Inflammatory criteria
#
      
- Intraepithelial lymphocytes   9 8 1 0 0 
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Table 8 – continued 
Histologic  findings 
  Severity of lesions
†
 
 N Normal Mild Moderate Severe 
 
- Lamina propria LPC   9 7 1 1 0 
- Lamina propria eosinophils   9 9 0 0 0 
- Lamina propria neutrophils   9 7 1 1 0 
- Lamina propria macrophages   9 9 0 0 0 
- Lymphofollicular hyperplasia   9 8 1 0 0 
Duodenum (composite score
$
) 23 1 19 2 1 
   Morphologic criteria
#
      
- Villus stunting 23 3 19 0 1 
- Epithelial injury 23 20 2 1 0 
- Crypt distension 23 12 9 2 0 
- Lacteal dilation 23 18 3 2 0 
- Mucosal fibrosis 23 22 1 0 0 
  Inflammatory criteria
#
      
- Intraepithelial lymphocytes 23 19 3 1 0 
- Lamina propria LPC 23 4 18 1 0 
- Lamina propria eosinophils 23 21 2 0 0 
- Lamina propria neutrophils 23 19 3 0 1 
- Lamina propria macrophages 23 21 2 0 0 
Colon (composite score
$
)   7 2 3 1 1 
   Morphologic criteria
#
      
- Epithelial injury   7 5 1 0 1 
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Table 8 – continued 
Histologic  findings 
  Severity of lesions
†
 
 N Normal Mild Moderate Severe 
 
- Crypt hyperplasia   7 4 3 0 0 
- Crypt dilation and distortion   7 3 3 1 0 
- Mucosal fibrosis and atrophy   7 6 1 0 0 
  Inflammatory criteria
#
      
- Lamina propria LPC   7 6 1 0 0 
- Lamina propria eosinophils   7 7 0 0 0 
- Lamina propria neutrophils   7 5 0 1 1 
- Lamina propria macrophages   7 7 0 0 0 
N: sample size; LPC: lymphocytes/plasma cells; MA: mucosal atrophy; 
†
using the WSAVA criteria for histologic 
evaluation of gastrointestinal inflammation; 
#
individual criteria were graded as normal (grade 0), mild (grade 1), moderate 
(grade 2), or severe lesions (grade 3); 
$
the composite score reflects the highest grade for any individual morphologic and/or 
inflammatory criteria within the respective gastrointestinal segment.
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Figure 28 – Fecal canine S100A12 concentrations in healthy dogs and dogs with IBD. 
FcA12 concentrations in single spot samples were significantly higher in the 26 dogs 
with IBD (median [IQR]: 223 [21–3477] ng/g) than in the 90 healthy controls (median 
[IQR]: 9 [5–31] ng/g; P < 0.0001). Box plots indicate the median and interquartile range 
of fcA12 concentrations, the whiskers represent the inner Tukey fences, and the dashed 
lines represent the optimal criterion concentrations (59 and 174 ng/g) for distinguishing 
dogs with IBD from healthy controls. 
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(95% confidence interval [CI]: 44–83%) and 84% (95%CI: 75–91%), respectively, with 
an area under the ROC curve (AUC) of 81% (95%CI: 71–91%) and a misclassification 
of 20%. A cut-off concentration of 174 ng/g yielded a specificity of >90% (93%; 
95%CI: 86–98%) but a lower sensitivity (54%, 95%CI: 33–73%) and a misclassification 
rate of 16%. 
 
4.3.3.1. FcA12 and CCECAI, endoscopic lesions, and histologic disease severity in dogs 
with IBD 
 The fcA12 concentration and CCECAI score were significantly associated (Table 
9). Moreover, fcA12 concentrations correlated with the severity of endoscopic lesions in 
the duodenum and colon (Table 9, Fig. 29), however, they failed to correlate with the 
sum score for histopathologic changes (Table 9). A total score comprising the composite 
endoscopic lesion score and CCECAI (weighted and unweighted) was found to have a 
slightly stronger association with fcA12 (Table 9). Only the endoscopic disease score in 
the duodenum and the composite endoscopic lesion score were significantly correlated 
with the CCECAI score (Spearman ρ = 0.6398, unadjusted P = 0.0006, Holm–
Bonferroni adjusted P = 0.0018 and Spearman ρ = 0.4413, unadjusted P = 0.0240, 
Holm–Bonferroni adjusted P = 0.0480, respectively) whereas the severity of histologic 
lesions was not associated with clinical disease activity. The severity of macroscopic 
(endoscopic) and microscopic (histologic) disease was not correlated. Of the 
histopathologic criteria, only the composite inflammation score in the colon was 
significantly associated with the concentration of fcA12 (Table 10). Fecal cA12 
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Table 9 – Correlation of fcA12 with disease activity scores. Correlation between fecal S100A12 (fcA12) concentrations and 
the clinical disease activity, and the severity of endoscopic lesions and histopathologic changes in dogs with inflammatory 
bowel disease (IBD; n=26). 
Parameter   correlated with   fecal canine S100A12 (ng/g)  
 N Spearman ρ unadjusted P
†
 adjusted P
#
 
     
CCECAI score 26  0.4778 0.0136 0.0408 
Endoscopic disease score (sum) 26  0.4378 0.0253 0.0506 
- Stomach 24  0.0703 0.7443 0.7443 
- Duodenum 25  0.4703 0.0177 0.0354 
- Colon   5  0.9747 0.0048 0.0144 
Histologic disease score (sum) 26 -0.1400 0.4952 0.4952 
- Stomach 10  0.1776 0.6234 0.6234 
- Duodenum 23 -0.1975 0.3664 0.7328 
- Colon   7  0.5426 0.2082 0.6246 
CCECAI 
+ composite endoscopic score
$
 
26  0.5335  
 (0.4951) 
0.0050 
(0.0101) 
0.0100 
(0.0303) 
CCECAI 
+ hypocobalaminemia 
+ composite endoscopic score
$
 
26  0.5520 
 (0.4018) 
0.0035 
(0.0419) 
0.0105 
(0.0419) 
CCECAI 
+ hypocobalaminemia
$
 
26  0.5109  
 (0.4298) 
0.0076   
(0.0284) 
0.0076  
(0.0568) 
N: sample size;
 
CCECAI: canine chronic enteropathy clinical activity index; 
†
without correction (P < .05);  
#
after Holm-
Bonferroni correction (n=3); 
$
unweighed (weighed).
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Figure 29 – Correlation of fecal canine S100A12 concentrations and macroscopic 
(endoscopic) disease severity. FcA12 concentrations in single spot samples correlated 
with the severity of endoscopic lesions in the colon (ρ = 0.9747, adjusted P = 0.0144; 
closed symbols) and the duodenum (ρ = 0.4703, adjusted P = 0.0354; open symbols). 
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Table 10 - Correlation of fcA12 with variables of the histologic score for canine IBD. Relationship between fecal S100A12 
(fcA12) concentrations and the severity of morphologic and inflammatory histologic lesions found within the gastrointestinal 
tract in dogs with inflammatory bowel disease (IBD; n=26). 
 
Histologic 
findings 
correlated with  fecal canine S100A12 (ng/g)  
 N Spearman ρ unadjusted P
†
 adjusted P
#
 
     
Duodenum (composite score) 23 -0.3264 0.1285 0.2570 
   Morphologic criteria (sum) 23 -0.4268 0.0422 0.0844 
- Villus stunting 23 -0.3297 0.1245 ns 
- Epithelial injury 23 -0.4365 0.0373 0.1865 
- Crypt distension 23 -0.2963 0.1698 ns 
- Lacteal dilation 23 -0.2147 0.3252 ns 
- Mucosal fibrosis 23 -0.3536 0.0979 ns 
  Inflammatory criteria (sum) 23 -0.1052 0.6328 ns 
- Intraepithelial lymphocytes 23  0.0974 0.6584 ns 
- Lamina propria LPC 23  0.3376 0.1151 ns 
- Lamina propria eosinophils 23 -0.1861 0.3952 ns 
- Lamina propria neutrophils 23 -0.5110 0.0127 0.0635 
- Lamina propria macrophages 23 -0.4187 0.0467 ns 
Colon (composite score) 7  0.5426 0.2082 ns 
   Morphologic criteria (sum) 7  0.2058 0.6579 ns 
- Epithelial injury 7  0.7572 0.0487 0.1948 
- Crypt hyperplasia 7 -0.4330 0.3318 ns 
- Crypt dilation and distortion 7  0.6172 0.1398 ns 
- Mucosal fibrosis and atrophy 7 -0.6124 0.1438 ns 
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Table 10 – continued 
Histologic 
findings 
correlated with  fecal canine S100A12 (ng/g)  
 N Spearman ρ unadjusted P
†
 adjusted P
#
 
     
  Inflammatory criteria (sum) 7  0.8669 0.0115 0.0230 
- Lamina propria LPC 7  0.2041 0.6606 ns 
- Lamina propria eosinophils 7 - - - 
- Lamina propria neutrophils 7  0.7572 0.0487 0.0974 
- Lamina propria macrophages 7 - - - 
N: sample size; LPC: lymphocytes/plasma cells; ns: non-significant;
 †
without correction (P < .05); 
#
after Holm-
Bonferroni correction (n=2, 4, or 5).
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concentrations were higher if the inflammatory infiltrate had a phagocytic component 
(i.e., neutrophils and macrophages) (median: 15,830 ng/g, IQR: 19–110,400 ng/g; n = 3 
vs. median: 174 ng/g, IQR: 21–2640 ng/g; n = 23), but this difference did not reach 
significance (P = 0.1991). 
 Having a concentration of 273 ng fcA12/g or greater distinguished dogs with at 
least moderate endoscopic disease (a score ≥2) in any GI section from dogs with at most 
mild endoscopic disease (a score ≤1) with a sensitivity of 71% (95%CI: 44–90%) and a 
specificity of 89% (95%CI: 52–100%; AUC: 75%, 95%CI: 55–95%). Dogs with a 
duodenal lesion score of ≥2 were separated from dogs with a duodenal lesion score of ≤1 
at the same fcA12 concentration (273 ng/g) and with a sensitivity and specificity of 75% 
(95%CI: 48–93%) and 89% (95%CI: 52–100%), respectively (AUC: 76%, 95%CI: 57–
96%). Patients with very severe clinical disease (i.e., a CCECAI score of ≥12) were 
separated from those patients with a CCECAI score of <12 at the same cut-off 
concentration (273 ng/g) with 90% sensitivity (95%CI: 56–100%) and 75% specificity 
(95%CI: 48–93%; AUC: 82%, 95%CI: 66–98%) (Fig. 30). 
 
4.3.3.2.  FcA12 and clinicopathologic abnormalities and clinical presentation in dogs 
with IBD 
 In dogs with IBD, fcA12 concentrations were numerically higher in those with 
serum albumin concentrations <20 g/L (median 741 ng/g, IQR: 113–3,700 ng/g; n = 12) 
than in those with higher serum albumin concentrations (median: 55 ng/g, IQR: 10–
2,297 ng/g; n = 14), but this difference was not significant (P = 0.1358). Also, no 
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Figure 30 – Fecal canine S100A12 concentrations in IBD dogs dichotomized by the 
CCECAI score and the score reflecting endoscopic disease severity. (a) FcA12 
concentrations were significantly higher in IBD dogs with very severe clinical disease 
(i.e., a CCECAI score of ≥12) (median [IQR]: 1,821 [371–9,485] ng/g) than in dogs a 
CCECAI score of less than 12 (median [IQR]: 30 [9–1395] ng/g; P = 0.0078). (b) Dogs 
with IBD and at least moderate severity of endoscopic lesions (i.e., a score of at least 2) 
in any of the GI segments had significantly higher fcA12 concentrations (median [IQR]: 
1,001 [42–4,675] ng/g) than dogs with at most mild endoscopic disease severity (i.e., a 
score of ≤1) (median [IQR]: 36 [10–126] ng/g; P = 0.0461). Box plots show the median 
and IQR for fcA12concentration, the whiskers represent the inner Tukey fences, and the 
dashed lines represent the optimal fcA12 concentration (273 ng/g) for distinguishing the 
groups of dogs. 
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difference in fcA12 concentrations was seen between dogs with serum cobalamin 
concentrations <200 ng/L (median: 1,001 ng/g, IQR: 174–3,808 ng/g; n = 11) and those 
with serum cobalamin concentrations ≥200 ng/L (median: 59 ng/g, IQR: 8–2,640 ng/g; n 
= 15; P = 0.0821). Hypoalbuminemia and hypocobalaminemia were significantly 
associated (Pearson’s χ2= 7.72, P = 0.0055). The concentration of serum albumin was 
negatively related to the severity of clinical disease (Spearman ρ = −0.5642, unadjusted 
P = 0.0096, Holm–Bonferroni adjusted P = 0.0288) but was not associated with the 
severity of endoscopic lesions (Spearman ρ = −0.0684, P = 0.7745) or histologic 
changes (Spearman ρ = 0.4526, unadjusted P = 0.0451, adjusted P = 0.0902). 
 Fecal cA12 concentrations in IBD dogs that had received steroids at the time of 
evaluation (median: 155 ng/g, IQR: 22–3,700 ng/g; n = 8) did not differ from those in 
dogs that had not (median: 288 ng/g, IQR: 17–2,925 ng/g; n = 18; P = 0.9778). Fecal 
cA12 concentrations were also not different in dogs with IBD that had received 
antibiotics prior to evaluation (median: 49 ng/g, IQR: 7–2,782 ng/g; n = 8) compared to 
dogs that had not been treated with antimicrobials (median: 442 ng/g, IQR: 47–3,801 
ng/g; n = 16; P = 0.3123). FcA12 concentrations did not correlate with the chronicity of 
GI signs observed (ρ = −0.0741, P = 0.7369). Although the number of dogs with large 
intestinal involvement was small (n = 5), concentrations of fcA12 did not differ 
significantly between this patient group (median: 174 ng/g, IQR: 10–63,115 ng/g) and 
dogs with only confirmed small intestinal disease (median: 273 ng/g, IQR: 23–3,008 
ng/g; n = 21; P = 0.7450). 
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4.4.  Discussion 
 Endoscopy, histopathologic confirmation of inflammation, and ruling out known 
causes of intestinal inflammation are considered the gold standard for diagnosing canine 
IBD (Washabau et al., 2010). However, endoscopy is time-consuming and invasive and, 
in veterinary medicine, it requires general anesthesia and, before colonoscopy, thorough 
preparation of the colon. Surrogate biomarkers that objectively reflect mucosal disease 
severity and could help the clinician monitor GI inflammation might be useful in clinical 
practice. 
 To our knowledge, this paper is the first to report fcA12 concentrations in dogs 
with IBD. Concentrations of fcA12 were significantly higher in dogs with IBD, which 
agrees with a more than 10-fold observed up-regulation of S100-mRNA at the mucosal 
level in dogs with IBD in one study (Wilke et al., 2012). However, there was also an 
overlap of fcA12 concentrations between dogs with IBD and healthy dogs. 
Concentrations of fcA12 in healthy dogs were comparable to those found in healthy 
people (Kaiser et al., 2007). However, the fcA12 concentrations in dogs with IBD were 
lower than those in people with active Crohn’s disease (CD) or ulcerative colitis (Kaiser 
et al., 2007; van de Logt and Day, 2013). This difference could be explained by the 
smaller number of granulocytes found in the intestinal mucosa of dogs with IBD. 
Alternatively, it could be due to differences in S100A12 expression and release from 
canine granulocytes and other cell lines, or species-specific differences in the pathways 
involved in canine granulocyte activation. Likewise, the cut-off for distinguishing dogs 
with active IBD from healthy dogs was about 10-fold lower than that in people (Kaiser 
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et al., 2007). It should also be noted that immunoassays are not truly analytical because 
they are based on antigen–antibody binding which can be affected by several factors, 
such as antibody avidity. Thus, the difference between fcA12 in people and in dogs may 
not represent a true difference in fecal concentrations between these two species, but 
rather a difference in the efficiency of the two assay systems to measure S100A12. 
Regardless, the significant difference in fcA12 concentrations between dogs with IBD 
and healthy control dogs suggests that the number of infiltrating phagocytes, which tend 
to appear later in the course of IBD, and/or their activation status in dogs is sufficient to 
cause increases in fcA12. These results also support that phagocyte activation plays a 
role in the pathophysiology of canine IBD. An increased expression and/or secretion of 
the proinflammatory (Yang et al., 2001; Hofmann et al., 1999), phagocyte-specific 
DAMP molecule S100A12 support the important role of the innate immunity in canine 
IBD (Burgener et al., 2008; Luckschander et al., 2010; Kathrani et al., 2012) and could 
be an important factor for the recruitment of cells of the acquired immunity. 
 The diagnosis of IBD requires the collection of biopsies, which may not be 
practical to routinely re-assess disease activity at follow-up examinations. FcA12 
concentrations and the CCECAI scores were equally correlated with the severity of 
endoscopic disease in the duodenum. FcA12 correlated slightly more closely with 
endoscopic disease severity in the colon, although the sample size was very small. This 
is consistent with findings in people with CD (van de Logt and Day, 2013) and suggests 
that fcA12 could be a marker to assess the severity of endoscopic lesions. A possible 
explanation for a closer correlation offcA12 with the endoscopic disease severity in the 
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colon could be an increased granulocytic expression of cA12 in canine IBD localized to 
the colon and/or lack of stability of extracellular cA12 as it travels aborad through the GI 
tract. However, further studies are needed to confirm these findings and to determine 
whether fecal fcA12 concentrations decrease with endoscopic mucosal healing and could 
thus be useful to monitor endoscopic remission. Although endoscopic disease activity 
has received little attention in canine IBD, severe mucosal lesions in the duodenum were 
associated with a negative outcome in dogs with chronic enteropathies (Allenspach et 
al., 2007). Also, endoscopic lesions improved with successful treatment of dogs with 
chronic enteropathies (García-Sancho et al., 2007). Thus, further research to determine 
the practical value of fcA12 as an inflammatory marker for dogs with IBD is warranted. 
 Like others (García-Sancho et al., 2007; McMahon et al., 2010; Mandigers et al., 
2010), we found no correlation between clinical signs and the severity of histologic 
lesions in dogs with IBD. Also, the lack of a relationship between endoscopic and 
histologic disease severity (assessed by an unweighted scoring system that considers 
both morphologic and inflammatory changes), as seen in this study, has been reported 
previously (Allenspach et al., 2007; García-Sancho et al., 2007). This may reflect the 
localized nature of the disease process. The lack of a correlation between clinical disease 
severity and the degree of histologic changes could also be explained by the functional 
pathophysiology of canine IBD. Inflammation and inflammatory mediators (even if 
localized to only a segment of the GI tract) can significantly affect intestinal epithelial 
cell function and structure. On the other hand, a change in GI physiology and epithelial 
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barrier function can cause immune-mediated mucosal damage and inflammatory 
mediator expression. 
 FcA12 concentrations were not associated with the site of inflammatory lesions 
within the GI tract which agrees with one study in people with IBD (Kaiser et al., 2007). 
However, it contrasts with the strong dependence on disease location demonstrated by 
others, who found a significantly higher release of S100A12 from the colonic mucosa 
than from the ileal mucosa in patients with active CD (Föll et al., 2008). However, not 
all dogs in our study had both upper and a lower GI endoscopy performed. Also, the 
potential contribution of colonic and/or ileal lesions to fcA12 concentrations cannot be 
ruled out in these cases. Likewise, the possibility of lesions in sections of the GI tract 
that are not within reach of the endoscope (e.g., the jejunum) cannot be excluded. 
Another assumption made for analytes measured in fecal samples is their ability to 
withstand the GI passage. Although we have demonstrated the short-term stability of 
cA12 in fecal samples stored at −80°, −20°, +4°, and approximately +23°C for 7 days 
(Heilmann et al., unpublished data), its stability within the GI tract has not been 
investigated and further studies are needed to clarify this issue. 
 FcA12 and CCECAI were correlated in this study which is consistent with the 
relationship between fecal S100A12 and the colitis activity index (CAI; a scoring system 
based on clinical disease severity scores similar to the CCECAI) in human patients with 
ulcerative colitis but not the lack of correlation with the CD activity index (a clinical 
disease activity index used in people with CD) (Kaiser et al., 2007). Interestingly, 2 dogs 
in our study group that had ulcerative lesions in the colon and a mixed inflammatory 
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infiltrate were assessed as having very severe (CCECAI score of 13 and 17) clinical 
disease. However, these 2 cases were not found to be the main contributors to the 
significant relationship between fcA12 and CCECAI. Lack of a correlation between 
fcA12 and the severity of histologic changes is in contrast with findings in people with 
CD or ulcerative colitis where fecal A12 showed a moderate correlation with an 
inflammation score reflecting histologic disease severity (Kaiser et al., 2007). This may 
again reflect the localized nature of the disease process, the smaller number of 
granulocytes found in the intestinal mucosa of dogs with IBD, and/or species-specific 
differences in the functional pathophysiology of canine IBD. 
 Although fcA12 concentrations ranged between 1 and 1,810 ng/g in the healthy 
control group of dogs and were significantly different from concentrations of fcA12 in 
dogs with IBD (range: 5–110,400 ng/g), an overlap between both groups was noted. 
However, in most of the healthy dogs (93%), fcA12 concentrations were <170 ng/g, with 
the remaining dogs clustering between 635 and 1,810 ng/g. The higher fcA12 
concentrations in 6 of the control dogs might be explained by biological variation. 
However, because ethical considerations prevented us from performing more invasive 
studies in the control dogs, the presence of subclinical intestinal inflammation in 
individual dogs, which may have led to falsely classifying dogs with subclinical 
inflammation of the GI mucosa as healthy, cannot be definitively ruled out. There was 
no reason to remove these 6 dogs as outliers from the data set, and establishment of 
fcA12 concentrations in healthy dogs and further stratification of the reference sample 
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group (e.g., by body condition score, recent vaccination) will be needed to clarify 
whether these are true outliers. 
 Interestingly, serum cobalamin concentration was decreased in more than 50% of 
dogs with IBD in this study, and more than 80% of the dogs had a serum cobalamin 
concentration <400 ng/L. These numbers are higher than previously reported in dogs 
with GI diseases (Allenspach et al., 2007; Berghoff et al., 2013), but are consistent with 
the frequency of hypoalbuminemia in dogs in this study. This finding indicates that, 
beyond the need of cobalamin supplementation in the majority of dogs with IBD, ileal 
lesions would have remained undiagnosed. However, cobalamin-dependent metabolites, 
such as the concentration of serum methylmalonic acid and/or serum homocysteine, 
were not evaluated in this study. 
 A major limitation of the study is the fact that the patients were from 2 different 
institutions, introducing inter-operator variation. Also, endoscopic disease severity in 
dogs (n = 9) enrolled at the second center (RVC) was graded retrospectively based on 
endoscopy reports that were generated using currently accepted guidelines (Washabau et 
al., 2010; Day et al., 2008). The inclusion of only dogs with a histopathologic diagnosis 
of IBD and no concurrent diseases that could affect the GI tract as well as the tertiary 
care setting are sources of potential bias. Such a bias may have artificially increased the 
diagnostic accuracy (Bossuyt et al., 2003a) of fcA12 found in this study. Also, fcA12 
was measured in samples that had been stored for up to 15 months. Although we have 
demonstrated that fcA12 is stable at various temperatures for 7 days (Heilmann et al., 
unpublished data), the long-term stability of fcA12 warrants further study. A further 
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limitation of this study is that ileal lesions, which often do not correlate with lesions 
found in the duodenum or colon (Washabau et al., 2010; Casamian-Sorrosal et al., 
2010), were not evaluated. Also, chronic enteropathies in dogs are classified according 
to the response to therapeutic intervention as food-responsive diarrhea, antibiotic-
responsive diarrhea, or steroid-responsive idiopathic IBD (Allenspach et al., 2007). As it 
was the aim of this study to evaluate the association of fcA12 concentrations with 
clinical, endoscopic and histologic disease severity, the potential of fcA12 to distinguish 
dogs with IBD that may respond to various therapies was not investigated. Thus, further 
prospective studies are needed to evaluate this possibility by further stratifying the 
patient population according to the response to diet, antibiotics, or steroids and/or other 
immunosuppressant medications as well as according to disease outcome. Further work 
is also needed to determinefcA12 concentrations in infectious gastroenteritis. 
 The results of this study are a first step toward the clinical evaluation of fcA12 as 
a non-invasive marker for diagnosing and monitoring GI inflammation in dogs. Further, 
evaluation of the role of cA12 in spontaneous inflammatory diseases in dogs (such as 
IBD) can potentially be translated to human medicine, where rodent models cannot be 
used to study A12 as it has been lost during rodent evolution (Fuellen et al., 2004). 
 
4.5.  Conclusions 
 In summary, fecal canine S100A12 (fcA12) concentrations were increased in 
dogs with IBD compared to healthy control dogs, but were only moderately accurate in 
distinguishing dogs with IBD from healthy controls. In dogs with IBD, fcA12 correlated 
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with the clinical disease activity, the severity of intestinal endoscopic (macroscopic) 
lesions, and with the histologic inflammatory changes in the colon but not with the 
severity of histologic lesions overall. These results suggest that fcA12 may be a useful 
adjunct for assessing macroscopic (endoscopic) disease severity in canine IBD. Further 
research is needed to assess the utility of measuring fcA12 in clinical practice and to 
evaluate the potential of fcA12 in canine IBD to reflect clinical remission and/or 
mucosal healing. 
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5. SYSTEMIC LEVELS OF THE ANTI-INFLAMMATORY DECOY RECEPTOR 
SOLUBLE RAGE (RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS) 
ARE DECREASED IN DOGS WITH INFLAMMATORY BOWEL DISEASE
§
 
 
5.1  Introduction 
 Inflammatory bowel disease (IBD) is a common disease in dogs and a 
dysregulated innate immunity appears to play a major role in its pathogenesis (Jergens 
and Simpson, 2012). S100A12 (also known as extracellular newly identified RAGE 
binding protein [EN-RAGE]) is an endogenous damage-associated molecular pattern 
(DAMP) molecule that is involved in phagocyte activation and has been shown to be 
increased in serum and fecal specimens from dogs with IBD (Heilmann et al., 2012b). 
Fecal canine S100A12 concentrations were also associated with endoscopic disease 
severity in dogs with IBD (Heilmann et al., 2014a). S100/calgranulins, such as 
S100A12, a family of small calcium-binding proteins that accumulate at sites of 
inflammation, represent ligands for the receptor of advanced glycation end products 
(RAGE) (Hofmann et al., 1999), a multi-ligand pattern-recognition receptor and member 
of the immunoglobulin superfamily with potential similarities to the family of Toll-like 
receptors. Results of studies in humans with IBD suggest a role of RAGE in chronic 
inflammation (Hofmann et al., 1999). The ligand–RAGE interaction has been shown to 
                                                 
§
Reprinted with permission from Heilmann, R.M., Otoni, C.C., Jergens, A.E., Grützner, 
N., Suchodolski, J.S., Steiner, J.M., 2014. Systemic levels of the anti-inflammatory 
decoy receptor soluble RAGE (receptor for advanced glycation end products) are 
decreased in dogs with inflammatory bowel disease. Veterinary Immunology and 
Immunopathology 161, 184-192, Copyright (2014) by Elsevier. 
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induce sustained post-receptor signaling, including activation and nuclear translocation 
of nuclear factor (NF)-kappa B (Basta et al., 2002; Bucciarelli et al., 2002), and the 
upregulation of RAGE itself is believed to lead to perpetuation and amplification of the 
inflammatory response (Bierhaus et al., 2005; Li and Schmidt, 1997). 
 Human RAGE is only constitutively expressed in the lung and skin, whereas in 
other cell lines (e.g., monocytes/macrophages, endothelial cells) postembryonic RAGE 
expression is induced by either accumulation of its ligands and/or activation of 
transcription factors (e.g., NF-kappa B) that regulate RAGE expression (Schmidt et al., 
2000; Bierhaus et al., 2005). Human RAGE is believed to have the potential to convert a 
transient inflammatory response (e.g., cell stress, NF-kappa B activation) into a 
sustained cellular inflammatory response (Bierhaus et al., 2005). The expression of 
RAGE coincides with a proinflammatory microenvironment (e.g., in IBD), and the 
upregulation of RAGE has been shown to increase the recruitment of inflammatory cells 
through the upregulation of endothelial adhesion molecules VCAM-1 and ICAM-1 
(Schmidt et al., 2000; Bierhaus et al., 2005). 
 Soluble RAGE (sRAGE), a truncated splice-variant of RAGE, functions as a 
decoy receptor sequestering ligands such as DAMPs (e.g., S100A12) thus preventing 
ligand interaction with cell surface RAGE. Soluble RAGE has been shown to be 
decreased in humans with chronic inflammatory diseases (Bierhaus et al., 2005) such as 
inflammatory bowel disease (Meijer et al., 2014), juvenile idiopathic arthritis (Myles et 
al., 2011), Sjögren’s syndrome (Stewart et al., 2008), asthma and chronic obstructive 
pulmonary disease (Sukkar et al., 2012) and acute Kawasaki disease (Wittkowski et al., 
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2007). Soluble RAGE has also been suggested to be a potential therapeutic target in 
patients with chronic inflammatory conditions (Hudson et al., 2003) based on an 
improved outcome in an experimental model of colitis (Hofmann et al., 1999). 
Moreover, experimental studies suggest that sequestration of ligands by sRAGE pre-
vents interaction of these ligands with RAGE, but also with other pattern-recognition 
receptors (Bierhaus et al., 2005). 
 Canine RAGE has been characterized (Murua Escobar et al., 2006; Sterenczak et 
al., 2009), and the existence of its naturally occurring splicing variants and the 
expression of RAGE in different tissues has been described (Sterenczak et al., 2009, 
2011). However, the sRAGE/RAGE axis has not been studied in canine IBD. Thus, this 
study aimed to validate an ELISA for the measurement of sRAGE in dogs, and to 
evaluate serum sRAGE and serum/fecal S100A12 concentrations in the diagnosis and 
treatment of canine IBD. We hypothesized that (1) serum sRAGE concentrations are 
decreased in dogs with IBD compared to healthy controls, and (2) the serum 
concentration of sRAGE in dogs with IBD correlates with clinical disease activity, 
severity of histologic lesions, outcome, and/or the concentration of S100A12 in serum 
and/or fecal specimens. 
 
5.2  Materials and Methods 
5.2.1.  Study population 
 Serum and fecal samples were collected from 35 dogs between 2011 and 2013. 
The study was approved by the Iowa State University (ISU) Institutional Animal Care 
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and Use Committee and the Institutional Clinical Research Review Committee at Texas 
A&M University, and owner consent was obtained before enrollment of dogs. 
Information on some of the dogs used in this study has been previously reported (Otoni 
et al., 2012). 
 
5.2.1.1.  Patient group 
 Twenty of the dogs were presented to the ISU Veterinary Teaching Hospital for 
further evaluation of chronic gastrointestinal signs (i.e., vomiting and/or diarrhea of at 
least 3 weeks duration). Dietary and antibiotic trials had been performed in 8 and in 9 of 
the dogs, respectively. Prior to presentation, 3 dogs had received prednisone and 3 dogs 
had received supplemental cyanocobalamin injections weekly. A complete work-up was 
performed in all dogs, which included an upper gastrointestinal endoscopy 
(esophagogastroduodenoscopy) and collection of endoscopic tissue biopsies. The 
histopathologic criteria established by the World Small Animal Veterinary Association 
(WSAVA) Gastrointestinal Standardization group (Day et al., 2008; Washabau et al., 
2010) were used to assess histologic disease. Clinical disease activity was assessed using 
the canine IBD activity index (CIBDAI) scoring system (Jergens et al., 2003). A serum 
sample and 3 fecal samples collected on 3 consecutive days were obtained upon 
presentation. Following the diagnostic workup, dogs received prednisone, prednisone 
and cyclosporine, or budesonide and/or metronidazole, and were given a commercial 
elimination (i.e., novel protein or hydrolyzed protein) diet. Six dogs received parenteral 
supplemental cobalamin, and a fiber supplement was added in 2 patients. An additional 
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serum and 3 fecal samples were collected when patients were re-evaluated 
approximately 3 weeks after the initial evaluation at the ISU Veterinary Teaching 
Hospital after initiation of medical treatment. At that time the response to treatment was 
assessed using the CIBDAI scoring system (complete clinical remission was defined as a 
≥75% decrease in CIBDAI; partial response was defined as a 25–75% decrease in 
CIBDAI; and no response was defined as a ≤25% decrease in CIBDAI). 
 
5.2.1.2.  Healthy controls 
 Serum was collected from 15 healthy control dogs (based on a non-invasive 
assessment of health) at the College of Veterinary Medicine at Texas A&M University 
(n = 2) and at the ISU Veterinary Teaching Hospital (n = 13). Fecal samples from 3 
consecutive days were also collected from the 13 healthy dogs enrolled at ISU. 
 
5.2.2.  Canine RAGE Western blot 
5.2.2.1.  Extraction of tissues 
 For anti-canine RAGE analysis, a leukocyte extract was prepared as follows: 
white blood cells were harvested after dextran sedimentation and hypoosmolar 
erythrolysis. Cells were then suspended in lysis buffer (0.05 M Tris/HCl, 0.15 M NaCl, 
1% [v/v] Igepal-630 [NP-40], pH 7.4; with one proteinase inhibitor tablet [Complete 
EDTA-free proteinase inhibitor cocktail tablets, Roche Diagnostics, Mannheim, 
Germany] added per 10 mL of buffer) followed by repeated sonication and freeze-thaw 
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cycles, and finally, harvesting the supernatant fraction after centrifugation at 15,000×g 
for 12 min at +4°C and clearance by filtration through a 0.45 μm-pore size filter. 
 Based on the tissue expression of RAGE in humans (Schmidt et al., 2000), 
canine lung and cerebral cortex were included as positive control tissues. Canine lung 
and brain tissue extracts for anti-canine RAGE analysis were prepared by adding 30 mL 
of lysis buffer to 5 g of surplus tissue, followed by repeated sonication and freeze–thaw 
cycles, and finally, harvesting the supernatant fraction after high-speed centrifugation 
and filtration. 
 
5.2.2.2.  Western blotting 
 All samples were subjected to SDS–PAGE (10% Bis/Tris gel, Invitrogen, 
Carlsbad, CA, USA) followed by electrotransfer onto a PVDF membrane for 7 min at 20 
V (iBlot
®
, Invitrogen, Carlsbad, CA, USA). Prior to immunoblot analysis, membranes 
were blocked overnight at 4°C with 0.01 M Tris/HCl, 0.15 M NaCl, 0.05%Tween, 10% 
(w/v) BSA; pH 7.6 (block buffer) followed by a 1 h-incubation at room temperature 
(approximately 23°C) with the primary Ab (i.e., goat polyclonal anti-recombinant human 
RAGE [AHP594, AbD serotec, Bio-Rad Laboratories, Hercules, CA, USA] diluted 
1/500-1/5000 or sheep polyclonal anti-recombinant canine RAGE [Sheep anti-
recombinant canine RAGE, R&D Systems, Minneapolis, MN, USA] at 50 μg/L). 
Subsequently, membranes were washed 4 times 5 min in 0.01 M Tris/HCl, 0.15 M NaCl, 
0.05% Tween, pH 7.6 (wash buffer) and then incubated for 1 h at approximately 23°C 
with secondary biotin-conjugated Ab (Biotin-conjugated rabbit anti-goat IgG, Thermo 
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Scientific, Rockford, IL, USA; Biotin-conjugated rabbit anti-sheep IgG; Thermo 
Scientific, Rockford, IL, USA; 60 μg/L). Following another 4 times 5 min washes in 
wash buffer, membranes were incubated for 45 min at approximately 23°C with 
NeutrAvidin-Horseradish peroxidase (NeutrAvidin-horseradish peroxidase [NA-HRP], 
Thermo Scientific, Rockford, IL, USA; 200 μg/L). Finally, blots were washed 4 times 5 
min in wash buffer and protein bands were detected by use of a stabilized substrate (1-
Step™ TMB-Blotting solution, Thermo Scientific, Rockford, IL, USA). 
 
5.2.3.  Canine serum soluble RAGE (sRAGE) ELISA 
5.2.3.1.  ELISA procedure 
 Enhanced-binding ELISA plates (MaxiSorp™ Nunc-Immuno™ Plates, Thermo 
Scientific, Rockford, IL,USA) were coated with affinity-purified polyclonal anti-canine 
RAGE Ab (Sheep anti-recombinant canine RAGE, R&D Systems, Minneapolis, MN, 
USA; 150 ng/well) in 0.2 M carbonate-bicarbonate; pH 9.4, incubated for 1 h at 37°C, 
and washed twice with 0.1 M PBS, pH 7.2 and once with PBS containing 0.05% (v/v) 
polyoxyethylene-20 sorbitan monolaurate. Nonspecific binding sites were blocked with 
PBS supplemented with 30% (v/v) newborn calf serum, 1% (v/v) Triton X-100; pH 8.0 
(assay buffer), plates were incubated for 1 h at 37°C and again washed three times as 
described. Calibrator solutions with different canine RAGE concentrations 
(Recombinant canine RAGE, R&D Systems, Minneapolis, MN, USA; 5, 2, 1, 0.5, 0.2, 
0.1, and 0.02 ng/mL in assay buffer) and test samples (assayed in a 1:2 dilution in assay 
buffer) were applied to each plate in duplicates of 100 μL solution. For the blanks, the 
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canine RAGE standard was replaced by assay buffer. Plates were incubated again for 1 h 
at 37°C and washed as described. To detect captured Ag, plates were incubated with 
biotinylated anti-canine RAGE (Biotinylated anti-recombinant canine RAGE, R&D 
Systems, Minneapolis, MN, USA; 60 ng/well) for another hour at 37°C and washed 
three times. Then, the plates were incubated with NA-HRP diluted in PBS, 1% (w/v) 
BSA (20 ng/well) for another hour at 37°C, washed three times, and developed with a 
stabilized 3,3’,5,5’-tetramethylbenzidine substrate (1-Step™ Ultra TMB-ELISA, 
Thermo Scientific, Rockford, IL, USA). After 10 min incubation, the reaction was 
stopped by adding 4 M acetic acid, 0.5 M sulfuric acid, and the absorbance was 
measured in each well at 450 nm using an automated plate reader (Synergy 2 Alpha 
Microplate Reader, BioTek
®
, Winooski, VT, USA). A commercial software (Gen5™ 
Data Analysis Software [v1.05], BioTek
®
, Winooski, VT, USA) was used to calculate a 
5-parameter logistic curve fit (y = f [x] = d + [(a–d)/(1 + (x/c)b)e], where y is the 
dependent variable, x is the independent variable, and a through e describe the shape of 
the curve) and to determine canine serum sRAGE concentrations in test samples. 
 
5.2.3.2.  Partial analytical validation of the ELISA 
 The RAGE ELISA was analytically validated by determination of the lower 
detection limit, dilutional parallelism, spiking recovery, and intra- and inter-assay 
variability. Lower detection limit of the assay was determined by calculating the mean 
response plus three SD for 5 replicates (10 wells) of the blank solution and transposing 
this value onto the standard curve. Dilutional parallelism was determined by evaluating 
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one serum sample at a serial 2-fold dilution from 1:2 to 1:8 and three samples with 
higher serum canines RAGE concentrations at serial twofold dilutions from 1:2 to 1:16. 
The remaining validation parameters were determined using four different serum 
samples in a dilution of 1:2 with assay buffer. Spiking recovery was determined by 
adding 0, 0.025, 0.05, 0.1, 0.25, 0.5, 1.0, and 2.5 ng/mL recombinant canine RAGE 
(R&D Systems) to each of four test samples and calculating the percentage of standard 
Ag recovery ([observed value (ng/mL)/expected value (ng/mL)] × 100). Intra-assay 
variability of the ELISA was evaluated by assaying four serum samples 8 times each 
within the same assay and calculating the intra-assay coefficients of variation for each 
sample (%CV = [SD/mean] × 100). Inter-assay variability of the assay was determined 
by analyzing four serum samples in 8 consecutive assay runs and calculating inter-assay 
%CVs. 
 
5.2.4.  Serum sRAGE and serum and fecal S100A12 analysis 
 Serum sRAGE concentrations were measured in serum samples (diluted 1:2) 
using the canine sRAGE ELISA described above. Serum and fecal canine S100A12 
(cS100A12) concentrations were measured by an in-house ELISA previously described 
(Heilmann et al., 2014). 
 
5.2.5.  Data and statistical analysis 
 Statistical analyses were performed using commercial software packages (JMP
®
 
v10.0, SAS Institute, Cary, NC, USA; GraphPad Prism
®
 v5.0, GraphPad Software, San 
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Diego, CA, USA). A Shapiro–Wilk W and a Brown–Forsythe test were used to assess 
normality and equal variances of the data. A Wilcoxon rank sum test was used to 
compare values in dogs with IBD vs. healthy controls, and in dogs with a positive 
outcome (i.e., clinical remission) vs. those that were euthanized. A Spearman rank sum 
correlation coefficient was used to assess the potential relationship of serum sRAGE 
concentrations with clinical disease activity (using the CIBDAI scoring system), serum 
and fecal cS100A12 concentrations, and histologic disease severity (using a 4-point 
semi-quantitative grading system). Associations were tested using a Fisher’s exact test or 
the likelihood ratio test, as appropriate, and the odds ratio (OR) and the 95% confidence 
interval (CI) were calculated. A receiver-operating characteristic curve was generated 
and the likelihood ratio was used to calculate sensitivity and specificity at the optimum 
sRAGE concentration to distinguish dogs with IBD from healthy controls. 
 
5.3.  Results 
 Canine RAGE-pAb was demonstrated to be specific for canine RAGE as 
indicated by Western blot analysis (Fig. 31) whereas the polyclonal anti-recombinant 
human RAGE did not detect the canine RAGE protein. An ELISA for measuring canine 
sRAGE concentrations in serum samples was established and analytically validated. The 
lower detection limit of the canine sRAGE assay was 26 ng/L, which translates into a 
serum canine sRAGE concentration of 52 ng/L considering a 1:2 dilution used for serum 
samples. Observed-to-expected (O/E) ratios for dilutional parallelism of four serum 
samples ranged from 73.2 to 122.0% (mean ± SD: 103.3 ± 18.3%), and O/E ratios for
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Figure 31 – Antibody specificity evaluated by Western blotting. Western blot analysis 
using the polyclonal anti-recombinant canine RAGE (α-rcRAGE) revealed (a) 
monomeric and dimeric forms of rcRAGE (red arrows) and (b) canine RAGE in tissue 
extracts from dogs, with two different isoforms of monomeric canine RAGE as well as 
an assembly of dimers found in the lung (gray arrows) where RAGE is constitutively 
expressed. Only faint bands of monomeric as well as dimeric canine RAGE were 
detected in the extract of cerebral cortex (blue arrows). No bands were detected in canine 
white blood cells (WBC) where postembryonic RAGE expression is induced. (c) 
Loading controls (SDS-PAGE) for the tissue extracts are also shown. 
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spiking four different serum samples with seven different canine RAGE concentrations 
ranged from 76.3 to 103.9% (mean ± SD:91.3 ± 7.3%). Coefficients of variation for 
intra- and inter-assay variability were 10.7, 8.1, 4.1, and 3.7% and 19.3, 11.5, 21.7, and 
6.5%, respectively. Serum canine sRAGE concentrations in 15 healthy dogs ranged from 
below the detection limit of the assay (52 ng/L) – 802 ng/L (median: 448 ng/L). 
 Serum sRAGE concentrations were significantly lower in dogs with IBD 
(median [interquartile range, IQR]: <52 [<52–309] ng/L) than in healthy controls (448 
[326–536] ng/L; p = 0.0003; Fig. 32). Although the sample size was small, using 340 
ng/L as a cut-off, the sensitivity and specificity of serum sRAGE to distinguish dogs 
with IBD from healthy controls was 90% and 73% (area under the curve: 83%). Patient 
characteristics and serum and fecal variables are summarized in Tables 11 and 12, 
respectively. No differences were seen in age (p = 0.174) and sex distribution (p = 
1.000) between both study groups. Serum sRAGE concentrations were not associated 
with the severity of histologic changes (ρ = 0.2009; p = 0.4241), the CIBDAI score 
before (ρ = 0.3922; p = 0.0967) or after treatment (ρ = −0.3929; p = 0.1067), the serum 
cS100A12 concentration before (ρ = 0.0173; p = 0.9214) or after treatment (ρ = 
−0.1937; p = 0.4411), the fecal cS100A12 concentration before (ρ = −0.3160; p = 
0.0732) or after treatment (ρ = −0.1153; p = 0.6596), or with the individual outcome (p = 
0.4066). Clinical remission (p = 0.5727) and the change in serum (ρ = 0.1241, p = 
0.6126) and fecal cS100A12 (ρ = −0.0500, p = 0.8439) were not significantly associated 
with a change in serum sRAGE concentration after initiation of treatment.
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Figure 32 – Serum sRAGE concentrations in dogs with IBD compared to healthy 
control dogs. Pre-treatment serum sRAGE concentrations were significantly lower in 
dogs with IBD (median [IQR]: <52 [<52–309] ng/L) than in healthy controls (448 [326–
536] ng/L; p = 0.0003). 
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Table 11 – Clinical characteristics of dogs with IBD. 
  
Age (median [range]), years 7.5 [2-12]  
Sex (male/female)     8/12 
Treated with glucocorticosteroids at the time of study (n [%])    3 [15%] 
Treated with antimicrobials at the time of study (n [%])    9 [45%] 
Clinical disease activity, CIBDAI score (median [range])    6 [1–13] 
- mild (n [%])    7 [35%] 
- moderate (n [%])    6 [30%] 
- severe (n [%])    7 [35%] 
Histologic disease severity, grade (median [range])
#,$
    1 [1–3] 
- mild, grade 1 (n [%])    4 [21%] 
- moderate, grade 2 (n [%])  14 [74%] 
- severe, grade 3 (n [%])    1  [5%] 
IBD diagnosis  
- ARD/FRD IBD (n [%])    4 [20%] 
- Idiopathic IBD (n [%])  16 [80%] 
- Hypoalbuminemic (n [%])    9 [56%] 
- Normoalbuminemic (n [%])    7 [44%] 
Response to treatment  
- complete remission (n [%])  16 [80%] 
- partial response (n [%])    3 [15%] 
- no response (n [%])    1  [5%] 
Outcome
‡
  
- alive at the end of the study (n [%])  13 [68%] 
- euthanized due to IBD (n [%])    6 [32%] 
CIBDAI: canine IBD activity index (range of possible scores: 0–18; insignificant 
disease: 0–3, mild disease: 4–5, moderate disease: 6–8, severe disease: ≥9) (Jergens 
et al., 2003); 
#
sum of all segments evaluated (range of possible scores: 0–3). $not 
reported for one patient. 
‡
one patient was censored due to euthanasia for a condition 
unrelated to IBD. ARD/FRD: antibiotic-/food-responsive disease.
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Table 12 – Serum and fecal variables in dogs with IBD. 
    
Parameter Pre-treatment, 
median [IQR] 
Post-treatment, 
median [IQR] 
P-value 
    
Serum soluble RAGE <52 [<52-309] ng/L <52 [<52-182] ng/L 0.9097 
Serum cS100A12 138 [83-294] μg/L 251 [134-313] μg/L 0.0671 
Fecal cS100A12 591 [28-1359] ng/g 26 [4-283] ng/g  0.0014
$
 
RAGE: receptor for advanced glycation end products; IQR: interquartile range. 
$
significant difference between pre- and post-treatment concentrations (p<0.05). 
 
 
 
 
 
 
However, serum sRAGE concentrations increased only in IBD dogs with complete 
clinical remission (n = 15) whereas sRAGE remained the same or decreased in dogs with 
partial or no response to treatment (n = 4). In healthy dogs, serum sRAGE 
concentrations were inversely correlated with age (ρ = −0.5658; p = 0.0279), but a 
similar relationship was not identified in dogs with IBD (p = 0.5852). 
 Sixteen of the IBD dogs were diagnosed with idiopathic IBD based on chronic 
gastrointestinal signs, an inadequate response to dietary and antibiotic trials, 
histopathologic changes on endoscopic tissue biopsies consistent with a diagnosis of 
IBD, and the need for anti-inflammatory/immunosuppressive treatment. The remaining 4 
dogs were classified as having antibiotic- or food-responsive disease (ARD/FRD). Dogs 
with idiopathic IBD had lower serum sRAGE (median [IQR]: <52 [<52–228] ng/L) and 
higher fecal cS100A12 concentrations (median [IQR]: 626 [39–2,147] ng/g) than dogs 
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with ARD/FRD (333 [121–340] ng/L and 31 [15–913] ng/g, respectively) but both 
differences did not reach significance (p = 0.1335 and 0.2772, respectively). No 
differences were seen between both groups of dogs in serum cS100A12 (p = 0.1126). 
Age was not significantly different between both groups of dogs (p = 0.1216). 
 Patients with IBD and hypoalbuminemia and thus being suspected of having 
protein-losing enteropathy (PLE), were older (median [IQR]: 9 [5.5–10.5] years) than 
those with a normal serum albumin concentration (median [IQR]: 4 [2–10] years), but 
this difference did not reach significance (p = 0.1970). However, outcome was 
significantly associated with hypoalbuminemia (p = 0.0031). Patients with 
hypoalbuminemia were more likely to be euthanized than patients with a normal serum 
albumin (OR = 39.000 [95%CI]: 1.720–884.300]). Also, dogs that were euthanized due 
to their chronic gastrointestinal disease had significantly higher fecal cS100A12 
concentrations at the time of diagnosis (1,760 [758–3,162] ng/g; n = 6) than dogs that 
were alive at the end of the study (55 [12–771] ng/g; p = 0.0124; n = 13) (Fig. 33). 
Clinical disease severity (p = 0.3129), serum sRAGE (p = 0.9337), and serum (p = 
0.5183) and fecal cS100A12 (p = 0.1106) concentrations were not significantly different 
between IBD dogs with or without hypoalbuminemia. 
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Figure 33 – Fecal S100A12 concentrations and short-term outcome in dogs with IBD. 
Dogs with IBD that were alive at the end of the study had significantly lower 
pretreatment fecal S100A12 concentrations (55 [12–771] ng/L) than dogs that had been 
euthanized (1760 [758–3162] ng/g; p = 0.0124). 
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5.4.  Discussion 
 The present study is the first to describe serum sRAGE concentrations in dogs 
with IBD. Canine sRAGE-pAb were shown to be specific for canine RAGE and the 
ELISA for measuring canine sRAGE in serum was shown to be sufficiently analytically 
sensitive, linear, accurate, precise, and reproducible. 
 Similar to the situation in humans, we found two different canine RAGE 
isoforms in canine lung tissue extracts, presumed to be full-length RAGE 
(approximately 50 kDa) and its truncated variant sRAGE (approximately 42 kDa), as 
well as an assembly of dimers (approximately 80 kDa). The protein bands detected in 
canine brain extract by Western blot analysis (approximately 47 kDa and 70–80 kDa) 
suggest the presence of a monomeric and dimeric form of RAGE that is structurally 
different from that in the canine lung, a finding that is consistent with previous studies in 
dogs (Sterenczak et al., 2009). These molecular weights are in agreement with those 
expected based on the primary sequence published for cRAGE (Ensembl Genome 
Browser web-site: Canis familiaris (CanFam3.1); available at: http://useast.ensembl.org 
[accessed 7-6-2014]). 
 Further, this study showed that serum sRAGE concentrations are decreased in 
dogs diagnosed with IBD compared to healthy dogs, suggesting that similar to chronic 
inflammatory diseases in humans, such as IBD (Meijer et al., 2014), sRAGE/RAGE may 
be involved in the pathogenesis of chronic gastrointestinal inflammation in dogs. Lower 
circulating concentrations of sRAGE in dogs with IBD, acting as a decoy receptor, may 
allow ligand interaction with cell surface RAGE and lead to sustained activation of the 
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RAGE pathway, and thus a perpetuation of the inflammatory response (Bierhaus et al., 
2005). Although our study did not evaluate canine RAGE at the tissue level and post-
RAGE signaling has also not been studied in dogs, blockade of canine RAGE by sRAGE 
to neutralize RAGE activity, as demonstrated in humans (Bierhaus et al., 2005), may 
also be a protective mechanism in inflammatory diseases in dogs, such as canine IBD. 
Furthermore, as has been reported in humans (Hudson et al., 2003), blockade of canine 
RAGE activation by sRAGE may be an interesting therapeutic strategy for chronic 
inflammatory diseases in dogs. 
 It appears plausible that a decrease in sRAGE may result in reduced ligand 
trapping and may shift the sRAGE/RAGE balance toward RAGE signaling and thus a 
proinflammatory response. However, a cause-and-effect relationship, i.e., whether the 
decrease in sRAGE is due to sRAGE consumption or decreased production, cannot be 
extrapolated from our data. Also, RAGE ligands or even anti-sRAGE-autoantibodies 
could potentially cause epitope masking and interfere with binding in the assay, but this 
has been shown to have no significant effect in humans (Lorenzi et al., 2014). 
 Lack of a correlation between sRAGE and cS100A12 concentrations would be 
consistent with sRAGE functioning as a non-specific circulating (pattern recognition) 
receptor. However, this study did not evaluate cS100A12-RAGE binding or measure 
RAGE ligands other than cS100A12 (such as high-mobility group box-1 [HMGB-1], 
calgranulin A/B, or other DAMPs). Also, while sRAGE has been shown to act as a 
decoy receptor with the potential to bind free advanced glycation end products (AGE) 
and other RAGE ligands, thus competing with membrane-bound RAGE for ligand 
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binding, it is unknown whether sRAGE/RAGE show the same affinity for cS100A12 in 
dogs as demonstrated in humans (Hofmann et al., 1999). Further studies are thus needed 
to evaluate the formation of cS100A12-RAGE complexes. 
 The trends of lower serum sRAGE concentrations and higher fecal cS100A12 
concentrations in dogs with idiopathic IBD compared to ARD/FRD dogs are interesting, 
and the lack of statistical significance could be a result of the small sample size of the 
subgroups. Lack of a relationship between systemic sRAGE concentrations and clinical 
(CIBDAI) or histologic disease scores in dogs with IBD is in line with findings in human 
patients with Crohn’s disease (Malickova et al., 2010; Meijer at el., 2014; Leach et al., 
2007), but contrasts to findings in patients with ulcerative colitis (Meijer et al., 2014). 
However, performance of only esophagogastroduodenoscopy in dogs in this study 
presents a limitation as lesions in the ileum or colon could have been missed. 
 Interestingly, increases in sRAGE concentrations were only seen in patients with 
a complete response to treatment. This effect was independent of the disease group 
(idiopathic IBD vs. ARD/FRD, and hypoalbuminemia vs. normal albumin), disease 
severity, and the serum sRAGE concentration at presentation. It would further support 
the hypothesis that sRAGE is an anti-inflammatory receptor and that sRAGE-ligand 
binding has the potential to down-regulate the proinflammatory response mediated by 
RAGE. Further research is warranted to evaluate the gastrointestinal mucosal expression 
of membrane-bound RAGE in healthy and diseased dogs, and to further evaluate the 
potential imbalance between sRAGE and its proinflammatory protein ligands. 
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 An inverse correlation of sRAGE with age in healthy dogs is consistent with 
findings in people (Koyama et al., 2005; Geroldi et al., 2006). It is possible that the 
relationship between sRAGE and age reflects changes associated with aging, such as the 
accumulation of AGEs. This has been described in people where high sRAGE 
concentrations were shown to be a marker of longevity (Geroldi et al., 2006). 
 Commercial polyclonal Ab generated against the recombinant canine RAGE 
extracellular domain (ED; 315 amino acids [AA]) was used in this study. Because full-
length canine RAGE consists of the ED (318 AA), the transmembrane segment (19 AA), 
and the cytoplasmic domain (43 AA), the ED sequence is not unique to the canine 
sRAGE isoform (Murua Escobar et al., 2006; Sterenczak et al., 2011). Thus, it is 
reasonable to assume that the Ab used in this study detect both canine sRAGE and 
canine full-length RAGE. Western blot analysis appears to be a suitable method to 
answer this question, but the sensitivity of our Western blot did not allow detection of 
sRAGE in canine serum samples. Thus, future studies will need to clarify this issue. 
 Interestingly, in this study pre-treatment fecalcS100A12 concentrations were 
higher in dogs with a negative outcome (euthanasia) compared to dogs that were alive at 
the conclusion of the study. Outcome data may be inherently biased due to euthanasia 
being an owner’s decision. However, our group has previously shown that fecal 
cS100A12 concentrations are associated with the severity of endoscopic lesions in the 
duodenum and colon in dogs with IBD. Heilmann et al. (2014) and Allenspach et al. 
(2007) showed that severe endoscopic lesions in the duodenum are a negative prognostic 
factor in dogs with IBD (Allenspach et al., 2007). Thus, fecal cS100A12 may be a good 
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marker to assess outcome in dogs with IBD. However, further studies are needed to 
confirm this finding and to determine the impact of pre-treatment fecal cS100A12 
concentrations on outcome. 
 
5.5.  Conclusion 
 In conclusion, the current study has demonstrated that sRAGE concentrations are 
decreased in dogs with IBD. These results suggest that sRAGE may serve a biomarker 
for inflammatory diseases such as IBD in dogs. Further studies are warranted to 
determine the role of sRAGE/RAGE in canine IBD and to evaluate the expression of 
RAGE at the tissue level. 
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6. FECAL INFLAMMATORY MARKERS AND MICROBIAL CHANGES IN DOGS
WITH THE ACUTE HEMORRHAGIC DIARRHEA SYNDROME (AHDS)
**
6.1  Introduction 
Idiopathic acute hemorrhagic diarrhea syndrome (AHDS), formerly known as 
hemorrhagic gastroenteritis (HGE), is characterized by a peracute onset of hemorrhagic 
diarrhea, vomiting, depression, and anorexia, and can be associated with a high mortality 
if untreated (Hall and German, 2010). The etiology of AHDS is unknown, but it has 
been speculated that an abnormal response to bacterial endotoxins, bacteria (e.g., toxin-
producing C. perfringens), or dietary components play a role (Cave et al., 2002; Schlegel 
et al., 2012; Busch et al., 2014). 
AHDS is characterized by an increased vascular and mucosal permeability (Hall 
and German, 2010). Intestinal mucosal necrosis of different severity in individual 
patients is the principal histological lesion found in endoscopic biopsies from dogs with 
AHDS, with a minor influx of inflammatory cells into the intestinal mucosa (Unterer et 
al., 2014). However, less invasive markers that reflect gastrointestinal inflammation and 
intestinal microbial changes have not been studied in dogs with AHDS during the acute 
phase of the disease. 
**
Manuscript submitted: Heilmann, R.M., Markel, M.E., Steiner, J.M., Suchodolski, J.S., 
Unterer, S., 2015. Fecal inflammatory markers and microbial changes in dogs with the 
acute hemorrhagic diarrhea syndrome (AHDS). The Veterinary Journal. 
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6.2  Objective 
This study aimed to repeatedly evaluate fecal canine calprotectin (cCP) and 
S100A12 (cA12, both markers of inflammation), α1-proteinase inhibitor (cα1PI, a marker 
of gastrointestinal protein loss), and bacterial groups that have previously been shown to 
be decreased (i.e., Faecalibacterium spp., Ruminococcaceae, Bifidobacterium spp.) or 
increased (i.e., Proteobacteria) in fecal samples from dogs with AHDS. 
6.3  Materials and Methods 
Dogs (n=7) with AHDS were enrolled into a treatment trial at the Veterinary 
Teaching Hospital at the Ludwig-Maximilians University Munich, Germany (Unterer et 
al., 2011). The study was conducted in accordance with the German animal welfare law. 
Each dog had a complete blood count, chemistry profile, coagulation profile, and serum 
total bile acids measured at the time of enrollment. A blood culture was also performed 
for each dog and fecal examination included a direct examination, flotation, culture 
(IDEXX Vet Med Labor GmbH, Ludwigsburg, Germany), and specific diagnostic 
testing for Giardia sp. (ProSpecT Giardia Microplate Assay, Remel, Lenexa, KS, USA), 
canine parvovirus (Snap Parvo Test, IDEXX Laboratories, Westbrook, ME, USA), and 
C. perfringens enterotoxin (Clostridium perfringens enterotoxin ELISA, Tech Lab Inc, 
Blacksburg, VA, USA). Diagnostic imaging and other diagnostic tests (e.g., ACTH 
stimulation test) were performed at the discretion of the attending clinician. Clinical 
disease severity was evaluated daily using the canine HGE activity index
 
(Unterer et al., 
2011), which considers the clinical parameters: general attitude, appetite, vomiting, stool 
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consistency, stool frequency, and dehydration. 
Dogs were hospitalized for at least 3 days and treated using a standard protocol 
consisting of intravenous crystalloid fluid therapy, antiemetic (maropitant [Cerenia
®
,
Pfizer Pharma GmbH, Karlsruhe, Germany] 1 mg/kg SC 24-hourly for 2 days), antacid 
(ranitidine [Sostril
®
, GlaxoSmithKline, Verona, Italy] 2 mg/kg IV 8-hourly for 2 days),
and low-molecular-weight heparin for prophylaxis of consumption coagulopathy 
(dalteparin [Fragmin D
®
, Pfizer Pharma GmbH, Karlsruhe, Germany] SC 12-hourly for
3 days: 75 IU/kg [day 1], 38 IU/kg [day 2], and 19 IU/kg [day 3]). As part of the 
randomized treatment trial, one dog received amoxicillin/clavulanic acid (Synulox
®
,
Pfizer Pharma GmbH, Karlsruhe, Germany; 12.5 mg/kg PO 12-hourly for 7 days), 
whereas the remaining 6 dogs were not administered antibiotics (Unterer et al., 2011). 
Fecal samples were collected non-invasively as part of the routine diagnostic 
work-up of all dogs included in the study (Fig. 34), with no extra samples taken for 
study purposes. An aliquot of fecal material was frozen after collection, stored frozen at 
-80 °C, and shipped to the Gastrointestinal Laboratory at Texas A&M University on dry 
ice. Fecal samples were then thawed, extracted as described (Heilmann et al., 2011a; 
Heilmann et al., 2011b), and fecal cCP, cA12, and cα1PI concentrations measured by in-
house immunoassays (Heilmann et al., 2008; Heilmann et al., 2011a; Heilmann et al., 
2011b). Bacterial DNA was extracted from each fecal sample and was analyzed for 
Faecalibacterium spp., Proteobacteria, Ruminococcaceae, and Bifidobacterium spp. 
using quantitative PCR assays as previously described (Suchodolski et al., 2012). 
Concentrations of fecal cCP, cA12, and cα1PI and the abundance of bacterial DNA were
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Figure 34 – Flowchart summarizing the fecal sample collection in dogs with acute 
hemorrhagic diarrhea syndrome (AHDS). 
compared using a Friedman test with Dunn’s post-hoc tests. 
6.4  Results 
Dogs enrolled in the study were 4.5 years (median; range: 2–8 years) of age. 
Breeds represented by n>1 dog included Jack Russell Terrier and mixed breed (both 
n=2). At the time of presentation, fecal cCP, cA12, and cα1PI were above the suggested 
reference intervals in 6 (86%), 6 (86%), and 5 (71%) of the 7 dogs, respectively. Until 
day 3, this number decreased to 2 (29%), 1 (14%), and 4 (57%), respectively. The HGE 
score was not correlated with any fecal marker and a significant correlation among those 
markers was only seen between cCP and cA12 on day 1 (ρ=0.79) and day 3 (ρ=0.76). 
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Concentrations of fecal cCP, cA12, and cα1PI and the abundance of Ruminococcaceae 
significantly decreased over the study period, with no differences observed in the 
abundances of Faecalibacterium spp., Bifidobacterium spp., or Proteobacteria (Table 
13). 
6.5  Discussion and Conclusions 
Fecal markers of inflammation (cCP, cA12) and gastrointestinal protein loss 
(cα1PI) were increased in dogs with AHDS. Although the number of patients was small, 
following the initiation of treatment, all fecal markers decreased significantly. This 
suggests a loss of protein into the intestinal lumen at the onset of AHDS, which subsides 
within 48 hours after initiating treatment. It also suggests the loss of inflammatory cells 
or intestinal inflammation in the same time period. Compared to cα1PI, both cCP and 
cA12 decreased between days 2–3, suggesting that intestinal inflammation is a more 
likely explanation of the increased fecal cCP and cA12 concentrations than loss of 
inflammatory cells, though further studies need to definitively differentiate these 
possibilities. This differentiation is of special interest as a previous study did not identify 
histopathological evidence of significant intestinal inflammation in canine AHDS 
(Unterer et al., 2014). Lack of significant increases of Faecalibacterium spp., 
Bifidobacterium spp., and Ruminococcaceae, and decreases in Proteobacteria may 
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Table 13 – Clinical disease severity, fecal markers of inflammation or protein loss, and abundances of selected bacterial 
groups in dogs with AHDS. For each parameter, medians not sharing a common superscript (marked in bold) are significantly 
different at P<0.05. 
Parameter Day 1 Day 2 Day 3 P-value 
Canine HGE activity 
index
#,$
 
14
A
 
[8–15] 
4 
[2–9] 
3
B
 
[1–7] 
0.017 
Fecal canine calprotectin 
(cCP), in μg/g$ 
87.7
A,B
 
[31.7–127.3] 
64.8
A
 
[55.8–136.1] 
6.8
B
 
[2.9–66.9] 
0.016 
Fecal canine S100A12 
(cA12), in μg/g$ 
8.9
A,B
 
[3.0–163.4] 
10.1
A
 
[2.7–93.0] 
0.5
B
 
[0.5–1.2] 
0.016 
Fecal canine α1-proteinase 
inhibitor (cα1PI), in μg/g
$
 
114.0
A
 
[15.3–191.0] 
19.7
A,B
 
[13.7–183.0] 
22.0
B
 
[3.7–81.4] 
0.012 
Faecalibacterium spp.
$
 7.8×10
3 
[0.4×10
3–0.1×106] 
44.0×10
3 
[0.7×10
3–1.8×106] 
0.5×10
3 
[1–6.6×103] 
0.085 
Bifidobacterium spp.
$
 1
 
[1–6.9] 
1
 
[1–1] 
1
 
[1–1] 
0.192 
Proteobacteria
$
 1
 
[1–2.5×106] 
0.6×10
6 
[1–2.8×106] 
0.2×10
6 
[0.1×10
6–4.8×106] 
0.305 
Ruminococcaceae
$
 137×10
3 A,B 
[1–833×103] 
237×10
3 A 
[133×10
3–593×103] 
21.7×10
3 B 
[0.1×10
3–213×103] 
0.008 
     
#
Unterer et al., 2011; 
$
shown are the medians and interquartile ranges (IQR)
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suggest an ongoing intestinal dysbiosis. The abundances of most bacterial groups were 
unchanged over the 3-day study period, suggesting that the intestinal dysbiosis outlasts 
gastrointestinal protein loss. Further longitudinal studies including larger numbers of 
dogs with AHDS are warranted to evaluate intestinal dysbiosis in canine AHDS. 
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7. SUMMARY AND CONCLUSIONS 
 
 Idiopathic inflammatory bowel disease (IBD) in dogs is a chronic inflammation 
of the small and/or large intestine that may also involve the stomach of an unknown 
etiology. Canine IBD is a chronic relapsing condition, and its diagnosis and management 
can be challenging for the veterinarian and frustrating for the owner. The diagnosis of 
canine IBD requires comprehensive diagnostic testing, including invasive diagnostic 
procedures, to exclude other causes of chronic gastrointestinal signs such as FRD, ARD, 
infiltrative infectious diseases, or neoplasia. Traditionally, clinical improvement is being 
used to determine the success of medical management in canine patients with IBD. 
 The exact cause of IBD is unknown. Current consensus is that the pathogenesis 
of IBD in dogs involves an impaired immunoregulation in a genetically predisposed host 
that results in an inflammatory response against dietary and/or microbial antigens. Cells 
of the adaptive immune system have been associated with the pathogenesis of idiopathic 
IBD in dogs, but recent evidence suggests a critical role of the innate immune system in 
the development of canine IBD. Thus, biomarkers of phagocyte activation, such as the 
S100/ calgranulin Ca
2+
-binding EF-hand protein S100A12 have potential clinical utility 
as markers of inflammation in dogs with IBD. Soluble RAGE (sRAGE), a truncated 
variant of RAGE, has been shown to function as a decoy receptor sequestering ligands 
such as damage-associated molecular pattern molecules (e.g., S100A12), thus preventing 
their interaction with cell surface RAGE and abrogating cellular RAGE signaling. 
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 Both S100A12 and the sRAGE/RAGE axis had not previously been studied in 
dogs with IBD. Thus, this project sought to determine if S100A12 has clinical utility as a 
biomarker of gastrointestinal inflammation in dogs and if the sRAGE/RAGE axis plays a 
role in canine IBD. Canine IBD is also currently considered the best spontaneous animal 
model of human IBD (i.e., Crohn’s disease, ulcerative colitis, and indeterminate colitis) 
owing to the similarities of the clinical features, etiopathogenesis, and diagnostic and 
management strategies, as well as the shared environment of dogs and humans. Thus, 
results of studies in dogs with IBD can potentially translate directly to human IBD, and 
studying S100A12 and sRAGE in dogs with IBD contributes to comparative 
gastroenterology involving S100A12/sRAGE for diagnosing inflammation, assessing 
disease progression, and as potential novel therapeutic strategies in patients with chronic 
autoinflammatory conditions. 
 
7.1  Summary 
 Canine S100A12 was purified for the first time. Purification involved a multistep 
protocol comprising leukocyte enrichment from canine blood and extraction of the 
soluble cytosol fraction, ammonium sulfate precipitation, and hydrophobic interaction 
and ion-exchange chromatography. Partial characterization of the canine S100A12 
protein by determination of its molecular weight and relative molecular mass, isoelectric 
point, specific absorbance, tryptic peptide mass fingerprint, N-terminal amino acid 
sequence analysis, and immunologic cross-reactivity revealed similarities between 
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canine, human, porcine, bovine, and rabbit S100A12 with regard to structural as well as 
biochemical properties. 
 Anti-canine S100A12 polyclonal antibodies were generated, purified by affinity 
chromatography, and demonstrated to be specific for canine S100A12. Canine S100A12 
was successfully labelled with radioactive iodine (
125
I), and a competitive, double 
antibody radioimmunoassay for the measurement of serum and fecal canine S100A12 
concentrations was successfully developed. Analytical validation of the canine S100A12 
radioimmunoassay included determination of the assay working range (lower and upper 
detection limits of the assay), analytical specificity, assay linearity (dilutional 
parallelism), assay accuracy (spiking recovery), precision and reproducibility (intra- and 
inter-assay variability), endogenous interference of hyperlipidemia, non-parametric 
reference intervals, biological variation of canine S100A12 in serum and fecal samples, 
and its distribution in feces. The radioimmunoassay was analytically sensitive and 
specific, linear, accurate, precise, and reproducible. Using a population-based reference 
interval for serum canine S100A12 may or may not be reasonable, and moderate 
changes in serum canine S100A12 are needed to be considered as clinically relevant. 
 Fecal canine S100A12 concentrations were evaluated in dogs with chronic 
gastrointestinal signs and a diagnosis of IBD based on clinical, clinicopathologic, 
endoscopic, and histopathologic criteria. Routine blood work and diagnostic imaging 
was performed in these dogs, and the clinical disease severity was assessed using the 
CCECAI scoring system. Endoscopic evaluation served to visually inspect the 
gastrointestinal mucosa in stomach, duodenum, ileum, and/or colon, score the severity of 
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lesions using a 4-point grading system, and collect tissue biopsies. Formalin-fixed and 
paraffin-embedded tissue biopsies were used for histological evaluation using guidelines 
established by the WSAVA Gastrointestinal Standardization group. The control group 
was comprised of healthy dogs. Canine S100A12 was quantified in fecal samples from 
each dog. Fecal S100A12 concentrations were compared between dogs with IBD and 
healthy controls, with the sensitivity and specificity calculated, followed by assessment 
of the relationship between fecal S100A12 concentrations and histologic, endoscopic, 
and clinical disease severity, and the negative prognostic factors hypoalbuminemia and 
hypocobalaminemia. The investigation showed that fecal canine S100A12 
concentrations are increased in dogs with IBD compared to healthy control dogs, and are 
moderately accurate in distinguishing dogs with IBD from healthy controls. In dogs with 
IBD, fecal canine S100A12 concentrations correlated with the clinical disease activity, 
the severity of intestinal macroscopic (endoscopic) lesions in the duodenum and colon, 
and with the histologic inflammatory changes in the colon but not with the severity of 
histologic lesions overall. A fecal canine S100A12 concentration of ≥273 ng/g 
distinguished dogs with moderate to severe endoscopic disease in any section of the 
gastrointestinal tract from dogs with at most mild endoscopic disease (sensitivity: 71%, 
specificity: 89%). The same cut-off concentrations separated dogs with very severe 
clinical disease (i.e., a CCECAI score of ≥12) from dogs with a CCECAI score of <12 
(sensitivity: 90%, specificity: 75%). 
 Specificity of the polyclonal anti-recombinant canine RAGE antibody was tested, 
and a sandwich enzyme-linked immunosorbent assay was successfully developed and 
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analytically validated for the measurement of canine sRAGE concentrations in serum. 
The canine sRAGE enzyme-linked immunosorbent assay was demonstrated to be 
analytically sensitive, linear, accurate, precise, and reproducible. Canine sRAGE 
concentrations were evaluated in serum samples from dogs with chronic gastrointestinal 
signs (i.e., vomiting and/or diarrhea of ≥3-weeks duration) that had failed dietary and 
antibiotic trials and were diagnosed with IBD based on further diagnostic work-up, 
including an upper gastrointestinal endoscopy and collection of tissue biopsies. The 
histopathologic criteria by the WSAVA Gastrointestinal Standardization group were 
used to grade histologic disease, and clinical disease activity was assessed using the 
CIBDAI scoring system. Following the diagnostic work-up, dogs received prednisone, 
prednisone and cyclosporine, or budesonide and/or metronidazole, and were given a 
commercial elimination diet. An additional set of samples were collected upon patient 
re-evaluation approximately 3 weeks later, when response to treatment was assessed 
using the CIBDAI score (complete clinical remission: ≥75% decrease in CIBDAI; partial 
response: 25–75% decrease in CIBDAI; no response: ≤25% decrease in CIBDAI). 
Serum was also collected from a group of healthy control dogs. Serum sRAGE was 
measured in all serum samples, and canine S100A12 was also quantified in serum and 
feces. Serum sRAGE and serum/fecal S100A12 were compared in dogs with IBD vs. 
healthy controls, with calculation of sensitivity and specificity, and in dogs with a 
positive outcome (clinical remission) vs. those that were euthanized. This was followed 
by testing the relationship between serum sRAGE concentrations and the CIBDAI score, 
histologic disease severity, and serum and fecal canine S100A12 concentrations. The 
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study demonstrated that serum sRAGE concentrations are significantly decreased in 
dogs with IBD, but are not correlated with the severity of histologic lesions, the CIBDAI 
score or serum canine S100A12 concentration before or after treatment, or outcome. 
Clinical remission and the change in serum sRAGE concentration after treatment were 
not associated, but an increase in serum sRAGE concentrations was only seen in IBD 
dogs with complete clinical remission. Dogs that were euthanized had significantly 
higher fecal S100A12 concentrations than those that were alive at the end of the study. 
 Markers of gastrointestinal inflammation (fecal canine calprotectin and canine 
S100A12), protein loss (α1-proteinase inhibitor), and changes in the intestinal microbiota 
(Faecalibacterium spp., Proteobacteria, Ruminococcaceae, and Bifidobacterium spp.) 
were also studied in a group of dogs with AHDS. Fecal samples were collected from 3 
consecutive days starting on the day of hospital admission. The study showed that all 
fecal markers evaluated were significantly increased at the time of presentation and 
decreased significantly within 48 hours after initiating treatment. No differences in the 
abundances of bacterial groups were seen over time, except for a decrease in 
Ruminococcaceae. 
 
7.2  Conclusions 
 The results of this investigation suggest that measurement of canine S100A12 in 
fecal samples may be a useful adjunct for assessing macroscopic (endoscopic) disease 
severity in dogs with IBD, that sRAGE/RAGE may be involved in the pathogenesis of 
canine IBD, and that sRAGE may also serve a biomarker for inflammatory diseases such 
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as IBD in dogs. Lack of a correlation between sRAGE and S100A12 concentrations is 
consistent with sRAGE functioning as a non-specific decoy receptor. 
 Canine AHDS is a clinical entity that is different from canine IBD. However, 
fecal canine S100A12 concentrations are also increased in dogs with AHDS at the time 
of presentation, and canine AHDS is associated with a significant but transient intestinal 
loss of protein, intestinal inflammation, and an intestinal dysbiosis that appears to outlast 
the gastrointestinal loss of proteins. 
 This investigation is an important first step to evaluate canine S100A12 and 
sRAGE as novel disease markers in dogs with IBD. However, further research is needed 
to evaluate the potential of fecal canine S100A12 to reflect clinical remission and/or 
mucosal healing in dogs with IBD, to evaluate the gastrointestinal mucosal expression of 
RAGE in healthy and diseased dogs, and to demonstrate the formation of canine 
S100A12-canine sRAGE/RAGE complexes. Results of these studies will help to further 
determine the clinical utility of canine S100A12 and sRAGE as surrogate tests to aid in 
the diagnosis and monitoring of dogs with chronic gastrointestinal inflammation. The 
availability of immunological methods to quantify canine S100A12 and sRAGE will 
also allow for studying their role in other autoinflammatory conditions in dogs. 
 
7.3  New Hypotheses 
 Based on the current knowledge, the following hypotheses are proposed 
regarding the mechanism of the canine S100A12-RAGE/sRAGE interaction in canine 
IBD: Canine S100A12 accumulates at sites of inflammation or cell damage, forming 
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oligomers in the presence of Ca
2+
 and Zn
2+
 or complexes with PAMPs (e.g., LPS) or 
other DAMPs (e.g., AGEs, HMGB-1). In the presence of glycans and an oxidized state, 
this higher order canine S100A12-complex is recognized by the RAGE receptor, which 
is expressed by activated mononuclear phagocytes and endothelial cells. The ligand-
RAGE interaction activates the NF-κB signal transduction pathway (Fig. 35), leading to 
an increased production of pro-inflammatory cytokines and chemokines (e.g., TNF-α, 
S100/calgranulins, MMPs) and an up-regulation of RAGE. This mechanism increases 
the availability of S100/calgranulins for host defense against microorganisms by 
sequestering essential trace elements (e.g., Zn
2+
) and, via chemotaxis, attracts monocytes 
and mast cells to the site of inflammation or tissue damage. MMPs initially facilitate 
leukocyte chemotaxis by breaking down tissue matrix, but are later on counteracted by 
accumulating S100/calgranulins (e.g., S100A12) due to the sequestration of essential 
Zn
2+
. Soluble RAGE, and possibly also dominant-negative and N-truncated RAGE, act 
as a mechanism of receptor regulation by competitively sequestering ligands such as 
DAMPs (e.g., S100/calgranulins) and thus preventing their interaction with full-length 
cell surface RAGE. 
 Under normal conditions, the immune response using the pathway described 
should be self-limiting with all steps involved being tightly controlled by positive and 
negative regulators. However, a dysregulation in this pathway (e.g., due to dysregulation 
or mutation of the full-length receptor[s], decoy receptor[s], adaptor protein[s], and/or 
negative or positive regulator[s]; increased accumulation of DAMPs and/or PAMPs as 
ligands; and/or a microenvironment that favors their higher-order complex formation)
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Figure 35 – Proposed mechanism of canine S100/calgranulin-RAGE/sRAGE and/or 
TLR interaction in view of current knowledge. Several aspects of this new hypothesis 
have been evaluated in canine IBD. In addition to a significant increase in S100A12 and 
a decrease in sRAGE, increased NF-κB activation was shown in the duodenal lamina 
propria in dogs with chronic enteropathies. A large gene expression study identified 
several genes that were up-regulated in the intestinal mucosa in dogs with IBD, which 
included genes encoding TNF, S100/calcium-binding proteins, and MMPs. Several 
studies have also analyzed and found TLR4 dysregulation and a genomic instability in 
the TLR4 gene in canine IBD. 
IRAK = IL-1 receptor-associated kinase; Kras = V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog; LPS = lipopolysaccharide; MAPK = mitogen-activated protein 
kinases; MyD88 = myeloid differentiation factor 88; NF-κB = nuclear factor-kappa B; 
RAGE = receptor for advanced glycation end products; S100 = S100 protein; sRAGE = 
soluble receptor for advanced glycation end products; TLR4 = Toll-like receptor 4; 
TNF-α = tumor-necrosis factor α; TRAF = TNF-receptor associated factor. 
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could modulate the immune response leading to sustained post-receptor signaling and 
thus, its amplification and perpetuation beyond the traditional inflammatory response. A 
dysregulation in the S100/calgranulin-RAGE/sRAGE pathway could also be involved in 
the pathogenesis of chronic autoinflammation such as IBD. However, further research is 
needed to confirm or disprove this hypothesis and to further evaluate the 
S100/calgranulin-RAGE/sRAGE axis in canine IBD. 
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